Drug, bio-affecting and body treating compositions inventions 11/07

20070275894 - Modulators of the abc transporter family and methods for their use: An isolated factor derived from the bacterium Pseudomonas aeruginosa and confirmed by proteomics to be a protein that reduces expression of ABC transmembrane proteins and active fragments and mimetics thereof are provided. Also provided is a method for inhibiting expression of ABC transmembrane proteins in cells by administering to the... Agent: Licata & Tyrrell P.C.

20070275923 - Cationic peptides for sirna intracellular delivery: What is described is a composition for delivery of a RNA molecule to a cell, comprising: a double stranded RNA (dsRNA) molecule of about 15 to about 40 base pairs; and a polynucleotide delivery-enhancing peptide, comprising a region of alternating lysine and histidine residues, or of alternating D and L... Agent: Nastech Pharmaceutical Company Inc

20070275930 - Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.... Agent: Louis J. Wille Bristol-myers Squibb Company

20070275871 - Epo mimetic peptides and fusion proteins: EPM peptides, including EPM peptide-fusion proteins with increased serum half-life or serum stability are disclosed. Compositions comprising the EPM peptides or fusion proteins and methods of treating or preventing disorders by administering a therapeutically or prophylactically effective amount of an EPM peptide or fusion protein to a patient in need... Agent: Pfizer Inc. Patent Department, Ms 8260-1611

20070275875 - Method for preventing colon cancer: Provided are novel colon cancer preventives, and digestible food/drink additives and health supplements which not only are effective in body weight control and constipation prevention/treatment, but also have the action of accelerating the intestinal absorption of minerals. Sericin or it's hydrolyzed product is used as a colon cancer preventive, food/drink... Agent: Dilworth & Barrese, LLP

20070275876 - Method to increase the bioavailability of cysteine: A method for increasing the bioavailability of cysteine within an animal by reducing extracellular cysteine disulfide molecules to produce extracellular cysteine molecules. A membrane permeable thiol molecule that forms a membrane permeable disulfide molecule after becoming oxidized participates in thiol-disulfide exchange reactions on both sides of the cellular membrane, crossing... Agent: David M. Ott

20070275873 - Methods and compositions comprising protein l immunoglobulin binding domains for cell-specific targeting: The present invention provides a fusion protein comprising a first amino acid sequence of at least one immunoglobulin-binding domain of Protein L and a second amino acid sequence of a peptide or protein that does not bind an immunoglobulin Fc region, as well as methods of making and using the... Agent: Myers Bigel Sibley & Sajovec

20070275872 - Peptides with anti-obesity activity and other related uses: Novel peptides and uses thereof, including polypeptides and related molecules with uses, for example, in weight loss and for the treatment of obesity and related conditions associated with, for example, increased mass of adipocytes.... Agent: Duane Morris LLP

20070275874 - Use of leptin in wound healing: As described herein, leptin treatment significantly increased wound contraction and epithelial regeneration while reducing granulation tissue and wound area, consistent with a healing augmentation effect. Specifically, in leptin-treated wounds, the inventor found increased expression of smooth muscle-actin (-SMA) and collagens I, III and IV. Taken together, the inventor's results indicate... Agent: Davis Wright Tremaine LLP

20070275877 - Methods for treating or ameliorating ghrelin-associated diseases and disorders: Methods for modulating the effective levels of ghrelin are disclosed. These methods include the use of amylin, amylin agonists and amylin antagonists to regulate the effective levels of ghrelin. Methods for the prevention, treatment, or amelioration of ghrelin-associated diseases or disorders utilizing the methods for modulating ghrelin are also disclosed.... Agent: Intellectual Property Department Amylin Pharmaceuticals, Inc.

20070275878 - No-modified hemoglobins and uses therefor: Nitrosylhemoglobin can be produced by introducing gaseous NO into an aqueous solution of hemoglobin. It has been demonstrated that nitrosylhemoglobin in aqueous solution can be converted to SNO-hemoglobin upon introduction of oxygen to the solution, as is postulated to occur in the lungs. Nitrosylhemoglobin can be used in methods to... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070275883 - 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections: The 3′-L-valine ester of β-D-2′-C-methyl-ribofuranosyl cytidine provides superior results against flaviviruses and pestiviruses, including hepatitis C virus. Based on this discovery, compounds, compositions, methods and uses are provided for the treatment of flaviviridae, including HCV, that include the administration of an effective amount of val-mCyd or its salt, ester, prodrug... Agent: King & Spalding LLP

20070275882 - Nature-identical erythropoietin: The present invention relates to Erythropoietin, (i.e. Haemopoietin, Haematopoietin, or erthropoietic stimulating factor) (EPO) having glycoform profiles or a glycoform close or identical to naturally occurring EPO (nEPO) as well as processes and means for the production thereof. The present invention also concerns usage of the EPO obtained according to... Agent: Ostrolenk Faber Gerb & Soffen

20070275881 - Oligosaccharide compositions and use thereof in the treatment of infection: Oligosaccharides and oligosaccharides linked to backbones such as proteins, methods for making such oligosaccharides and methods for using them to treat and/or prevent various disorders are described.... Agent: Fish & Richardson PC

20070275879 - Use of ulinastatin and its pharmaceutical composition for treating severe acute respiratory syndrome: The present invention relates to use of Ulinastatin and its pharmaceutical composition for treating and/or preventing Severe Acute Respiratory Syndrome (SARS). Ulinastatin is effective for treating and/or preventing SARS, particularly Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS). Ulinastatin is generally used as the pharmaceutical composition, preferably in... Agent: Ohlandt, Greeley, Ruggiero & Perle, LLP

20070275880 - Virally-safe factor viii with a low content of higher multimers: La present invention pertains to a composition of plasma-derived virally-safe factor VIII, obtained after nanometric filtration, said composition comprising von Willebrand factor (vWF) at a rate of 15% or less of decamers and higher multimers. Such compositions have a reduction factor of the virus titre higher than 4 log and... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20070275885 - Microcystins as agents for treatment of cancer: This invention relates to the use of microcystins as agents for treatment of cancer. Also provided are methods of screening for microcystins with improved cytotoxicity.... Agent: Buchanan, Ingersoll & Rooney PC

20070275884 - Use of modified cyclosporins for the treatment of hcv disorders: Disclosed are non-immunosuppressive cyclophilin-binding cyclosporins, e.g. of formula (I, Ia or II) as defined herein, having useful properties in the prevention or treatment of Hepatitis C infections.... Agent: Novartis Corporate Intellectual Property

20070275886 - Phalloidin derivatives and methods for their synthesis: The invention provides a cyclomonomer having actin-binding activity. The cyclomonomer is of utility for the study of the molecular biology of actin polymerization. The cyclomonomer is also useful for the study of and treatment of the toxic effects of Amanita sp. poisoning.... Agent: Bell & Associates

20070275890 - Chaperonin 10 modulation of toll-like receptor-inducible cytokine and chemokine secretion: Methods of use of Chaperonin 10 (Cpn10) are provided for regulating Toll-like receptor signaling and/or Toll-like receptor inducible immunomodulator secretion. Cpn10 negatively regulates Toll-like receptor agonist-induced pro-inflammatory cytokine and chemokine secretion, examples being IL-6 and RANTES, respectively. Cpn10 positively regulates Toll-like receptor agonist-induced anti-inflammatory cytokine and chemokine secretion, an example... Agent: Knobbe Martens Olson & Bear LLP

20070275897 - Collagen mimics: Novel collagen mimics are disclosed with a tripeptide unit having the formula (Xaa-Yaa-Gly)n, where one of the positions Xaa or Yaa is a bulky, non-electron withdrawing proline derivative. By substituting a proline derivative at either the Xaa or Yaa position in the native collagen helix, the stability of the helix... Agent: Quarles & Brady LLP

20070275893 - Compositions for enhanced epithelial permeation of peptide yy for treating obesity: Pharmaceutical compositions comprising PYY(3-36), a cyclodextrin, and a compound selected from phosphatidylcholine or diglyceride, wherein the PYY(3-36) is present in an amount effective to alleviate one or more symptom(s) of obesity in a subject, and the cyclodextrin and the compound selected from phosphatidylcholine or diglyceride are present in an amount... Agent: Nastech Pharmaceutical Company Inc

20070275895 - Follistatin-3: The present invention relates to a novel follistatin-3 protein which is a member of the family of inhibin-related proteins. In particular, isolated nucleic acid molecules are provided encoding the human follistatin-3 protein. Follistatin-3 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20070275889 - Gene expression technique: The present invention provides a method for producing heterologous protein comprising: (a) providing a host cell comprising a 2 μm-family plasmid, the plasmid comprising a gene encoding a protein comprising the sequence of a chaperone protein and a gene encoding a heterologous protein; (b) culturing the host cell in a... Agent: Synnestvedt & Lechner, LLP

20070275887 - Method of inhibiting secretase activity: The present invention provides a method for inhibiting secretase activity. A method for promoting the sensitivity of a secretase inhibitor, a method for binding synoviolin to Herp (homocysteine-inducible endoplasmic reticulum stress-inducible ubiquitin-like domain member 1), or the like is employed to inhibit secretase activity.... Agent: Dickstein Shapiro LLP

20070275892 - Novel chemokine mimetics synthesis and their use: The present disclosure generally teaches compositions comprising SDF-1 mimetics and methods of using them to modulate an activity of a cell having an SDF-1 receptor by binding the SDF-1 receptor to an SDF-1 mimetic. The cell can be a hematopoietic cell, for example, and can be selected from a group... Agent: Technology & Intellectual Property Strategies Group PC Dba Tips Group

20070275891 - Obg3 globular head and uses thereof: The present invention relates to the field of obesity research. Obesity is a public health problem that is serious and widespread. A compound, globular OBG3, has been identified that reduces weight gain in animals. This compound should be effective for reducing body mass and for treating obesity-related diseases and disorders.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070275888 - Preventive/remedy for cancer: The present invention provides a substance that inhibits the binding of a protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 4, SEQ ID NO: 7 or SEQ ID NO: 10, its partial peptide... Agent: Edwards Angell Palmer & Dodge LLP

20070275896 - Use of polypeptides in treating tissue injury: Provided are methods and compositions for treating tissue injury.... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20070275898 - Protein crystal comprising the processivity clamp factor of dna polymerase and a ligand, and its uses: The present invention relates to a protein crystal comprising the processivity clamp factor of DNA polymerase and a peptide of about 3 to about 30 amino acids, in particular of about 16 amino acids, said peptide comprising all or part of the processivity clamp factor binding sequence of a processivity... Agent: Young & Thompson

20070275899 - Treatment of demyelinating autoimmune disease with modified ordered peptides: Compositions and methods are provided for the treatment of demyelinating autoimmune disease. Therapeutic doses are administered of a combination of therapeutic ordered peptides or one or more modified therapeutic ordered peptide(s) comprising amino acids representing a consensus sequence of a protein identified as a target of the autoimmune T and... Agent: Townsend And Townsend And Crew, LLP

20070275900 - Prodrugs cleavable by cd26: The present invention provides a new prodrug technology and new prodrugs in order to increase the solubility, to modulate plasma protein binding or to enhance the biovailability of a drug. In the present invention the prodrugs are conjugates of a therapeutic compound and a peptide (eg tetrapeptide or hexapeptide) wherein... Agent: Clark & Elbing LLP

20070275901 - Synthesis, modification and reduction of primary structure of hypotensive peptides present in scorpion venom for optimizing their use as a hypotensive medicament: The present invention relates to synthetic and recombinant peptide primary structures including an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 12, wherein the primary structure includes an +aa-Pro-Pro amino acid in which “+aa” is Lys, Arg, His or a modified amino acid having... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20070275902 - Treatment of phosphatidylinositol phospholipid disorders: Disclosed is a method of treating cell proliferative disorders, such as cancer, with amounts of chlorotoxin and/or derivatives, analogs or fragments thereof, which are effective to bind to phosphoinositol phospholipids.... Agent: Choate, Hall & Stewart LLP

20070275904 - Conjugates of aziridinyl-epothilone analogs and pharmaceutical compositions comprising same: The present invention is directed to conjugated compounds comprising a folate, or an analog or derivative thereof, and an aziridinyl epothilone analog, as further described herein, and/or pharmaceutically-acceptable salts and/or solvates thereof, useful in the treatment of cancer or other folate-receptor associated conditions.... Agent: Fitzpatrick Cella (bristol-myers)

20070275905 - Salts of trimebutine and n-desmethyl trimebutine: Unique salts of trimebutine and N-monodesmethyl trimebutine, and their corresponding stereoisomers, having improved analgesic properties useful in the treatment of visceral pain are provided. The salts of the present invention are particularly useful in the treatment of conditions characterized by abdominal pain, such as inflammatory bowel disease (IBD) and irritable... Agent: Bennett Jones C/o Ms Roseann Caldwell

20070275903 - Tripeptide prodrug compounds: The prodrug of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide of three amino acids, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by a trouase enzyme such as Thimet oligopeptidase. Also disclosed are methods of making... Agent: Lahive & Cockfield, LLP

20070275906 - Compounds and compositions as channel activating protease inhibitors: The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating channel activating proteases, and methods for, using such compounds to treat, ameliorate or prevent a condition associated with a channel activating protease, including but not limited to prostasin, PRSS22, TMPRSS11 (e.g., TMPRSS11B, TMPRSS11E), TMPRSS2, TMPRSS3, TMPRSS4 (MTSP-2),... Agent: Genomics Institute Of The Novartis Research Foundation

20070275907 - Glucose transport inhibitors and methods of use: Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition.... Agent: Townsend And Townsend And Crew, LLP

20070275908 - Methods and compositions for the enzymatic synthesis of gangliosides: Novel synthetic glycosphingolipids and pharmaceutical compositions containing such synthetic glycosphingolipids are described. Methods of making the novel synthetic glycosphingolipid compounds and compositions as well as their use in the field of neuroprotection and cancer treatment is also described.... Agent: Townsend And Townsend And Crew, LLP

20070275909 - Novel hypocholesterolemic compounds: The present invention relates to novel hypocholesterolemic compounds of formula (I) useful in the treatment and prevention of atherosclerosis and for the reduction of cholesterol levels as well as to pharmaceutical compositions comprising said compounds alone or in combination with other active agents.... Agent: The Webb Law Firm, P.C.

20070275910 - Phosphoramidate derivatives: The present invention provides a phosphoramidate compound comprising the structure (I) Formula (I) wherein: X comprises a monosaccharide group comprising the structure (II) or (III), 8 Formula (II), (III) B and B are independently selected from the group consisting of —O—, —CH2— and a bond, preferably —O—; R1 is selected... Agent: Fish & Richardson PC

20070275911 - Targeted drug-formaldehyde conjugates and methods of making and using the same: The invention provides a prodrug platform technology for improving the therapeutic value of a variety of parent drug compounds by altering and improving drug characteristics such as aqueous solubility, hydrolytic stability, therapeutic index, toxicity profile, pharmacolcinetics and selectivity while allowing the potential for synthetic elaboration. The prodrug platform is particularly... Agent: Sheridan Ross PC

20070275913 - Compositions and their uses directed to hepcidin: Disclosed herein are compounds, compositions and methods for modulating the expression of hepcidin in a cell, tissue or animal or preventing, ameliorating or treating anemia. Also provided are methods for prevention, amelioration or treatment of anemia, and for increasing red blood cell count in an animal. Also provided are methods... Agent: Knobbe, Martens, Olson & Bear, LLP

20070275912 - Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase: The present invention provides nucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B... Agent: Merck And Co., Inc

20070275925 - Asthma diagnosis and therapy: The invention provides drug assays, methods of diagnosing, and methods and compositions for treating asthma and other lung disease based upon the identification and/or use of agents which modulate CST1, HDAC9 or PRR4 levels or activity.... Agent: Townsend And Townsend And Crew, LLP

20070275918 - Induction of cellular senescence by cdk4 disruption for tumor suppression and regression: The invention provides methods of inhibiting growth of tumor cells comprising contacting the cells with a Cdk4 inhibitor. The invention also provides methods of treating patients having, suspected of having, or at a high risk for developing, a cancer, comprising treatment with a Cdk4 inhibitor. The invention also relates to... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070275920 - Method for chromatographic separation of a nucleic acid mixture: The invention relates to a method for chromatographic separation of a nucleic acid mixture, particularly to the separation and purification of plasmid DNA from other components of the nucleic acid mixture, particularly other nucleic acids. The inventive method is particularly characterized in that plasmid DNA can be separated without adding... Agent: Mcdermott Will & Emery LLP

20070275916 - Methods of identifying compounds which modulate granulocite-colony stimulating factor (g-csf) dependent processes by modulation of the levels of suppressor of cytokine signaling (socs): The present invention relates generally to compounds which modulate cytokine-dependent processes. More particularly, the compounds of the present invention modulate responses to a colony stimulating factor and even more particularly to granulocyte-colony stimulating factor (G-CSF) by modulating the levels of molecules which inhibit G-CSF such as but not limited to... Agent: Scully, Scott, Murphy & Presser, P.C.

20070275921 - Oligomeric compounds that facilitate risc loading: The present invention provides double stranded compositions wherein one of the strands is useful in, for example, influencing the preferential loading the opposite strand into the RISC (or cleavage) complex. In particular, the present invention provides oligomeric compounds that comprise chemical modifications in at least one of the strands to... Agent: Woodcock Washburn LLP

20070275919 - Rna amidates and thioamidates for rnai: The present disclosure relates to RNA amidates and thioamidates useful for RNA interference applications. The RNA amidates and thioamidates contain at least one internucleoside linkage chosen from ribo-N3′→P5′ phosphoramidate (NP) and ribo-N3′→P5′ thiophosphoramidate (NPS) linkages, and optionally further containing at least one covalently conjugated lipid moiety. Compositions comprising the amidates... Agent: Perkins Coie LLP

20070275917 - Rna capable of suppressing expression of klf5 gene: An RNA capable of suppressing the expression of KLF5 gene, which comprises a sequence consisting of 15 to 30 contiguous nucleotides of KLF5 mRNA and a sequence complementary to the sequence, and which has been designed from the nucleotide sequence of Kruppel-like factor 5 (KLF5) cDNA. Specifically, a double-stranded RNA... Agent: Greenblum & Bernstein, P.L.C

20070275922 - Rnai-mediated inhibition of igf1r for treatment of ocular angiogenesis: RNA interference is provided for inhibition of IGF1R mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (PSNV), and neovascular glaucoma, and for treating patients at risk of developing such conditions.... Agent: Winstead PC

20070275924 - Synthetic lipid rafts and methods of use: Compositions and methods for delivering cargo to cells are provided. One aspect provides a synthetic vesicle containing caveolin 1 or a fragment thereof in an amount effective to form lipid rafts in the vesicle. The synthetic vesicles can be used to deliver polynucleotides, proteins, therapeutic agents, or a combination thereof... Agent: Patrea L. Pabst Pabst Patent Group LLP

20070275914 - Therapeutic compositions: Therapeutic sRNA agents and methods of making and using are enclosed.... Agent: Fish & Richardson PC

20070275915 - Tmprss2 regulatory sequences and uses thereof: The present invention generally relates to substances and methods useful for the treatment of neoplastic disease. More specifically, it relates to cancer selective promoters and their use in oncolytic adenoviral vectors. The oncolytic adenoviral vectors are useful in methods of gene therapy. The promoters and the oncolytic adenoviral vectors are... Agent: Ropes & Gray LLP Patent Docketing 39/361

20070275926 - Treatment of disorders of the peripheral nervous system: Pleiotrophin is used to treat various conditions, disorders, and diseases which involve damage to the peripheral nervous system. Such conditions include traumatic nerve damage, Charcot-Marie-Tooth disease, amyotrophic lateral sclerosis, spinobulbar muscular atrophy, spinal muscular atrophy, diabetic neuropathy, and uremic neuropathy. Pleiotrophin can be provided as a protein or as a... Agent: Banner & Witcoff, Ltd.

20070275927 - Cosmetic use of polysaccharide compounds containing non-polymer siloxane graft(s): The invention relates to the cosmetic use of polysaccharide compounds containing non-polymer siloxane graft(s) that may be obtained by reacting a polysaccharide and a siloxane compound corresponding to formula (I), especially for the cosmetic treatment of keratin materials. The invention also relates to compositions comprising the said polysaccharide compounds in... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070275928 - Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes: or repaglinide and at least one other antidiabetic compound selected from the group consisting of thiazolidinedione derivatives (glitazones), sulfonyl urea derivatives and metformin for simultaneous, separate or sequential use in the prevention, delay of progression or treatment of diseases, especially metabolic disorders and in particular type 2 diabetes and diseases... Agent: Novartis Corporate Intellectual Property

20070275929 - Composition and method for controlling the transmission of noroviruses: Antimicrobial compositions having a rapid effectiveness against noroviruses and against bacteria are disclosed. The antimicrobial compositions contain a disinfecting alcohol, an organic acid, and water, wherein the composition has a pH of about 5 or less and the nonvolatile components of the composition are capable of forming a barrier film... Agent: Marshall, Gerstein & Borun LLP (dial)

20070275931 - Bisphosphonate compounds and methods: The invention provides, inter alia, novel bisphosphonate compounds and methods of making and using. In embodiments, the invention provides compounds and methods in connection with research and therapeutic applications, e.g., for tumor cell growth inhibition, activation of gammadelta T cells, inhibition of farnesyldiphosphate (FPPS) and/or undecaprenyldiphosphate synthase enzymes, bone resorption... Agent: Greenlee Winner And Sullivan P C

20070275932 - Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders: Disclosed are aryl, heteroaromatic and bicyclic aryl nitrone compounds and pharmaceutical compositions containing such derivatives. The disclosed compositions are useful for preventing and/or treating pain, neurodegenerative, autoimmune and inflammatory diseases or conditions in mammals.... Agent: Jones Day

20070275933 - Method for the treatment of acne: A method for treatment of acne with tetracyclines is provided. A lower sustained dose and no loading dose is employed, with an optional once-a-day dosing regimen.... Agent: Knobbe Martens Olson & Bear LLP

20070275934 - Treatment of pancreatic cancer with active vitamin d compounds in combination with other treatments: The present invention relates to a method for treating or ameliorating pancreatic cancer in an animal by administering to the animal active vitamin D compounds by high dose pulse administration in combination with one or more chemotherapeutic agents or radiotherapeutic agents/treatments.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070275935 - Estratriene derivatives: Compounds and methods for modulating mesenchymal cell function, for instance smooth muscle and fibroblast proliferation or cytokine expression, and for treating conditions associated with mesenchymal cell function, for instance airway hyperresponsiveness associated with asthma. The compounds also suppress inflammation. The compounds are a class of estratriene derivates, and includes various... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070275936 - Formulations and treatment methods: The invention provides compositions comprising formula 1 steroids, e.g., 16α-bromo-3β-hydroxy-5α-androstan-17-one hemihydrate and one or more excipients, including compositions that comprise a liquid formulation comprising less than about 3% v/v water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds... Agent: Hollis-eden Pharmaceuticals, Inc.

20070275939 - Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis: The sulfated oxysterol 5-cholesten-3β, 25-diol 3-sulphate, a nuclear steroid metabolite that increases cholesterol secretion and degradation, is provided as an agent to lower intracellular and serum cholesterol and/or triglycerides. Methods which involve the use of this sulfated oxysterol to treat conditions associated with high cholesterol and/or high triglycerides (e.g. hypercholesterolemia,... Agent: Whitham, Curtis & Christofferson & Cook, P.C.

20070275937 - Therapeutic treatment methods: The invention relates to the use of compounds to ameliorate or treat a condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3β-hydroxy-17β-aminoandrost-5-ene, 3β-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3α-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3β-hydroxy-16β-fluoro-17β-aminoandrost-5-ene, 1α,3β-dihydroxy-4α-fluoroandrost-5-ene-17-one, 1α,3β,17β-trihydroxy-4α-fluoroandrost-5-ene, 1β,3β-dihydroxy-6α-bromoandrost-5-ene, 1α-fluoro-3β,12α-dihydroxyandrost-5-ene-17-one, 1α-fluoro-3β,4α-dihydroxyandrost-5-ene and 4α-fluoro-3β,6α,17β-trihydroxyandrostane.... Agent: Hollis-eden Pharmaceuticals, Inc.

20070275938 - Therapeutic treatment methods: The invention relates to the use of compounds to ameliorate or treat a condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3β-hydroxy-17β-aminoandrost-5-ene, 3β-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3α-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3β-hydroxy-16β-fluoro-17β-aminoandrost-5-ene, 1α,3β-dihydroxy-4α-fluoroandrost-5-ene-17-one, 1α,3β,17β-trihydroxy-4α-fluoroandrost-5-ene, 1β,3β-dihydroxy-6α-bromoandrost-5-ene, 1α-fluoro-3β,12α-dihydroxyandrost-5-ene-17-one, 1α-fluoro-3β,4α-dihydroxyandrost-5-ene and 4α-fluoro-3β,6α,17β-trihydroxyandrostane.... Agent: Hollis-eden Pharmaceuticals, Inc.

20070275940 - Composition containing vitamin d and phytoestrogens: The present invention relates to compositions and methods for preventing the development of epithelial ovarian cancer by administering compounds in an amount capable of regulating TGF-β expression in the ovarian epithelium and/or capable of optimally altering expression of other surrogate biomarkers identified by microarray technology. HRT and OCP regimens comprising... Agent: Jenner & Block, LLP

20070275941 - Salt sensitivity and prevention of hypertension with drospirenone: The present invention relates to the use of drospirenone for manufacture of a medicament for prevention of development of high blood pressure (>140/90 mm Hg) in a patient who is predisposed to develop high blood pressure. The present invention further refers to methods of prevention of development of high blood... Agent: Millen, White, Zelano & Branigan, P.C.

20070275942 - Compositions and uses of et 743 for treating cancer: Et 743 is used in the preparation of a medicament for the treatment of the human body for cancer.... Agent: King & Spalding

20070275943 - Method and composition for treatment or prophylaxis of amyloidosis disorders: A method of treatment or prophylaxis of amyloidosis disorders in a patient the method comprising topically applying to an area of skin of the patient a composition comprising: one or more zinc chelators; and one or more dermal penetration enhancers.... Agent: Foley And Lardner LLP Suite 500

20070275944 - Antioxidants and methods of their use: The invention relates to compounds and compositions to treat some neurodegenerative diseases. In some embodiments, the invention relates to an antioxidant comprising a selenium atom and nitroxide group. In further embodiments, the antioxidant comprises peroxidase and superoxide dismutase activity. In some embodiments, the antioxidants are effective in treating neurodegenerative diseases... Agent: Medlen & Carroll, LLP

20070275945 - Immobilized 1,2-benzisothiazolin-3-one: The present invention provides novel antimicrobial immobilized 1,2-benzisothiazolin-3-one/zinc oxide (BIT/ZnO) complexes useful as antimicrobial agents because of their resistance to being leached from the substrate to which they are attached. The present invention is also directed to methods for preparing the BIT/ZnO complexes, to BIT/ZnO complexes prepared by the novel... Agent: Robert F. Tavares C/o Troy Corporation

20070275946 - Cytokine inhibitors: e

20070275947 - Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.... Agent: Louis J. Wille Bristol-myers Squibb Company

20070275948 - 7-[4-(4-chlorobenzyloxy)benzenesulfonyl]-8-methoxy-3-methyl-2,3,4,5-tetrahydro-1h-3-benzazepinium maleate or tosylate as antipyschotics: The present invention relates to novel salts of 7-[4-(4-chlorobenzyloxy)benzenesulfonyl]-8-methoxy-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine and a pharmaceutically acceptable solvate thereof, pharmaceutical formulations, processes for their preparation, and their use in medicine. The chemical entities are useful in therapy, in particular as antipsychotic agents.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070275949 - Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases: The present invention relates to substituted-2,3,4,5-tetrahydro-3-benzazepine derivatives that are modulators of the 5HT2C receptor. Accordingly, compounds of the present invention are useful for the prophylaxis treatment of 5HT2C receptor associated diseases, conditions or disorders, such as, obesity and related disorders.... Agent: Fish & Richardson P.C.

20070275950 - 2-phenylpyridine derivative: The present invention relates to a novel 2-phenylpyridine derivative or a salt thereof, wherein the pyridine ring is substituted with a carboxyl group or the like and the benzene ring has an electron-withdrawing group such as a cyano group and an electron-donating group such as a substituted alkoxy group at... Agent: Sughrue-265550

20070275951 - Selected cgrp-antagonists, process for preparing them and their use as pharmaceutical compositions: wherein A and R1 to R3 are defined as in claim 1, the tautomers, the diastereomers, the enantiomers, the hydrates thereof, the mixtures thereof and the salts thereof and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids, pharmaceutical compositions containing these compounds,... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070275952 - Tie-2 modulators and methods of use: The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinases, particularly Tie-2. Methods of using the compounds and pharmaceutical compositions thereof to treat kinase-dependent diseases and... Agent: Mcdonnell Boehnen Hulbert @ Berghoff LLP

20070275953 - 2-pyridinone derivatives, having hiv inhibiting properties: The present invention relates to 2-Pyridinone derivatives, more specifically 5-ethyl-6-methyl-2-pyridinone derivatives, according to general formula I that inhibit human immunodeficiency virus type 1 (HIV-1) replication and are therefore of interest in the treatment of Acquired Immune Deficiency Syndrome (AIDS). The present invention further relates to the synthesis of said compounds... Agent: Merchant & Gould PC

20070275954 - Novel fused heterocycles and uses thereof: This invention relates to novel compounds having the Formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment or prophylaxis of H. pylori infection.... Agent: Astrazeneca R&d Boston

20070275955 - Method of treating tumors: A method of treatment for preventing or reducing tumor growth in a patient includes administering to the patient an effective about of taurolidine, taurultam or a mixture thereof, so as to prevent or reduce the tumor growth in the patient.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070275956 - Novel heterocyclic compounds: Disclosed are novel compounds of formula (I, having hypolipidaemic and hypocholesterolemic properties, their tautomeric forms, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them.... Agent: Nixon & Vanderhye, PC

20070275957 - Use of n-desmethylclozapine to treat human neuropsychiatric disease: Disclosed herein is a method to treat neuropsychiatric diseases including psychosis, affective disorders, dementia, neuropathic pain, and glaucoma. Treatment is carried out by administering a therapeutically effective amount of N-desmethylclozapine to a patient suffering from a neuropsychiatric disease.... Agent: Knobbe Martens Olson & Bear LLP

20070275958 - Use of oxicam compounds: The invention relates to the use of lornoxicam or analogues thereof which inhibit cyclo-oxygenase 1 and cyclo-oxygenase 2 (COX 1 and COX 2), cannot penetrate the blood-brain barrier under physiological conditions, and reduce the prostaglandin E2-induced induction of the amyloid-precursor-protein (APP), for producing a pharmaceutical composition for the treatment or... Agent: Fulbright & Jaworski L.L.P.

20070275959 - Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents: Carbamoyl esters inhibit cholinesterase activity and, upon hydrolysis release a pharmacologically active agent. In one embodiment, the carbamoyl ester has the following structure: Formula (I) wherein A is selected from the group consisting of an unsubstituted aryl, a substituted aryl, an unsubstituted heteroaryl and a substituted heteroaryl. The carbamoyl esters... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070275960 - Phenyl and pyridyl compounds for inflammation and immune-related uses: r

20070275961 - Triazolo ' 1, 5-a ! pyrimidines and their use in medicine: Compounds of formula (IA) or (AB) are kinase inhibitors, especially of CDK2, and/or PDK1 and/or CHK1: wherein Ring A is an optionally substituted aryl, heteroaryl, carbocyclic or heterocyclic radical, Alk represents an optionally substituted clivaient C1-C6 alkylene radical; n is 0 or 1; Q represents a radical of formula -(Alk1)p-(X),(Alk2)s-Z... Agent: Banner & Witcoff, Ltd.

20070275962 - Heterobicyclic compounds as pharmaceutically active agents: Described are heterobicyclic compounds such as 4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylic acid amides, 4,7-dihydro-5H-thieno[2,3-c]thiopyran 3-carboxylic acid amides, 4,7-dihydro-5H-thieno[2,3-c]pyran-3-carboxylic acid amides, or benzo[b]thiophene-3-carboxylic acid amides and pharmaceutically acceptable salts thereof, the use of these derivatives for the prophylaxis and/or treatment of various diseases such as infectious diseases, including mycobacteriainduced infections and opportunistic diseases, prion diseases,... Agent: Brooks Kushman P.C.

20070275964 - Cannabinoid receptor ligands and uses thereof: Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein.... Agent: Pharmacia Corporation Global Patent Department

20070275963 - Pyrazolo[1,5-a]pyrimidines: In its many embodiments, the present invention provides certain pyrazolo[1,5-a]pyrimidine compounds which can have utility as inhibitors of cyclin dependent kinases as well as methods of preparing such compounds. The compounds can have potential utility for the treatment, prevention, inhibition, or amelioration of one or more diseases associated with the... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070275965 - Cxcr4 modulators: The present invention is directed to novel compounds and pharmaceutical compositions that inhibit the binding of the SDF-1 chemokine to the chemokine receptor CXCR4 and/or the binding of the SDF-1 or I-TAC chemokines to the chemokine receptor CCXCKR2 (CXCR7). These compounds are useful in preventing tumor cell proliferation, tumor formation,... Agent: Townsend And Townsend And Crew, LLP

20070275966 - Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators: e

20070275967 - Pyrazolinols:

20070275968 - Substituted biphenyl derivative: R1 represents a C6-C10 aryl group which is substituted with one to three group(s) each independently selected from the group consisting of a group defined by formula R-L-, a di-(C1-C6 alkyl)amino group, a di-(C1-C6 alkyl)aminosulfonyl group, a hydroxyaminocarbonyl group, and a halogen atom, and so on; R represents a C1-C6... Agent: Morgan & Finnegan, L.L.P.

20070275969 - Nanoparticles for oral administration of pharmaceutical agents of low solubility: The present invention relates to pharmaceutical compositions for the oral administration of pharmaceutical agents having low water solubility. Those agents are solubilized with a polymer suitable for the formation of nanoparticles, especially from the EUDRAGIT L and S series which release the active agent in specific target regions of the... Agent: Novartis Corporate Intellectual Property

20070275970 - Compositions for affecting weight loss: Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are... Agent: Knobbe Martens Olson & Bear LLP

20070275971 - Insecticidal compositions: s

20070275972 - Pyridopyrazines and the use thereof as kinase inhibitors: The invention relates to novel pyrido[2,3-b]pyrazine derivatives of the general Formula I, their preparation and use as medicaments, in particular for the treatment of malignant and other disorders based on pathological cell proliferations.... Agent: Goodwin Procter L.l.p

20070275973 - Aryl fused azapolycyclic compounds: e

20070275975 - 3-quinuclidinyl amino-substituted biaryl derivatives: wherein A is N or N+—O−; n is 0, 1, or 2; Y is O, S, —NH—, and —N-alkyl-; Ar1 is both 6-membered aromatic rings; Ar2 is 5- or 6-membered aromatic rings with a —NR8R9 group, as defined herein. The compounds are useful in treating conditions or disorders prevented by... Agent: Robert Deberardine D-377/ap6a-1

20070275974 - Pharmaceutical composition of piperazine derivatives: The present invention relates to a liquid composition containing an active substance belonging to the family of substituted benzhydryl piperazines with reduced amounts of preservatives.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070275976 - N-phenylpyrazole derivatives as pesticides: The invention relates to bis-5-pyrazolyl derivatives of formula (I) or salts thereof: wherein the various symbols are as defined in the description, to processes for their preparation, to compositions thereof, and to their use for the control of pests (including arthropods and helminths).... Agent: Frommer Lawrence & Haug

20070275977 - N-oxides of pyridylmethyl -piperazine and -piperidine derivatives: wherein the substituents have the meanings given in the description, and wherein the oxidized nitrogen atom can be the nitrogen atom in the pyridyl ring of R5, or the nitrogen atom in the piperidine ring (when Z is carbon) or either one of the nitrogen atoms in the piperazine ring... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070275978 - Of at use of an antagonist compound of at least one receptor selected from a group comprising beta-adrenergic receptors, a at1, 5-ht5 and galanin receptor for preparing a pharmaceutical composition for treating rosacea: The invention relates to the use of an antagonist of at least one receptor chosen from the group comprising the beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, the 5-HT5 receptor and the galanin receptor, for the preparation of a pharmaceutical composition for treating rosacea.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20070275979 - Novel compounds: This invention relates to novel phenyl sulfone compounds having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of CNS and other disorders.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20070275980 - Amide derivatives, process for preparation thereof and use thereof as insecticide: Q2 represents a phenyl group or heterocyclic group having one or more substituents, at least one of the substituent being any of a C1-C4 haloalkoxy group, a C2-C6 perfluoroalkyl group, a C1-C6 perfluoroalkylthio group, a C1-C6 perfluoroalkylsulfinyl group and a C1-C6 perfluoroalkylsulfonyl group, an insecticide comprising the compound as the... Agent: Amin, Turocy & Calvin, LLP

20070275981 - (hetero)cyclycarboxamides for controlling pathogenic fungi: The invention relates to the use of (hetero)cyclylcarboxamides of general formula (I) and to the agriculturally useful salts thereof for controlling plant pathogenic fungi, the variables in formula (I) having the following designations: A represents phenyl or an at least monosaturated five-membered or six-membered heterocycle with 1, 2 or 3... Agent: Birch Stewart Kolasch & Birch

20070275982 - Method: A therapeutic agent for administration to a bacterium or to the environment thereof which agent comprises synergistically effective amounts of (i) an RNA polymerase inhibitor and (ii) an ALS enzyme inhibitor.... Agent: Astrazeneca R&d Boston

20070275983 - Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors: In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition,... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070275984 - Novel thieno-pyridine and thieno-pyrimidine derivatives and their use as positive allosteric modulators of mglur2-receptors: The present invention relates to novel compounds, in particular novel thieno-pyridine and thieno-pyrimidine derivatives according to Formula (I), wherein all radicals are defined in the application. The compounds according to the invention are positive allosteric modulators of metabotropic receptors—subtype 2 (“mGluR2”) which are useful for the treatment or prevention of... Agent: Gardner Groff Greenwald & Villanueva. PC

20070275985 - Triazolopyrimidines: e

20070275986 - Use of purine derivatives for the production of medicaments for the treatment of mucoviscidosis and diseases related to protein addressing errors in cells: The invention relates to the use of purine derivatives for the production of medicaments for the treatment of mucoviscidosis and diseases related to protein addressing errors in cells, said derivatives being of formula (I): where R2, R6 and R9, independently=halogen, a R—NH—, R—NH—NH—, NH2—R′—NH or R—NH—R′—NH— group, where R=straight or... Agent: Harness, Dickey & Pierce, P.L.C

20070275987 - Novel pyridopyprimidinone derivatives which are hm74a agonists: wherein R1 to R8, X, Y, m and n are as defined in the description and in the claims. The compounds of the present invention are HM74A agonists with improved properties compared to niacin and can be used for the treatment and/or prevention of diseases such as dyslipidemia, atherosclerosis, diabetes,... Agent: Hoffmann-la Roche Inc. Patent Law Department

20070275988 - Transition state structure and inhibitors of thymidine phosphorylases: The transition state structure of thymidine phosphorylase is provided, along with thymidine phosphorylase inhibitors that resemble the charge and geometry of the thymidine phosphorylase transition state. Also provided are methods of inhibiting a thymidine phosphorylase, methods of treating cancer, and methods of inhibiting angiogenesis which utilize the thymidine phosphorylase transition... Agent: Amster, Rothstein & Ebenstein LLP

20070275989 - Therapeutic treatment: A combination comprising candesartan and rosuvastatin for the prevention or treatment of arteriosclerosis and for the prevention of cardiovascular events is described.... Agent: Morgan Lewis & Bockius LLP

20070275990 - Heterocyclic spiro compound: (wherein D and G are cyclic group which may have a substituent(s) or alkyl which may have a substituent(s), W and Y are a bond or a spacer of which main chain has an atom number of 1-4, ringA and ringB are heterocyclic ring which may have a substituent(s), containing... Agent: Sughrue Mion, PLLC

20070275991 - Drug delivery from embolic agents: An embolic composition comprises microspheres formed of water-insoluble water-swellable anionic polymer having swollen diameter more than 100 μm, and a cationic camptothecin compound, preferably irinotecan. The microspheres are preferably formed of crosslinked polyvinylalcohol, preferably of ethylenically unsaturated polyvinylalcohol macromer, crosslinked with anionic ethylenically unsaturated anionic comonomer. The compositions are used... Agent: Sughrue Mion, PLLC

20070275992 - Methods for synthesizing heterocycles and therapeutic use of the heterocycles for cancers: The present invention provides methods for synthesizing novel tetrahydroquinoline derivatives that are useful for cancer chemotherapy and anti-viral applications. The present invention provides compounds useful for cancer chemotherapy and methods for the preparation of these compounds. The present invention also includes cancer chemotherapy methods.... Agent: Watov & Kipes, P.C.

20070275993 - Combinations of an anti emetic agent and an enkephalinase inhibitor: The present invention concerns new combinations of an anti-emetic agent and an enkephalinase inhibitor, the uses of said combinations for treating diarrhea and/or gastroenteritis.... Agent: Stites & Harbison PLLC

20070275994 - Novel antinfective compounds: The present invention describes novel antiinfective compounds of formula (I), process for their preparation and pharmaceutical compositions containing them.... Agent: Nixon & Vanderhye, PC

20070275995 - Thiobenzimidazole derivatives: e

20070275996 - Use of statins for the treatment of metabolic syndrome: The present invention relates to the use of a pharmaceutical composition consisting of a statin (especially fluvastatin or pitavastatin) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier for the preparation of a medicament for the prevention or treatment of metabolic syndrome (or syndrome X).... Agent: Novartis Corporate Intellectual Property

20070275998 - Deoxynojirimycin and d-arabinitol analogs and methods of using: R1 is a substituted or unsubstituted alkyl group; W1-4 are independently selected from hydrogen, substituted or unsubstituted alkyl groups, substituted or unsubstituted haloalkyl groups, substituted or unsubstituted alkanoyl groups, substituted or unsubstituted aroyl groups, or substituted or unsubstituted haloalkanoyl groups; X1-5 are independently selected from H, NO2, N3, and NH2;Y... Agent: Foley And Lardner LLP Suite 500

20070275997 - Perhexiline for treating chronic heart failure: Disclosed are methods for the treatment of chronic heart failure, comprising administering to an animal in need thereof an effective amount of perhexiline, or a pharmaceutically acceptable salt thereof, to treat said chronic heart failure. The chronic heart failure may be non-ischaemic or ischaemic. Also disclosed is the use of... Agent: Hoffmann & Baron, LLP

20070275999 - Pharmaceutical compositions containing a hypoglycemic agent(s) for improving or treating impaired glucose tolerance, borderline diabetes, insulin resistance or hyperinsulinemia: The present invention provides a pharmaceutical composition containing a hypoglycemic agent(s) as an active ingredient for improving or treating impaired glucose tolerance, borderline diabetes, insulin resistance or hyperinsulinemia. The present invention further provides a pharmaceutical composition for preventing or delaying the progression from impaired glucose tolerance, borderline diabetes, insulin resistance... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20070276000 - Chemical compounds: The present invention relates to cycloalkylidene compounds with a variety of therapeutic uses, more particularly novel naphthalene compounds that are particularly useful for selective estrogen modulation.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070276001 - Biphenyl-pyrazolecarboxamide compounds: The present invention relates to biphenyl-pyrazole compounds and in particular biphenyl-pyrazolecarboxamides. The invention further provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by antagonism or inverse agonism of the CB1 receptor, such as obesity, smoking... Agent: Edwards Angell Palmer & Dodge LLP

20070276002 - Compounds and compositions as channel activating protease inhibitors: The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating channel activating proteases, and methods for using such compounds to treat, ameliorate or prevent a condition associated with a channel activating protease, including but not limited to prostasin, PRSS22, TMPRSS11 (e.g., TMPRSS11B, TMPRSS11E), TMPRSS2, TMPRSS3, TMPRSS4 (MTSP-2),... Agent: Genomics Institute Of The Novartis Research Foundation

20070276003 - Biphenyl derivatives: wherein R1, R2, R3, R4, R5, R6, R7, W, a, b and c are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The biphenyl derivatives of this invention possess both β2 adrenergic receptor agonist and muscarinic receptor antagonist activity and therefore, such biphenyl... Agent: Theravance, Inc.

20070276004 - Pharmaceutical composition comprising an immunosuppressant for use in the treatment of skin diseases: Synergistic combinations of a macrolide T-cell immunomodulator or immunosuppressant such as 33-epichloro-33-desoxyascomycin and an emollient such as dimethicone, glycerol or isostearyl isostearate are provided, which are useful in particular in the treatment of dermatological or mucosal diseases such as dry skin or atopic or contact dermatitis.... Agent: Novartis Corporate Intellectual Property

20070276005 - Tri-substitued 2-benzhydryl 5-benzlamino-tetrahydro-pyran-4-ol and 6-benzhydryl-4-benzylamino-tetrahydro-pyran-3-ol analogues, and novel 3,6 disubstituted pyran derivatives: Novel 3,6-disubstituted pyrans, optionally with a further substituent at the 4-position, are monoamine reuptake inhibitors with activity profiles of anti-depressants.... Agent: Brooks Kushman P.C.

20070276007 - Administration of pharmaceuticals: A new administration regimen giving an extended plasma concentration profile of a H+, K+-ATPase inhibitor. The extended plasma profile is received by two or more consecutive administrations of a unit dose of a H+, K+-ATPase with 0.5-4 hours interval or by a pharmaceutical composition with extended release, which may be... Agent: White & Case LLP Patent Department

20070276006 - Method for the treatment of gastrointestinal disorders: The present invention relates to combined use of (a) a specific prostaglandin (PG) compound and (b) a H+,K+-ATPase inhibitor for the treatment of gastrointestinal disorders.... Agent: Sughrue Mion, PLLC

20070276008 - Pharmaceutical formulation comprising glycine as a stabilizer: The present invention provides pharmaceutical formulations suitable for intravenous injection comprising a lyophilized anti-ulcerative agent reconstituted in isotonic solutions suitable for intravenous administration, such as 5% dextrose or 0.9% sodium chloride. The solutions are brought to a pH of between about 9 and about 12, preferably between about pH 10... Agent: Lahive & Cockfield, LLP

20070276009 - Compositions and methods for viral inhibition: The present invention discloses methods and compositions for viral inhibition, particularly inhibition of HCV and SARS. The invention also provides compositions including carbazole derivatives useful for viral inhibition.... Agent: Novartis Vaccines And Diagnostics Inc.

20070276010 - Aminopyrazole derivatives as gsk-3 inhibitors: The present invention provides compounds of formula (I) the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers, and prodrugs, wherein R1, R2, and R3 are as defined herein; pharmaceutical compositions thereof; combinations thereof; and uses thereof in the treatment of, inter alia, conditions, diseases, and... Agent: Pfizer Inc.

20070276013 - Active substance combinations with insecticidal properties: The present invention relates to novel active substance combinations containing thiacloprid and at least one of the active substances (1) through (24) listed in the disclosure and having very good insecticidal characteristics.... Agent: Bayer Cropscience Lp

20070276011 - Plasminogen activator inhibitor-1 inhibitor: e

20070276012 - Process for preparing thiazolidinediones: This invention provides a process for reducing an exocyclic double bond at the 5-position of a thiazolidinedione moiety of a thiazolidinedione precursor comprising the steps of: a) preparing a solution or suspension of the thiazolidinedione precursor in a non-ether solvent medium with a base, and b) combining the solution or... Agent: Novartis Corporate Intellectual Property

20070276014 - High concentration topical insecticies containing pyrethroids: A topical insecticide preparation is provided which can be safe to use and avoids many common deleterious side effects of conventional topical insecticides. The topical insecticide contains a combination of a first pyrethroid insecticide effective for killing fleas, a second pyrethroid insecticide effective for killing ticks, and an insect growth... Agent: Stroock & Stroock & Lavan LLP

20070276015 - Crystal modification of torasemide: The present invention relates to the characterization of a new crystal modification III of torasemide, to a process for the preparation thereof by the use of controlled acidifying of alkaline solutions of torasemide with inorganic or organic acids with or without addition of a crystal seed, to its use as... Agent: Buchanan, Ingersoll & Rooney PC

20070276016 - Benzo[1,2,5]thiadiazole compounds: Certain amidophenyl-sulfanylamino-benzo[1,2,5]thiadiazole compounds are CCK2 modulators useful in the treatment of CCK2 mediated diseases.... Agent: Philip S. Johnson Johnson & Johnson

20070276017 - Thiadiazoline derivative: [wherein R1 represents a hydrogen atom and the like, R2 represents a hydrogen atom, —COR5 (wherein R5 represents lower alkyl and the like) and the like, R3 represents lower alkyl and the like, R4 represents aryl and the like, A represents —(CH2)n— (wherein n represents an integer of 1 to... Agent: Greenblum & Bernstein, P.L.C

20070276018 - Aziridinyl-epothilone compounds: wherein K is —O—, —S—, or —NR7—; A is —(CR8R9)—(CH2)m-Z- wherein Z is —(CHR10)—, —C(═O)—, —C(═O)—C(═O)—, —OC(═O)—, —N(R11)C(═O)—, —SO2—, or —N(R11)SO2—; B1 is hydroxyl or cyano and R1 is hydrogen or B1 and R1 are taken together to form a double bond; R2, R3, and R5 are, independently, hydrogen, alkyl,... Agent: Fitzpatrick Cella (bristol-myers)

20070276019 - Haloalkyl containing compounds as cysteine protease inhibitors: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.... Agent: Millen, White, Zelano And Branigan, P.C. C/o Berlex Biosciences

20070276020 - Dicationic compounds for activity against trichomonas vaginalis: Dicationic compounds for the treatment of T. vaginalis infections are described. The presently described compounds exhibit in vitro activity against metronidazole-sensitive and -resistant T. vaginalis isolates. Furthermore, the presently described compounds demonstrate IC50 concentrations that were not elevated in the metronidazole resistant isolate, suggesting that their activity is not affected... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20070276021 - Method for treatment of neurodegenerative disorders: A method for treatment of multiple sclerosis and other neurodegenerative diseases, disorders or conditions. An alkyl ester of imidazole carboxylic acid, preferably methyl 4-imidazolecarboxylate, is administered in a therapeutic amount. It is hypothesized that the alkyl ester of imidazole carboxylic acid serves to restore and/or maintain the intracellular/extracellular osmolyte gradient... Agent: Todd N. Hathaway

20070276022 - Optically active carboxamides: m

20070276023 - Oil-based suspension concentrates: New, oil-based suspension concentrates composed of at least one room-temperature-solid compound of the formula (I′), at least one penetrant, at least one vegetable oil, at least one nonionic surfactant and/or at least one anionic surfactant, and optionally one or more additives from the groups of the emulsifiers, foam inhibitors, preservatives,... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070276024 - Methods for treating diseases and conditions with inverse agonists and for screening for agents acting as inverse agonists: The present invention describes a method for treating a disease or condition associated with the activity of a G protein coupled receptor (GPCR) comprising administering an inverse agonist for the GPCR, alone or in combination with an agonist for the GPCR, to an organism with a disease or condition associated... Agent: Catalyst Law Group, Apc

20070276025 - Indirubin-type compounds, compositions, and methods for their use: Compounds and compositions including 6-bromo-indirubin, 5-amino-indirubin and N-methyl-indirubins and related indirubin derivatives are provided that are useful as selective modulators of glycogen synthase kinase-3, cyclin-dependent protein kinases or aryl hydrocarbon receptors. Methods of inhibiting or modulating cell growth or cell cycling are provided using the compounds of the invention. In... Agent: Jones Day

20070276026 - Hydroxybenzamide derivatives and their use as inhibitors of hsp90: m

20070276027 - Crystalline forms of [r-(r* ,r*)]-2-(4-fluorophenyl)-beta, -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid: Novel crystalline forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid (atorvastatin free acid) designated Form A and Form B, characterized by their X-ray powder diffraction pattern and solid-state NMR spectra are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia,... Agent: Warner-lambert Company

20070276028 - Pesticidal n-phenylpyrazole derivatives: The invention relates to 5-(substituted dithio- or dioxy-alkylamino)pyrazole derivatives of formula (I) or salts thereof: wherein the various symbols are as defined in the description, to processes for their preparation, to compositions thereof, and to their use for the control of pests (including arthropods and helminths).... Agent: Frommer Lawrence & Haug

20070276029 - Glutamine-containing energy imparting amino acid composition or amino acid solution: [Problems] Amino acid composition with substantially no side effects which can not only efficiently supplement energy but also elevate the motor function. [Means for Solving Problems] Energy-imparting amino acid composition or amino acid solution containing glutamine comprising proline, alanine, valine, isoleucine, lysine and the glutamine. The energy-imparting amino acid composition... Agent: Young & Thompson

20070276030 - Pyranobenzothiophene derivatives to treat infection with hepatitis c virus: wherein substitutions fat R1, R2, R3-R12, and Y are set forth in the specification; pharmaceutical compositions comprising said compound, methods of treating or preventing a Hepatitis C viral infection in a mammal comprising contacting the mammal with an effective amount of said compound or pharmaceutical compositions including said compound and... Agent: Fitzpatrick Cella (wyeth)

20070276031 - Process for purifying (-)- 9-trans-tetrahydrocannabinol: A process for separating (−)-Δ9-trans-tetrahydrocannabinol from a mixture of cannabinoids is disclosed. The process comprises at least one chromatographic step wherein a mobile phase passes trough a stationary phase. The stationary phase comprises a derivatised polysaccharide and the mobile phase comprises carbon dioxide.... Agent: Ratnerprestia

20070276032 - Use of 8-prenylnaringenin for hormone replacement therapy: The invention provides a production method for the phytoestrogen 8-Prenylnaringenin, the preparation produced by this method and the use of 8-Prenylnaringenin for the production of a medicament for the prevention and treatment of hormone-dependent osteoporosis and of peri- and postmenopausal symptoms in women.... Agent: Mayer & Williams

20070276033 - Topical formulation including stabilized water-soluble and oil-soluble compositions: A topical formulation includes a water-soluble ingredient and an oil-soluble ingredient and includes a combination of water, a rheology modifier, and a water miscible organic solvent to stabilize the composition.... Agent: Tod R Nissle

20070276034 - Compounds, compositions and methods for the treatment of synucleinopathies: Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of synucleinopathies, such as Parkinson's disease, and the manufacture of medicaments for such treatment.... Agent: Proteotech, Inc.

20070276035 - Treatment of neurotic disorders: Use of escitalopram (the S-(+)-enantiomer of citalopram) or a pharmaceutically acceptable salt thereof for the preparation of a medicament useful in the treatment of neurotic disorders is provided, including anxiety states, in particular generalized anxiety disorder and social anxiety disorder, post traumatic stress disorder, obsessive compulsive disorder and panic attacks.... Agent: Darby & Darby P.C.

20070276036 - Non-glycosidic and non-peptidic select inhibitors, and the use thereof: is described, as well as methods for their production. These compounds represent a new class of non-toxic, in vivo anti-inflammatory effective inhibitors of selectins, and do not exhibit the disadvantages of the glycosidic inhibitor complexes, and are furthermore more potent in vitro, compared to the known drug bimosiamose. Furthermore, medicaments... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070276037 - Cytoprotective effects of ethyl pyruvate: The present invention provides methods for conferring cytoprotection and treating, suppressing or reducing the incidence of ischemia. The methods make use of an ester or amide of an alpha-ketoalkanoic acid, such as ethyl pyruvate, or compositions comprising the same.... Agent: Pearl Cohen Zedek Latzer, LLP

20070276038 - Esters with antimicrobial, bioresistant and fungal resistant properties: A bromine/nitro moiety linked into the backbone of an ester or other compound over a wide range of occurrence rates provides antimicrobial, bio-resistant and fungal resistant properties for metal working fluids (MWF)s and other coatings. The moiety can be have the bromo and nitro groups linked to the same or... Agent: Clifford Kraft

20070276039 - Pharmaceutical uses for alpha2delta ligands: b

20070276041 - Ppar activity regulators:

20070276040 - Peptidyl arginine deiminase type iv inhibitor: wherein R1, R2 and R3 each independently represent a hydrogen atom or an alkyl group having 1 to 3 carbon atoms, provided that at least one of R1, R2 and R3 does not represent a hydrogen atom; R4 represents an amino group which has a substituent; and R5 represents a... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070276042 - Preparation and utility of substituted carboxylic acid compounds: The present disclosure is directed to modulators of cyclooxygenase (COX) enzymes and pharmaceutically acceptable salts and prodrugs thereof, the chemical synthesis thereof, and the medical use of such compounds for the treatment and/or management of the severity and duration of non-specific pain, tension-type pain, headache, migraine, lower back pain, sciatica,... Agent: Wilson Sonsini Goodrich & Rosati

20070276043 - Tyrosine derivatives as ppar-gamma-modulators: Compounds of general formula I, and the salts and solvates thereof, wherein R1 represents the radical 2-benzoylphenylamino; R2 represents —(CH2)s—N(COR3)-A-J-T or —(CH2)S—N(R4)—B-J-T; and s, R3, R4, A, B, J and T have the meanings disclosed in the description. These compounds are PPARγ modulators and, therefore, are useful for the treatment... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070276044 - Peeling cosmetic method using a 8-hexadecene-1,16-dicarboxylic acid: The present invention relates to a cosmetic process for treating visible and/or tactile skin irregularities, comprising the steps consisting in: (a) topically applying to the skin a composition containing, in a physiologically acceptable medium, at least 10% by weight of 8-hexadecene-1,16-dicarboxylic acid, (b) leaving the composition in contact with the... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20070276045 - Anti-bacterial compounds: e

20070276046 - Alpha-aminoamide derivatives useful as anti-inflammatory agents: Methods of using certain a-aminoamide derivatives as anti-inflammatory agents. The anti-inflammatory agents of the invention are able to reduce or even stop inflammatory s conditions substantially without side effects.... Agent: Young & Thompson

20070276047 - Modified release formulations of a bupropion salt: The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20070276048 - Unit dose formulations comprising an inhalable solution of albuterol: The present invention relates to unit dose formulations comprising an inhalable albuterol solution, wherein the inhalation albuterol solution is formulated with albuterol free base, a tonicity adjusting agent, a pH adjusting agent and water. Methods of preparing the unit dose formulation are also provided.... Agent: Wilson Sonsini Goodrich & Rosati

20070276049 - Regulation of cell membrane-mediated effects: The invention features methods of inhibiting cell membrane-mediated effects of infectious microorganisms and of a variety of factors on vertebrate cells with one or more of a family of glycerol-based compounds. The cell membrane-mediated s effects are those resulting in, for example, infection of the vertebrate cells by relevant infectious... Agent: Fish & Richardson P.C.

20070276050 - Methods for identifying ask1 inhibitors useful for preventing and/or treating cardiovascular diseases: This invention is directed to methods for identifying apoptosis signal-regulated kinase 1 (“ASK1”) inhibitors useful for preventing and/or treating cardiovascular disease. This invention also relates to methods for preventing and/or treating cardiovascular disease in an animal by administering to the animal an ASK1 inhibitor.... Agent: Harness, Dickey, & Pierce, P.l.c

20070270362 - Methods and compositions for prevention or treatment of inflammatory-related diseases and disorders: Methods and compositions are provided for treating inflammatory-related diseases and related disorders in a mammalian subject. The method provides administering to the mammalian subject one or more modulators of cyclin dependent kinase 4 (Cdk4) activity in an amount effective to reduce or eliminate the inflammatory-related disease or disorder or prevent... Agent: Woodcock Washburn LLP

20070270373 - Substituted aryl piperidinylalkynyladenosines as a2ar agonists: t

20070270374 - 2'-c-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof: The present disclosure provides 2′-C-methyl-ribofuranosyl cytidine prodrugs, methods of making 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions of 2′-C-methyl-ribofuranosyl cytidine prodrugs, and methods of using 2′-C-methyl-ribofuranosyl cytidine prodrugs and pharmaceutical compositions thereof to treat viral diseases such as hepatitis C.... Agent: Dorsey & Whitney LLP

20070270384 - Process and intermediate: The invention relates to a new process useful in the preparation of pharmaceutical compounds such as 2-{ethyl[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]quinazolin-7-yl}oxy)propyl]amino}ethyl dihydrogen phosphate (AZD1152) and intermediates used therein.... Agent: Astrazeneca R&d Boston

20070270329 - Human derived monocyte attracting purified protein product useful in a method of treating infection and neoplasms in a human body, and the cloning of full length cdna thereof: Pure peptide products, derived from either human glioma cell line U-105MG or human peripheral blood mononuclear leukocytes are provided; the products have a molecular mass of about 8,400 daltons, and the products exhibit optimal monocyte chemotactic activity at a concentration of 1 nM. The cloning of full length cDNA for... Agent: Merchant & Gould PC

20070270332 - Methods and assays useful in the treatment of alcohol dependence or alcohol abuse: A method for the treatment of alcohol abuse using daidzin and compounds analogous to daidzin is disclosed. Also disclosed is a method for screening compounds having antidipsotropic activity.... Agent: Cv Therapeutics, Inc.

20070270331 - Modulators of gluconeogenesis: The present invention provides methods of affecting gluconeogenesis by altering the levels or activity of DUSP4 and/or EGR1. Pharmaceutical compositions comprising or encoding modulators of gluconeogenesis are also disclosed.... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP (formerly Kirkpatrick&lockhart Nicholson Graham)

20070270330 - Preventing airway mucus production by administration of egf-r antagonists: Hypersecretion of mucus in the lungs is inhibited by the administration of an epidermal growth factor receptor (EGF-R) antagonist. The EGF-R antagonist may be in the form of a small organic molecule, an antibody, or portion of an antibody that binds to and blocks the EGF receptor. The ESGF-R antagonist... Agent: Bozicevic, Field & Francis LLP

20070270333 - Methods of treating acute blood loss: The present invention relates to novel methods of using blood substitutes to treat acute blood loss and novel pharmaceutical compositions comprising blood substitutes. Blood substitutes useful for the methods of the present invention can (1) induce expression of erythropoietin as tested in a cell culture under normoxic conditions, and/or (2)... Agent: Jones Day

20070270335 - Methods for alleviating deleterious effects of 3-deoxyglucosone: Disclosed is a class of compounds which inhibit the enzymatic conversion of fructose-lysine into fructose-lysine-3-phosphate in an ATP dependent reaction in a newly discovered metabolic pathway. According to the normal functioning on this pathway, fructose-lysine-3-phosphate (FL3P) is broken down to form free lysine, inorganic phosphate and 3-deoxyglucosone (3DG), the latter... Agent: Dann, Dorfman, Herrell & Skillman

20070270334 - Pegylated soluble gp130-dimers useful as a medicament: A polypeptide-dimer comprising two soluble gp130 molecules is described, wherein at least one of said soluble gp130 molecules is covalently linked to polyethylene glycol. Furthermore, a pharmaceutical composition containing said dimer and various medical uses are described.... Agent: Wilson Sonsini Goodrich & Rosati

20070270336 - Method for accelerating cutaneous barrier recovery: A method for accelerating cutaneous barrier recovery by inducing efflux of potassium ion from an epidermal cell as well as a method for preventing epidermal hyperplasia induced by inducing efflux of potassium ion from an epidermal cell are provided.... Agent: Snider & Associates

20070270340 - Adp-ribosyl transferase fusion variant proteins: The present invention relates to novel chimeric C3-like Rho antagonists and their use for promoting repair and neuron survival in injured mammalian central and peripheral nervous system and for treating or preventing cancer.... Agent: Ogilvy Renault LLP

20070270342 - Biotinylated hexadecasaccharides, preparation and use thereof: The invention concerns novel biotinylated hexadecasaccharides of general formula (I) wherein: Biot is a biotin derivative; R, R1 and R2, represent independently of one another a C1-C6 alkoxy or and —0S03; R3 represents a C1-C6 alkoxy or an —OSO3, or R3 constitutes a —O—CH2-bridge; Pe represents a saccharide concatenation; as... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20070270346 - Compositions and methods comprising prostaglandin-related compounds and trefoil factor family peptides for the treatment of glaucoma with reduced hyperemia: Compositions, methods, and pharmaceutical products related to prostaglandin-related compounds and trefoil factor family peptides are disclosed herein. Of particular interest are compositions and methods useful for the treatment of glaucoma with a reduced occurrence of hyperemia.... Agent: Allergan, Inc.

20070270344 - Compositions and methods for treating ophthalmic disorders: The present invention relates to compositions and methods for treating ophthalmic disorders of humans or animals. The present compositions and methods are highly suitable for intraocular administration into the interior of an eye and provide therapeutic effects to the eye as they are effective in stabilizing, enhancing and/or improving a... Agent: Buchanan, Ingersoll & Rooney PC

20070270347 - Methods of treating constipation by administration of nerve growth factor: Method for administering nerve growth factor to treat various psychological conditions such as of depression, bi-polar disorders, anxiety disorders, panic attacks, agoraphobia, and attention deficit syndrome, and alleviate symptoms associated with premenstrual syndrome (PMS), premenstrual dysphoric disorder (PMDD), sleep disorders, tension headaches, and constipation that arise as complications from a... Agent: Marshall, Gerstein & Borun LLP

20070270343 - Novel mutant igfbp-3 molecules that do not bind to igfs, but retain their ability to functionally bind igfbp-3 receptor: There is disclosed novel mutant IGFBP-3 polypeptides and fragments thereof that have either no binding, or diminished binding to IGFs, yet retain their ability to bind to the human IGFBP-3 receptor (“P4.33”). The present invention provides novel mutant IGFBP-3 nucleic acid sequences, and expression systems. Additional embodiments provide for screening... Agent: Davis Wright Tremaine, LLP

20070270341 - Parathyroid hormone analogues and methods of use: The present invention is directed to novel methods of treating a subject with a bone deficit disorder. The methods generally include administering to a subject in need thereof a pharmaceutically acceptable formulation comprising a parathyroid hormone (PTH) peptide analogue in a daily dose sufficient to result in an effective pharmacokinetic... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070270338 - Pdja1, a cardiac specific gene, corresponding proteins, and uses thereof: The present invention provides novel nucleic acid and protein sequences for methods and compositions for treating, screening, and diagnosing cardiovascular disease and methods for using these genes and gene products for prevention of cardiac cell death and prevention of cardiac tissue damage resulting from ischemic events in cardiac tissue, as... Agent: Klauber & Jackson

20070270345 - Periocular drug delivery for diabetic retinopathy: This invention provides reagents and methods for delivering insulin, insulinomimetic agents, and the like to a vertebrate eye via subconjunctival routes, sub-Tenon's routes, or intravitreal routes for treatment of nerve-related vision disorders such as diabetic retinopathy, and formulations useful in the practice of the disclosed methods.... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20070270337 - Pharmaceutical compositions for preventing or treating th1-mediated immune diseases: [Means for Solving] There is obtained a pharmaceutical composition provided for prevention or treatment of Th1-mediated immune diseases, which comprises as an active ingredient a substance capable of acting on the NP receptor GC-A expressed on dendritic cells to enhance cGMP production and thereby driving T cells to differentiate into... Agent: Hunton & Williams LLP Intellectual Property Department

20070270339 - Use of gpcr54 ligands for the treatment of infertility: The present invention is directed to methods and compositions for the treatment of infertility.... Agent: Marshall, Gerstein & Borun LLP

20070270348 - Compositions and methods for modulating insulin-activated nitric oxide synthase: Compositions and methods are provided for increasing nitric oxide synthesis in cells or tissues through use of a non-insulin polypeptide. The uses of the polypeptide include treatment of cancer, diabetes mellitus and hyperglycemia.... Agent: Licata & Tyrrell P.C.

20070270349 - Glutathione derivatives and their uses for the treatment of viral diseases: Glutathione derivatives (GSH) of formula (I) are provided, wherein R is a thiol protection group. The derivatives are useful for the treatment of infections from Paramyxovirus, Orthomyxovirus, Herpes Simplex Virus and Acquired Immunodeficiency Syndrome Virus.... Agent: Marshall, Gerstein & Borun LLP

20070270350 - Methods and compositions for the prevention and treatment of inflammatory diseases or conditions: The present invention relates to methods and compositions of treating or preventing inflammatory diseases or conditions in a patient comprising administering to the patient a therapeutically effective amount of a composition comprising a glutathione donor, 5-amino 4-imidazolecarboxamide ribotide (AICAR), a 3-hydroxy-3-methylgluatryl-coenzymeA (HMG-CoA) reductase inhibitor, D-threo-1-Phenyl-2-decanoylamino-3-morpholino-1-propanol HCl (D-PDMP), and/or 1,5-(butylimino)-1,5-dideoxy-D-glucitol (Miglustat),... Agent: Michael R. Krawzsenek Fulbright & Jaworski L.L.P.

20070270351 - Methods and reagents for regulation of cellular responses in biological systems: This invention provides multivalent ligands which carry or display at least one recognition element (RE), and preferably a plurality of recognition elements, for binding directly or indirectly to cells or other biological particles or more generally by binding to any biological molecule. Provided are methods for inducing cellular chemotaxis by... Agent: Greenlee Winner And Sullivan P C

20070270353 - Method for reducing pain: The present invention is direct to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivicaine, clonidine, hydromorphone, baclofen, fentanyil, buprenorphine, and sufentanil, or its pharmaceutically... Agent: Howrey LLP

20070270352 - Method of treatment: The present invention relates generally to a method for preventing, inhibiting or otherwise reducing cell death. More particularly, the present invention contemplates a method for preventing, inhibiting or otherwise reducing neuronal cell death such as during neurodegenerative disease or following trauma The method of the present invention is generally practiced... Agent: Seed Intellectual Property Law Group PLLC

20070270354 - Azasugar derivatives, heparanase inhibitors, method for preparing same, compositions containing same, use thereof: The invention concerns heparanase inhibiting compounds of general formula (I) wherein R represents a hydrogen atom, an hydroxyl radical, a —OSO3− radical, a —O—(C1-C5)alkyl radical or an —O— aralkyl radical; Z represents a COO− radical or a hydroxyl radical; X represents —OH or a saccharide unit of formula A, Y... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20070270355 - Sport drink containing amino acids and carbohydrates: A composition includes a plurality of amino acids. The plurality of amino acids includes at least one essential amino acid and at least one non-essential amino acid. The plurality of amino acids also includes at least one branch-chain amino acid. The composition also includes a source of carbohydrates. The compositions... Agent: Winstead PC

20070270356 - Substituted 9a-n-[n'-(benzenesulfonyl)carbamoyl-y-aminopropyl] and 9a-n-[n'(b-cyanoethyl)-n'-(benzenesulfonyl)carbamoyl-y-aminopropyl]derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerithomycin a: The invention relates to substituted 9a-N—[N′-(benzenesulfonyl)carbamoyl-γ-aminopropyl] and 9a-N—[N′-(β-cyanoethyl)-N′-(benzenesulfonyl)carbamoyl-γ-aminopropyl] derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerithromycin A and 5-( )-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerithronolide A, novel semisynthetic macrolide antibiotics of the azalide series, of the formula (I) wherein R represents H or cladinosyl moiety, R1 represents H or β-cyanoethyl group an R2 represents II or fluoro, chloro and methyl... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070270357 - Bifunctional macrolide heterocyclic compounds and methods of making and using the same: The present invention relates generally to the field of anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents. More particularly, the invention relates to a family of bifunctional compounds useful as therapeutic agents. These compounds have both a macrolide ring and at least one heterocyclic moiety. The present invention further relates to processes... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070270358 - Cosmetic and/or pharmaceutical composition for the treatment of the rosacea: The invention concerns a cosmetic, pharmaceutical, or medical device composition based on dimethyl sulfone to be applied on the skin, both integral and damaged, for the treatment of rosacea, acne, psoriasis, atopic dermatitis, dermatitis seborrheica, erythema intending by erythema also cutaneous flushing as it is called in the cosmetics field.... Agent: Mcglew & Tuttle, PC

20070270359 - Nucleic acid-based compounds and methods of use thereof: The invention provides compounds capable of treating against hepatitis infections, particularly hepatitis B viral infections. Compounds of the invention are nucleic acid-based and preferably comprise 2, 3, 4, 5 or 6 nucleoside units.... Agent: Elmore Patent Law Group, PC

20070270368 - Compositions and methods for modulation of mcl-1 expression: Disclosed herein are compounds, compositions and methods for modulating the expression of Mcl-1 in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.... Agent: Knobbe, Martens, Olson & Bear, LLP

20070270371 - Dosing and scheduling of oligomers: The present invention relates to a method for treating a human patient having a proliferative disorder by administering an effective amount of a pre-treatment to the patient prior to administering an effective amount of a nucleotide-based composition that inhibits the over-expression of a target gene that causes the proliferative disorder.... Agent: Kenyon & Kenyon LLP

20070270366 - Double stranded nucleic acid molecules targeted to il-4 receptor alpha: Disclosed herein are compounds, compositions and methods for modulating the expression of IL-4R alpha in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.... Agent: Knobbe, Martens, Olson & Bear, LLP

20070270364 - Helicases: This document provides methods and materials involved in diagnosing breast cancer in a mammal, identifying molecules that inhibit RNA helicase activity, and treating cancer (e.g., breast cancer).... Agent: Fish & Richardson P.C.

20070270363 - Modulation of telomere length by oligonucleotides having a g-core sequence: Modified oligonucleotides having a GGG motif sequence and a sufficient number of flanking nucleotides to modulate the telomere length of a chromosome are provided. Methods of modulating telomere length of a mammalian chromosome in vitro and in vivo are also provided, as are methods for inhibiting the division of a... Agent: Isis Pharmaceuticals Inc

20070270370 - Novel bicyclonucleoside analogues: d

20070270360 - Rna interference mediated inhibition of severe acute respiratory syndrome (sars) gene expression using short interfering nucleic acid: The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA... Agent: Mcdonnell, Boehnen, Hulbert And Berghoff, LLP

20070270367 - Rybozyme-catalyzed insertion of targeted sequences into rna: Group I intron-derived ribozymes can be modified to perform a reaction called trans insertion-splicing (TIS) where the ribozyme binds two exogenous RNA substrates and inserts a sequence from one directly into the other. Reaction products are stable, with no visible loss at extended times. The ribozyme recognizes the two substrates... Agent: Buchanan, Ingersoll & Rooney PC

20070270361 - Sars nucleic acids, proteins, vaccines, and uses thereof: Codon-optimized nucleic acids, proteins, vaccines, and antibodies are provided herein.... Agent: Fish & Richardson PC

20070270365 - Treatment of eye disorders characterized by an elevated intraocular pressure by sirnas: Sequences and protocols for treatment of eye conditions by use of RNA interference are disclosed. Target genes are selected from those responsible for aqueous flow or aqueous outflow, while particularly preferred conditions to be treated include glaucoma and uveitis.... Agent: King & Spalding

20070270369 - Use of hepatitis b x-interacting protein (hbxip) in modulation of apoptosis: Novel methods of regulating cellular apoptosis by affecting the interaction of hepatitis B X-interacting protein (HBXIP) with Survivin are described. More specifically, these novel methods of enhancing apoptosis of neoplastic cells comprises inhibiting interaction of hepatitis B X-interacting protein (HBXIP) with Survivin using siRNA or antisense compounds.... Agent: Knobbe Martens Olson & Bear LLP

20070270372 - Organ arrest, protection and preservation: The present invention relates to a method for arresting, protecting and/or preserving an organ which includes administering effective amounts of (i) a potassium channel opener or agonist and/or an adenosine receptor agonist and (ii) local anaesthetic to a subject in need thereof. The present invention also relates to a method... Agent: Venable LLP

20070270375 - Novel analgesic compounds, extracts containing same and methods of preparation: Various compounds obtained from plants of the Barringtonia species which are derived from Barringtoside A and Barringtoside C as precursor compounds which especially have an arabinopyranosyl substituent at the 21 position which may optionally be further substituted with benzoyl, dibenzoyl, methyl butanoyl, methyl butyryl or tigloyl at the 3 or... Agent: Mathews, Shepherd, Mckay, & Bruneau, P.A.

20070270376 - Combinations of hyaluronic acid and polyunsaturated fatty acids: A pharmaceutical or veterinary composition comprises a hyaluronic acid or a salt thereof or an ester of hyaluronic acid with an alcohol of the aliphatic, heterocyclic or cycloaliphatic series, or a sulphated form of hyaluronic acid, together with at least one eicosanoid or tetraenoic polyunsaturated fatty acid or an ester... Agent: Conley Rose, P.C. David A. Rose

20070270377 - Oral flora-improving agent, antibacterial agent and growth promoter: It is intended to provide an oral flora-improving agent capable of forming a favorable flora in the oral cavity and a food or a drink for improving the oral flora. An oral flora-improving agent containing as an active ingredient a ganglioside and a food, a drink, or a feed for... Agent: Young & Thompson

20070270378 - Viscous agent for ophthalmic use: An object of the present invention is to provide an eyedrop which has a relatively low viscosity before instillation but is thickened on the eyeball surface at instillation. The eyedrop containing a viscous agent for ophthalmic use, which comprises a combination of hydroxyethylcellulose and dextran, exhibits a specific and synergistic... Agent: Frishauf, Holtz, Goodman & Chick, PC

20070270380 - Compositions useful for reducing nephrotoxicity and methods of use thereof: The present invention provides compositions and methods to reduce renal damage caused by nephrotoxic drugs. The invention provides compositions comprising an anionically substituted oligosaccharide, a nephrotoxic drug and a pharmaceutically acceptable carrier, where the oligosaccharide is present in an amount effective for substantially inhibiting the nephrotoxic effect of the drug.... Agent: Greenberg Traurig, LLP

20070270379 - Inclusion complexes containing piroxicam, a cyclodextrin and arginine: The invention relates to a method for preparing a soluble inclusion complex comprising one or several active substances which are hardly soluble in an aqueous medium and are included in one or several host molecules, characterised in that it comprises the following succesive stages: (a) one or several active substances... Agent: Birch Stewart Kolasch & Birch

20070270381 - Mitochondrially targeted antioxidants: The invention provides mitochondrially targeted antioxidant compounds. A compound of the invention comprises a lipophilic cation covalently coupled to an antioxidant moiety. In preferred embodiments, the lipophilic cation is the triphenyl phosphonium cation, and the compound is of the formula P(Ph3)+XR.Z- where X is a linking group, Z is an... Agent: Seed Intellectual Property Law Group PLLC

20070270382 - Composition for protecting skin: Disclosed are a composition for protecting skin and uses thereof. The composition comprises sphingomyelin as an active ingredient and protects the skin by inhibiting skin aging, treating a skin wound and improving a skin barrier.... Agent: Mcdermott Will & Emery LLP

20070270383 - Prodrugs of hiv protease inhibitors: s

20070270385 - Substituted propane phosphinic acid esters:

20070270386 - Selective inhibitors of rock protein kinase and uses thereof: Described herein are compounds that are useful as ROCK inhibitors. These compounds, and pharmaceutically acceptable compositions thereof, are useful for treating or lessening the severity of a variety of disorders, including cardiovascular, inflammatory, neurological, or proliferative diseases or disorders.... Agent: Vertex Pharmaceuticals Inc.

20070270387 - Therapeutic cyclopentane derivatives: s

20070270388 - Uses of 1-amino-3-(n,n-dimethylamino)-propylidene-1,1-bisphosphonic acid: The present invention relates to a method for maintaining a healthy bone structure by administering to a patient a bone health promoting effective amount of a medicament containing 1-amino-3-(N,N-dimethylamino)-propylidene-1,1-bisphosphonic acid, any of its soluble salts or any of its hydrates.... Agent: Akerman Senterfitt

20070270389 - 9-aminoacyl tetracycline compounds and methods of use thereof: A compound of formula (I):... Agent: Lahive & Cockfield, LLP

20070270390 - Method of the treament of acne: A method for treatment of acne with tetracyclines is provided. A lower sustained dose and no loading dose is employed, with an optional once-a-day dosing regimen.... Agent: Knobbe Martens Olson & Bear LLP

20070270391 - 2alpha-methyl and 2beta-methyl analogs of 19,26,27-trinor-(20s)-1alpha-hydroxyvitamin d3 and their uses: This invention discloses 2α-methyl and 2β-methyl analogs of 19,26,27-trinor-(20S)-1α-hydroxyvitamin D3 and pharmaceutical uses therefor. These compounds exhibit pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis... Agent: Thomas M. Wozny Andrus, Sceales, Starke & Sawall

20070270393 - Methods and compositions for modulation of sleep cycle: Methods and compositions for modulating the circadian rhythm of a subject are provided. In practicing the subject methods, modulation of the circadian rhythm of a subject is achieved by administering to the subject an effective amount of at least one of a glucocorticoid receptor antagonist, a CRH antagonist and an... Agent: Bozicevic, Field & Francis LLP

20070270392 - Use of a cyclopentenone prostaglandin for delaying the onset and/or preventing the continuation of labour: The present invention provides the use of a cyclopentenone prostaglandin in the manufacture of a medicament for delaying the onset and/or preventing the continuation of labour in a female. Preferably the cyclopentenone prostaglandin prevents and/or reduces an inflammatory response in the reproductive system of a female. Preferably, the cyclopentenone prostaglandin... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070270395 - Inhibitors of macrophage migration inhibitory factor and methods for identifying the same: e

20070270394 - Sex steroid precursor alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cgmp phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal:

20070270396 - Geldanamycin compounds and method of use:

20070270397 - Method for indexing crystalline solid forms: Crystalline solid forms may be characterized by their unit cell parameters through a process known as indexing. An embodiment of the invention searches for the unit cell parameters of a crystalline solid form using a Monte-Carlo algorithm that incorporates certain rules to reduce search space. Another embodiment refines the results... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070270399 - New compounds 302: The present invention relates to new compounds of formula I, to pharmaceutical compositions comprising said compounds, and to the use of said compounds in therapy. The present invention further relates to processes for the preparation of compounds of formula I.... Agent: White & Case LLP Patent Department

20070270400 - New compounds 303: The present invention relates to new compounds of formula I, to pharmaceutical compositions comprising said compounds, and to the use of said compounds in therapy. The present invention further relates to processes for the preparation of compounds of formula I.... Agent: White & Case LLP Patent Department

20070270398 - New compounds iii: The present invention relates to new compounds of formula I, to pharmaceutical compositions comprising said compounds, and to the use of said compounds in therapy. The present invention further relates to processes for the preparation of compounds of formula I.... Agent: White & Case LLP Patent Department

20070270401 - Thiazolyl-dihydro-indazole: e

20070270402 - Dealkylated derivatives of pyrrolo[2,1-b]benzothiazepines with atypical antipsy-chotic activity: Derivatives of pyrrolo[2,1-b]benzothiazepines with formula (I) where A is CH—CH2C═CH; R is hydrogen, halogen, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkyl, C5-C6 cycloalkyl; R1 is 1-peperazinyl, 1-homopiperazinyl and 1-piperidinyl; R2 is hydrogen, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkyl, CHO, CH═NOH,CH2OH. The formula (I) compounds are endowed with characteristic atypical anti-psychotic activity,... Agent: Nixon & Vanderhye, PC

20070270403 - Clozapine and cocaine effects on dopamine and serotonin release in nucleus accumbens during psychostimulant behavior and withdrawal: The present invention provides methods of treating cocaine-induced pyschosis by administering an atypical antipsychotic compound in an amount sufficient to increase serotonin concentration in the nucleus accumbens of a mammal. According to the invention, atypical antipsychotic compounds include, without limitation, clozapine, risperidone, olanzepine, quetiapine, ziprasidone, sertindole, ketanserin, aripiprazole, and haloperidol,... Agent: Morgan & Finnegan, L.L.P.

20070270404 - Tuberculosis treatment using pleuromutilin derivatives: A method of preventing or treating diseases caused by Mycobacterium, comprising administering to a subject in need of such treatment an effective amount of a pleuromutilin.... Agent: D. Peter Hochberg Co. L.p.a.

20070270405 - Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.... Agent: Louis J. Wille Bristol-myers Squibb Company

20070270406 - Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.... Agent: Louis J. Wille Bristol-myers Squibb Company

20070270407 - N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones: e

20070270408 - Pharmaceutical use of substituted pyrazolo[1,5-a]pyrimidines: The use of substituted pyrazolo[1,5-a]pyrimidines for modulating the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and the use of these compounds as pharmaceutical compositions are described. Also a novel class of substituted pyrazolo[1,5-a]pyrimidines their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture... Agent: Novo Nordisk, Inc. Patent Department

20070270409 - Medicament for preventing and/or treating ischemic cardiovascular disease: e

20070270411 - Novel diazepine compounds as ligands of the melanocortin 1 and/or 4 receptors: There is provided novel diazepines that function as agonists at the melanocortin 4 receptor and as agonists at the melanocortin 1 receptor, pharmaceutical compositions containing them, methods for their use in treatment, and processes for their preparation.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070270412 - Novel pharmaceuticals: This invention relates to compounds of formula (I)... Agent: Pfizer Inc.

20070270410 - Triazoles useful as inhibitors of protein kinases: The present invention relates to inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders... Agent: Vertex Pharmaceuticals Inc.

20070270413 - Mirtazapine for the treatment of neuropathic pain: This invention relates to a method of treatment of neuropathic pain comprising administering to a subject in need of treatment for neuropathic pain a therapeutically effective dose of S(+)-mirtazapine and the use of S(+)-mirtazapine for the manufacture of a medicine for the treatment of neuropathic pain and a pharmaceutical composition... Agent: Organon Usa, Inc. Patent Department

20070270414 - Substituted benzoylguanidines, method for production and use thereof as medicament or diagnostic and medicament comprising the same: i

20070270415 - Benzothiadiazine compounds:

20070270416 - Active compound combinations having insecticidal and acaricidal properties: The invention relates to novel insecticidal active compound combinations comprising, firstly, cyclic ketoenols or other insecticidally active compounds and, secondly, further insecticidally active compounds from the group of the anthranilamides, which combinations are highly suitable for controlling animal pests, such as insects and unwanted acarides.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070270417 - Antibacterial agents: Naphthalene, quinoline, quinoxaline and naphthyridine derivatives useful in the treatment bacterial infections in mammals, particularly humans, are disclosed herein.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070270418 - Inhibitors of p38 and methods of using the same: In general, the present invention relates to compounds capable of inhibiting p38, methods for inhibiting p38 in vivo or in vitro, and methods for treating conditions associated with p38 activity or cytokine activity.... Agent: Arnold & PorterIPDocketing

20070270419 - Pyridinylpyrazolopyrimidinone derivatives as pde 7 inhibitors:

20070270420 - Heteroaryl compounds useful as inhibitors of gsk-3: The present invention relates to compounds of formula I useful as inhibitors of GSK-3 and Lck protein kinases. The present invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders, such as diabetes, Alzheimer's... Agent: Vertex Pharmaceuticals Inc.

20070270424 - Heterocyclic inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1 and methods of using the same: The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1 and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1.... Agent: Fish & Richardson PC

20070270423 - Ih-indol-5-yl-piperazin-1-yl-methanone derivatives: e

20070270422 - Aromatic compounds:

20070270421 - Novel pyridine derivative and pyrimidine derivative (1): [R1 represents C1-6 alkyl or the like; R2 and R3 represent hydrogen; R4, R5, R6, and R7 may be the same or different and each represents hydrogen, halogen, C1-6 alkyl or the like; R8 represents hydrogen or the like; R9 represents C1-6 alkyl or the like; V1 represents oxygen or... Agent: Birch Stewart Kolasch & Birch

20070270425 - Substituted pyrimidinyl oxime kinase inhibitors: 1

20070270426 - Compounds for the treatment of neurodegenerative disorders: wherein R3, R5, R7, U, X, Y and Z are as defined. Compounds of the Formula I have activity inhibiting production of Aβ-peptide. This invention also relates to pharmaceutical compositions and methods of treating diseases, for example, neurodegenerative diseases, e.g., Alzheimer's disease, in a mammal comprising compounds of the Formula... Agent: Pfizer Inc Steve T. Zelson

20070270427 - Chemical compounds: Pyrimidine derivatives, which are useful as VEGFR2 inhibitors are described herein. The described invention also includes methods of making such pyrimidine derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070270428 - Use of cyclooxygenase-2 inhibitors for the treatment of depressive disorders: r

20070270429 - Function inhibitor of effector cell: The present invention relates to a function inhibitor of an effector cell comprising a CCR5 antagonist. Since the function inhibitor of an effector cell comprising a CCR5 antagonist inhibits the function of effector cells which play an important role in formation of diseases and the like, it is effective for... Agent: Sughrue-265550

20070270430 - Methods of treating cognitive disorders using pyridyloxymethyl and benzisoxazole azabicyclic derivatives: An aminomethylpyridyloxymethyl/benzisoxazole substituted azabicyclic compound, a pharmaceutical composition comprising same, and a method of treating a cognitive disorder selected from the group consisting of Asperger's disorder, Autistic Disorder, Oppositional Defiant Disorder, and Conduct Disorder.... Agent: Pfizer Inc Steve T. Zelson

20070270431 - Preventive and/or therapeutic medicine for rheumatoid arthritis: The present invention relates to a preventive and/or therapeutic medicine for rheumatoid arthritis containing 2-benzyl-5-(4-chlorophenyl-6-[4-(methylthio)phenyl]-2H-pyridazin-3-one and methotrexate. The medicine of the present invention can be administered orally and exhibits suppressed side effects and excellent potency for suppression of arthritis.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20070270432 - Novel method: The present invention relates to a novel method of promoting neuronal growth within the central nervous system of a mammal and to compounds and pharmaceutical compositions for use in such a method.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070270433 - Thiazolo-pyrimidine/pyridine urea derivatives: e

20070270434 - Sulfonyl-substituted bicyclic compounds as modulators of ppar: The present invention relates to compounds and methods useful as inhibitors of PPAR, particularly PPARδ, and for the treatment or prevention of PPAR-mediated diseases, including metabolic diseases.... Agent: Global Patent Group - Kal Attn: Ms Lavern Hall

20070270435 - Novel compounds: R3 is hydrogen or fluoro; R4 is —NH2 or —NHSO2R5; and R5 is hydrogen, —CF3, or C1-C6 alkyl, or pharmaceutically acceptable salts thereof, at least one process for making at least one compound in accordance with Formula I; at least one method for treating at least one δ receptor associated... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20070270436 - Novel amino- and imino-alkylpiperazines: Described are novel amino- and iminoalkyl piperazines having affinity for serotonergic receptors and pharmacological compositions thereof. These compounds and their isomers, including optical isomers, enantiomers, diastereomers, N-oxides, polymorphs, hydrates, solvates and pharmaceutically acceptable salts are useful in the treatment of patients with neuromuscular dysfunction of the lower urinary tract and... Agent: Darby & Darby P.C.

20070270437 - Benzimidazole thiophene compounds: The present invention provides benzimidazole thiophene compounds pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070270438 - Cycloalkylamino acid derivatives: and to pharmaceutically acceptable salts, prodrugs, solvates or hydrates thereof; wherein B, D, E, R1, R2, R3, R4, R5, R8, m, n, p, q, r, s, t and u are as defined herein. This invention also relates to a method of using such compounds in the treatment of hyperproliferative diseases... Agent: Pfizer Inc

20070270439 - Thrombin receptor antagonists: R13 and R14 together form a spirocyclic or a heterospirocyclic ring of 3-6 atoms; Het is a mono- or bi-cyclic optionally substituted heteroaryl group; and B is a bond, alkylene, or optionally substituted alkenylene or alkynylene, wherein the remaining substituents are as defined in the specification, are disclosed, as well... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070270440 - N-benzoyl- and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the histamine-3 receptor.... Agent: Wyeth Patent Law Group

20070270441 - Combination: The invention relates to the combined administration of a PDE4 or PDE3/4 inhibitor and a disease modifying anti-rheumatic drug (DMARDs) or anti-rheumatic or anti-arthritic drug.... Agent: The Nath Law Group

20070270443 - Methods and compositions for the treatment of viral infections: Compositions for treating flu comprise an M2 inhibitor, and optionally a neuraminidase inhibitor, wherein at least one of said M2 inhibitor or said neuraminidase inhibitor is provided in an extended release dosage form.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070270442 - Combination of a cdk inhibitor and cs-682 or a metabolite thereof: A first aspect of the invention relates to a combination comprising a CDK inhibitor and 1-(2-C-cyano-2-dioxy-β-D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof. A second aspect of the invention relates to a pharmaceutical product comprising a CDK inhibitor and 1-(2-C-cyano-2-dioxy-β-D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, as a combined preparation for simultaneous, sequential... Agent: Lahive & Cockfield, LLP

20070270444 - Pyrazole compounds useful as protein kinase inhibitors: wherein Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; Rx and Ry are independently selected from T-R3, or taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-8 membered ring having 1-3 ring... Agent: Vertex Pharmaceuticals Inc.

20070270445 - Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors: The invention relates to pyrimido[5,4-e][1,2,4]triazine-5,7-diamine compounds which are useful for inhibiting protein tyrosine phosphatases, particularly PTP1B, and are useful for lowering blood glucose concentrations in mammals.... Agent: Hoffmann-la Roche Inc. Patent Law Department

20070270446 - Reversed pyrimidinone compounds as calcilytics: Calcilytic compounds and methods of preparing them are disclosed. Methods of using the calcilytic compounds are also provided.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070270447 - Compositions and methods for coating medical implants: Medical implants are provided which release an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, and/or platinum complex, thereby inhibiting or reducing the incidence of infection associated with the implant.... Agent: Seed Intellectual Property Law Group PLLC

20070270448 - Methods of using and compositions comprising a jnk inhibitor for the treatment and management of asbestos-related diseases and disorders: Methods for treating, preventing and/or managing an asbestos-related disease or disorder are disclosed. Specific embodiments encompass the administration of a JNK Inhibitor, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent and/or chemotherapy, surgery, or radiation therapy. Pharmaceutical... Agent: Jones Day

20070270449 - 5 ht receptor mediated neurogenesis: The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of a 5HTR agent, optionally in combination with one or more other neurogenic agents, to stimulate or activate the... Agent: Townsend And Townsend And Crew, LLP

20070270450 - Compositions for affecting weight loss: Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are... Agent: Knobbe Martens Olson & Bear LLP

20070270451 - Methods of preparing pimecrolimus: The present invention provides a process for the preparation of pimecrolimus from ascomycin in which ascomycin is reacted with a conversion reagent that converts ascomycin to its activated derivative at C-32. The activated ascomycin is then reacted with chloride ion. The process of the invention requires fewer process steps than... Agent: Kenyon & Kenyon LLP

20070270452 - Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders: Novobiocin analogues and pharmaceutical composition containing such compounds useful for the treatment and/or prevention of neurodegenerative disorders and autoimmune disorders.... Agent: Stinson Morrison Hecker LLP Attn: Patent Group

20070270454 - Huperzine a compound for treatment of alzheimer's disease: wherein X comprises O or S, Y comprises —O—, —S—, —CH(R4)—, —C(R4)(R5)—, —C(R4)═C(R5)—, —C≡C—, —NH— or —N(R4)—, n is 0, 1 or 2, R3 is C(═X)—(Y)n-R1 provided that R2 is H or R2 and R3 are combined to form ═CH—Ar, wherein R1, R4 and R5 independently comprise hydrogen, C1-C32 alkyl,... Agent: Birch Stewart Kolasch & Birch

20070270453 - Tricyclic modulators of the glucocorticoid receptor, ap-1, and/or nf-kb activity and use thereof: e

20070270455 - Inhibition of nf-kb: Aminoacridines are inhibitors of NF-κB. Inhibiting NF-κB leads to reactivation of p53 in cancer cells with functionally blocked p53.... Agent: Polsinelli Shalton Flanigan Suelthaus PC

20070270456 - M3 muscarinic acetylcholine receptor antagonists: Muscarinic Acetylcholine receptor antagonists and methods of using them are provided.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20070270457 - Quinolinone-carboxamide compounds as 5-ht, receptor agonists: The invention provides novel quinolinone-carboxamide 5-HT4 receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds.... Agent: Theravance, Inc.

20070270458 - Nicotinic acetylcholine receptor ligands: e

20070270459 - Overactive bladder treating drug: A therapeutic agent for overactive bladder containing tamsulosin or a pharmaceutically acceptable salt thereof as an effective ingredient.... Agent: Sughrue Mion, PLLC

20070270460 - Substituted tetrahydroisoquinoline compounds, methods of making, and their use: Disclosed are novel substituted tetrahydroisoquinoline compounds, pharmaceutical compositions containing the compounds, methods of making the compounds, and methods of using the compounds to destroy a target cell, such as a cancer cell, and to treat or prevent a cancerous condition.... Agent: Donna J. Russell

20070270461 - Fungicide: 5,7-Dibromo-8-(2-hydroxyethoxy) quinoline, 5,7-dibromo-8-(2-methoxycarbonylethoxy) quinoline, fungicidal compositions containing these compounds and methods of treating plant diseases with these compounds.... Agent: Wood, Phillips, Katz, Clark & Mortimer

20070270462 - 8-hydroxyquinoline compounds for treating a polyglutamine (polyq)-expansion disease: The present invention provides compositions and methods of treating a polyglutamine (poly Q) expansion disease in a subject using an 8-hydroxyquinoline compound.... Agent: Paul, Hastings, Janofsky & Walker LLP

20070270463 - Novel product, method and intermediates for the preparation of azetidine derivatives: The present invention relates to a novel method for the preparation of azetidine derivatives such as N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-quinol-6-ylmethylsulfonamide and the dihydrochloride thereof and N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20070270465 - Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl) piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride: The present invention relates to crystalline 2,5-dione-3-(1-methyl-1H-indol-3-yl)-4-[1-(pyridin-2-yl-methyl)piperidin-4-yl)]-1H-pyrrole mono-hydrochloride salt, a pharmaceutical formulation containing said salt and to methods for treating cancer and for inhibiting tumor growth using said salt.... Agent: Eli Lilly & Company

20070270464 - Prodrugs of curcumin analogs: The invention provides sulfur-linked and nitrogen-linked peptidic conjugates of curcumin analogs that can provide increased water solubility and photostability as compared to the corresponding unmodified curcumin analogs without sacrificing therapeutic efficacy. The conjugates, which are believed to act as prodrugs, can be used therapeutically in the same manner as the... Agent: Alston & Bird LLP

20070270466 - Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists: provided that when R1 is C2-C6 alkyl or substituted C2-C6 alkyl, R2 is hydrogen or methyl; R3a, R3b and, when X is —C(R3c)═, R3c, are each independently hydrogen, fluoro, or methyl, provided that no more than one of R3a, R3b, and R3c may be other than hydrogen; R4 is hydrogen... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070270467 - Substituted piperidines as modulators of dopamine neurotransmission: o

20070270468 - New compounds for the treatment of neurological, psychiatric or pain disorders: The present invention is directed to novel compounds, their use in therapy and pharmaceutical compositions comprising said novel compounds.... Agent: Birch, Stewart, Kolasch & Birch, LLP

20070270469 - New compounds for the treatment of neurological, psychiatric or pain disorders: The present invention is directed to novel compounds, their use in therapy and pharmaceutical compositions comprising said novel compounds.... Agent: Birch, Stewart, Kolasch & Birch, LLP

20070270470 - N-[(4,5-diphenyl-3-alkyl-2-thienyl)methyl]amine [amide, sulfonamide, carbamate and urea) derivatives as cannabinoid cb1 receptor antagonists: e

20070270471 - Compounds which potentiate glutamate receptor and uses thereof in medicine: wherein R1 is C1-6alkyl, haloC1-6alkyl, C2-6alkenyl, amino, monoC1-4alkylamino or diC1-4alkylamino; B is —N(R4)— or —O—; A and D, which may be the same or different, are —C(R5)2—; each R2, which may be the same or different, is C1-6alkyl, halogen, haloC1-6alkyl, C1-4alkoxy, haloC1-4alkoxy, cyano, nitro or amino; n is 0, 1... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070270472 - Amino, amino acid or peptide conjugates of retinoic acid: The invention provides the use of retinoyl derivatives for the cosmetic treatment or prophylaxis of wrinkles, skin aging and/or for thickening the epidermis.... Agent: Nixon & Vanderhye, PC

20070270473 - Sulfonamide compounds and uses thereof: Compounds that modulate GHS-R are described, for examples compounds formula (I)... Agent: Fish & Richardson PC

20070270474 - Pyrazole compounds for treatment of neurodegenerative disorders: m

20070270475 - 4-methoxy-pyrrolidine-2-carboxylic acid compounds and derivatives thereof as hepatitis c virus inhibitors: wherein: A represents hydroxy; D represents 4-tert-butyl-3-methoxyphenyl; E represents 1,3-thiazol-2-yl or 5-methyl-1,3-thiazol-2-yl,; G represents methoxymethyl; J represents 1,3-thiazol-2-ylmethyl, 1,3-thiazol-4-ylmethyl, 1,2-thiazol-3-ylmethyl, or 1H-pyrazol-1-ylmethyl; and salts, solvates and esters thereof; provided that when A is esterified to form —OR where R is selected from straight or branched chain alkyl, aralkyl, aryloxyalkyl, or... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070270476 - Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors: e

20070270477 - Agent for prophylaxis or treatment of metabolic syndrome: The present invention provides an agent for the prophylaxis or treatment of metabolic syndrome, which comprises 2-ethoxy-1-[[2′-(5-oxo-2,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid or a salt thereof or a prodrug thereof and a PPAR agonist-like substance in combination.... Agent: Foley And Lardner LLP Suite 500

20070270478 - Acrylonitrile derivatives for inflammation and immune-related uses: e

20070270479 - New pyrazole derivatives and diabetic medicine containing them: The present invention provides pyrazole-O-glycoside derivatives represented by the following formulae, used as a diabetic medicine.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20070270480 - Biphenyl derived thiamides as calpain inhibitors: The present invention relates to compounds derived from biphenyl with activity as calpain inhibitors. One compound of the present invention is a 2,2′-disubstituted biphenyl, where the substituents in the 2 and 2′ positions of the biphenyl skeleton are chains containing structures related to amino acids, including fragments of aminocarbonylic compounds... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070270481 - Novel combination of anticholineric and beta mimetics for the treatment of respiratory diseases: The present invention describes a combination of anticholinergic and β mimetics for the treatment of respiratory diseases including airway inflammation or obstruction such as chronic obstructive pulmonary disease (COPD) and asthma. It further comprises the preparation of this combination in a locally applied (inhaled) formulation and application in an inhalation... Agent: Venable LLP

20070270482 - Cytotoxic agents comprising new c-2 modified taxanes: The invention relates to taxanes and to novel cytotoxic agents comprising taxanes and their therapeutic use as a result of delivering the taxanes to a specific cell population in a targeted fashion by chemically linking the taxane to a cell binding agent.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20070270483 - Process for the preparation of aryloxypropylamines: wherein each of R and R1 is independently C1-C6 alkyl or an amino-protecting group; and X is a leaving group; in the presence of a basic agent; and, if desired the conversion of a compound (I) to another compound (I); and/or, if desired, the separation of an isomeric mixture of... Agent: Griffin & Szipl, PC

20070270484 - 3'-n-substituted-3-o-substituted erythronolide a derivatives: This invention generally relates to macrolides, more particularly, the invention relates to 3-N-substituted-3-O-substituted erythronolide A derivatives, which are antibacterial agents effective against gram positive or gram negative bacteria and atypical pathogens. The compounds of this invention are more particularly effective against Staphylococcus aureus, Streptococcus pneumoniae, Enterococcus faecalis, Escherichia coli, Pseudomonas... Agent: Ranbaxy Inc.

20070270485 - Byrostatin analogues, synthetic methods and uses: Biologically active compounds related to the bryostatin family of compounds, having simplified spacer domains and/or improved recognition domains are disclosed, including methods of preparing and utilizing the same.... Agent: King & Spalding LLP

20070270486 - Compositions and methods for high throughput screening of pharmacological chaperones: Assays are provided for the screening and classification of biologically active agents that alter the conformation of conformationally defective proteins. The methods of the invention find use in the identification and classification of agents with chaperone activity, particularly the identification and classification of small molecule chemical and pharmacological chaperones. The... Agent: Bozicevic, Field & Francis LLP

20070270487 - Novel process and intermediates 085: The present invention relates to a novel process suitable for large-scale production of phenyl propane derivatives as well as to novel intermediates in the process.... Agent: White & Case LLP Patent Department

20070270488 - Treatment and assays: Described is a method to predict response of tumour cells to in vivo treatment with a platinum-based chemotherapeutic agent, the method based on the determination of the expression of one or more of the genes encoding BCRP protein, wherein enhanced expression of said gene correlates with enhanced resistance to the... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20070270489 - Remedy for cartilage-related diseases: The present invention relates an agent for treating cartilage-related disease comprising as an active ingredient a substance having an EP2 and/or EP3 agonist activity. A substance having an agonist activity to EP2 and/or EP3 has effects of stimulating chondrogenesis, stimulating chondrocyte growth, stimulating chondrocyte differentiation, inhibiting cartilage calcification and inhibiting... Agent: Sughrue-265550

20070270490 - Use of (-)(3-trihalomethylphenoxy)(4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia: The present invention provides the use of (−)(3-trihalomethylphenoxy)(4-halophenyl)acetic acid derivatives and compositions in the treatment of insulin resistance, Type 2 diabetes and hyperlipidemia.... Agent: Townsend And Townsend And Crew, LLP

20070270491 - Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy: Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gamma-hydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides... Agent: Schwegman, Lundberg & Woessner, P.A.

20070270492 - Nananoic acid derivatives as dipeptidyl peptidase inhibitors: The present invention is directed to novel nananoic acid derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DPP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, particularly in the treatment of type 2 diabetes and conditions that... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20070270493 - Composition with preventive or improvement effect on stress-induced brain function impairment and related symptoms or diseases: A composition with a preventive or improvement effect on stress-induced brain function impairment and related symptoms or diseases, comprising arachidonic acid and/or a compound comprising arachidonic acid as a constituent fatty acid.... Agent: Drinker Biddle & Reath (dc)

20070270494 - Polyunsaturated fatty acid production in heterologous organisms using pufa polyketide synthase systems: Disclosed are novel acyl-CoA synthetases and novel acyltransferases, nucleic acid molecules encoding the same, recombinant nucleic acid molecules and recombinant host cells comprising such nucleic acid molecules, genetically modified organisms (microorganisms and plants) comprising the same, and methods of making and using the same. Also disclosed are genetically modified organisms... Agent: Sheridan Ross PC

20070270495 - Use of cystine or cysteine for the prevention and treatment of oxidative stress cause by haemodialysis and of acute or chronic kidney diseases: The invention discloses the use of cystine and/or cysteine for the preparation of oral medicinal products for the prevention and treatment of oxidative stress resulting from haemodialysis treatment in patients suffering from chronic kidney failure as well as for the treatment and prevention of acute or chronic kidney diseases and... Agent: Ladas & Parry

20070270496 - Pharmaceutical composition for the treatment of pathologies caused by the general response of the immune system: The present invention relates to a pharmaceutical composition consisting of amides of mono- and di-carboxylic acids and hydroxystilbenes, and may be used for the treatment of pathologies caused, sustained and/or characterised by an abnormal general response of the immune system, in both humans and animals.... Agent: Merchant & Gould PC

20070270497 - Agent for recovery from cerebral fatigue: The present invention relates to a recuperative agent for cerebral fatigue and a recuperative food for cerebral fatigue, each including as active ingredients one or more members selected from the group consisting of chlorogenic acids, caffeic acid, ferulic acid, and pharmaceutically acceptable salts thereof. According to the present invention, recuperation... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20070270498 - Therapeutic fluoroethyl ureas: e

20070270499 - Use for 2-amino-2-propane-1, 3-diols: Disclosed is the identification of specific molecular targets and cellular pathways involved in the mechanism of action of 2-amino-2-propane-1,3-diols.... Agent: Novartis Corporate Intellectual Property

20070270500 - Compositions comprising cyclohexylamines and aminoadamantanes: The invention is directed to formulations of pharmaceutical compounds, such as the Cyclohexylamines and Aminoadamantanes which have antimicrobial properties. In particular, it is directed to aqueous based formulations with reduced amounts of preservatives which allow safe and convenient administration and flexible dosing and which, in the case of oral formulations,... Agent: The Firm Of Hueschen And Sage

20070270501 - Medicaments for treating barrett's eesophagus: The present invention relates to the use of a retinoic acid antagonist in the manufacture of a medicament for the treatment or prevention of Barrett's oesophagus (Barrett's mucosa). Furthermore, the invention relates to use of a retinoic acid antagonist in the manufacture of a medicament for the treatment or prevention... Agent: Marshall, Gerstein & Borun LLP

20070270502 - Formulations decreasing particle exhalation: Formulations have been developed for pulmonary delivery to treat or reduce the infectivity of diseases such as viral infections, especially tuberculosis, SARS, influenza and respiratory synticial virus in humans and hoof and mouth disease in animals, or to reduce the symptoms of allergy or other pulmonary disease. Formulations for pulmonary... Agent: Patrea L. Pabst Pabst Patent Group LLP

20070270503 - Penetration of active substances into cells and organs: The invention relates to the use of certain cyclic acetals or ketals for improving the penetration of pharmaceutical agents into cells and organs.... Agent: Jeffrey M. Greenman

20070270505 - Gefitinib sensitivity-related gene expression and products and methods related thereto: Disclosed is the identification, provision and use of a panel of biomarkers that predict sensitivity or resistance to gefitinib and other EGFR inhibitors, and products and processes related thereto. Specifically, a method is described for selecting a cancer patient who is predicted to benefit from therapeutic administration of an EGFR... Agent: Sheridan Ross PC

20070270504 - Identification of therapeutic agents using genetic fingerprinting: Methods for identifying compounds having similar biological activity based on similarity in genetic expression profile in cells contacted with one or more of said compounds, along with specifically identified compounds, are disclosed.... Agent: Carella, Byrne, Bain, Gilfillan, Cecchi, Stewart & Olstein

20070270506 - Novel human kinases and polynucleotides encoding the same, and uses thereof: Novel human polynucleotide and polypeptide sequences are disclosed that can be used in therapeutic, diagnostic, and pharmacogenomic applications.... Agent: Lexicon Pharmaceuticals, Inc.

20070265195 - Multifunctional blood substitute: A pharmaceutical formulation capable of supplying replacement blood volume and tissue oxygenation as well as other functions, such as procoagulation and pharmacological interventions, in order to enhance survivability in patients with severe blood loss. The invention also discloses a formulation and method of using the formulation in bridging severe blood... Agent: Naval Medical Research Center Attn: (code 00l)

20070265225 - Substituted monocyclic cgrp receptor antagonists: (wherein variables A1, A2, A3, A4, m, n, J, Q, R4, Ea, Eb, Ec, R6, R7, Re, Rf, RPG and Y are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as... Agent: Merck And Co., Inc

20070265185 - Phosphorylated vimentin serving as a marker of the aggressiveness and/or invasiveness of tumors: The invention relates to a novel method used for deter-mining the aggressiveness and/or invasiveness of a tumor. The invention also relates to a method for identifying an anticancer agent that makes it possible to reduce the aggressiveness and/or invasiveness of a tumor. The invention is based on the inventors' findings... Agent: Ip Group Of Dla Piper US LLP

20070265186 - Biotin-facilitated transport in gram negative bacteria: Biotinylation of compounds such as peptides and peptidomimetics facilitates illicit transport of the compounds into Gram negative bacteria.... Agent: Mueting, Raasch & Gebhardt, P.A.

20070265189 - Insulin and igf-1 receptor agonists and antagonists: Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind... Agent: Novo Nordisk, Inc. Patent Department

20070265188 - Ldl receptor-related proteins 1 and 2 and treatment of bone or cartilage conditions: LDL receptor-related proteins 1 and 2 (LRP-1 and LRP-2) and interaction between lactoferrin and LRP-1, LRP-2, or p42/44 MAP kinase in diagnosis and treatment of disorders such as bone or cartilage disorders. Also disclosed are methods of screening for related therapeutic compounds.... Agent: Fish & Richardson PC

20070265190 - Opioid depot formulations: The present invention relates to pre-formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein at least one opioid bioactive agent is dissolved... Agent: Nixon & Vanderhye, PC

20070265187 - Oral formulations comprising bone morphogenetic proteins for treating metabolic bone diseases: Methods and formulations for the administration of a bone morphogenetic protein (BMP) anywhere along the alimentary canal of an individual are described for use in treating osteoporosis or other metabolic bone diseases.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070265191 - Pharmaceutical compositions and methods for peptide treatment: wherein X and Y are defined above, m and n are integers having a value from 1 to 20 and the sum of m+n is not greater than 25, p is an integer having a value of 0 or 1, q is an integer having a value of 0 or... Agent: Raymond E. Stauffer, Esq. C/o Carella, Byrne, Bain, Gilfillan, Cecchi,

20070265192 - Telechelic homopolyamino acids functionalized with hydrophobic groups, and their applications, especially therapeutic applications: The invention relates to novel materials based on biodegradable homopolyamino acids and which can be used for the vectorization of (an) active ingredient(s) (AI). The invention also relates to novel pharmaceutical, cosmetic, dietetic or phytosanitary compositions based on said homopolyamino acids. The aim of the invention is to produce a... Agent: Patton Boggs LLP

20070265193 - Tetraazabenzo[e]azulene derivatives and analogs thereof: e

20070265194 - Agents for the treatment of viral infections: The invention relates to methods of treating a hepatitus virus infection by administering a therapeutically effective amount of a proteasome inhibitor and a pharmaceutically acceptable carrier to a subject in need thereof. Preferably, the protesome in hibitor inhibits or regulates a ubiquitin proteasome pathway.... Agent: Fulbright & Jaworski, LLP

20070265197 - Elastin-like polymer delivery vehicles: In invention concerns elastin-like polymer (ELP) delivery compositions and methods for the use thereof. In some aspects ELP compositions may be used to deliver therapeutic nucleic acids, polypeptides of small molecules. In some aspects, in vivo delivery with ELP compositions can directed to specific target sites by the application of... Agent: Fulbright & Jaworski L.L.P.

20070265196 - Method of modulating pro-inflammatory and inflammatory activity mediated by c-reactive protein: The present invention relates generally to a method of modulating the proinflammatory activity of C-reactive protein in endothelial cells. More particularly, the present invention relates to down-regulation of proinflammatory activity of C-reactive protein in vascular endothelial cells. Accordingly, the method of the present invention is useful, inter alia, in the... Agent: Scully Scott Murphy & Presser, PC

20070265202 - Compounds that modulate trh actions: The invention relates to compounds that inhibit thyrotropin-releasing hormone (TRH) degrading ectoenzyme and/or enhance, and/or mimic the biological actions of TRH. The compounds find therapeutic application, particularly in conditions involving neuronal cell injury and disturbances in neurobiological function.... Agent: Fulbright & Jaworski L.L.P.

20070265200 - Glycol linked fgf-21 compounds: The invention provides FGF-21 compounds covalently attached to at least one polyethylene glycol molecule or derivative thereof, resulting in a biologically active polypeptide with an extended elimination half-life and a slower clearance when compared to that of non-PEGylated polypeptide. These PEGylated FGF-21 compounds and compositions are useful in treating diabetes,... Agent: Eli Lilly & Company

20070265201 - Inhibitors of inflammatory cytokine transcription derived from hcmv protein ie2: The present invention provides novel inhibitors of inflammation and methods for treating inflammation by using these inhibitors. More specifically, the present invention provides transcription inhibitors, i.e., peptide fragments derived from internal regions of the Cytomegalovirus (CMV) IE2 protein that can inhibit production of inflammatory cytokines, e.g., Interleukin 1 beta(IFN-1β) and... Agent: Baker Botts L.L.P.

20070265204 - Materials and methods for reducing inflammation by inhibition of the atrial natriuretic peptide receptor: This invention pertains to inhibitors of atrial natriuretic peptide receptor A (NPRA) function, such as small interfering RNA (siRNA), useful for reducing the inflammation associated with many human diseases, such as asthma, respiratory syncytial virus (RSV) infection, and cancers (such as melanoma, lung cancer, and/or ovarian cancer) by interfering with... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070265203 - Methods and compositions for modulation of blood-neural barrier: Methods and compositions for modulating blood-neural barrier (BNB) for the treatment of CNS conditions such as edema, and for increased drug delivery efficacy across the BNB. The present invention further relates to improved tPA treatment of ischemic cerebrovascular and related diseases in combination with antagonism of the PDGF signaling pathway.... Agent: Baker Donelson Bearman Caldwell & Berkowitz, PC

20070265198 - Nucleic acids and polypeptides of c1 bacteriophage and uses thereof: The full-length nucleic acid sequence of the C1 bacteriophage is disclosed in the present application. The specific regions of the C1 genome encoding the PlyC lysin have also been identified and sequenced. The invention relates to the pharmaceutical and diagnostic utility of these sequences and provides for development of pharmaceutical... Agent: Klauber & Jackson

20070265205 - Pesticidal proteins: The subject invention concerns new classes of pesticidally active proteins and the polynucleotide sequences that encode these proteins. In preferred embodiments, these pesticidal proteins have molecular weights of approximately 40-50 kDa and of approximately 10-15 kDa.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070265199 - Recombinant factor viii having increased specific activity: The present invention relates to recombinant factor VIII having a specific activity that is higher than that of the corresponding wild-type factor VIII. The present invention also relates to methods of making and using the recombinant factor VIII. The present invention also relates to an isolated nucleic acid molecule that... Agent: Nixon Peabody LLP - Patent Group

20070265206 - Cyclic natriuretic peptide constructs: where R, R′, Q, Y, W, Z, J, x and n are as defined in the specification, and optionally at least one prosthetic group, pharmaceutical compositions including such cyclic constructs, and methods of treating congestive heart failure or other conditions, syndromes or diseases for which induction of anti-hypertensive, cardiovascular, renal... Agent: Palatin Technologies, Inc.

20070265207 - Pharmaceutical compositions including low dosages of desmopressin: The present invention is directed to a pharmaceutical composition comprising 0.5 ng to 20 μg desmopressin and a pharmaceutically acceptable carrier. The present invention is also directed to a pharmaceutical composition comprising desmopressin and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is effective to establish a steady plasma/serum desmopressin... Agent: Goodwin Procter LLP Patent Administrator

20070265208 - Association of calpain inhibitors and reactive oxygen species trapping agents: A pharmaceutical composition comprising, as active ingredient, at least one calpain inhibitor substance and at least one reactive oxygen species trapping substance, and optionally a pharmaceutically acceptable support.... Agent: Charles A. Muserlian C/o Hedman And Costigan

20070265209 - Cosmetic or pharmaceutical oil-in-water emulsion: A cosmetic or pharmaceutical oil-in-water (o/w) emulsion including an oil phase and a water phase, where at least 40% by weight of the oil phase is a wax component or a mixture of wax components is provided. A cosmetic or pharmaceutical oil-in-water (o/w) emulsion including 15% to 35% by weight... Agent: Cognis Corporation Patent Department

20070265210 - Administration of c-glycoside compounds for protecting and/or activating gammadeltat lymphocytes: are useful for protecting and/or stimulating the activity and/or the proliferation of gamma-delta T lymphocyte cells (γδT cells), and are advantageously formulated into cosmetic/pharmaceutical compositions suited for promoting skin tissue repair, for re-equilibrating epidermal proliferation and differentiation disorders which appear with lack of sleep, and for improving the appearance of... Agent: Buchanan, Ingersoll & Rooney PC

20070265211 - Novel composition and method effective in inhibiting the atherogenic process: The present invention provides biochemical compositions effective in inhibiting an atherogenic process, comprising ascorbic acid, lysine, magnesium, cysteine, pyridoxine HCL, riboflavin, folic acid, cyanocobalamin vitamin B12, S-Adenosyl-L-Methionine (SAMe), choline bitartrate, copper glycinate, epigallocatechin gallate, quercetin, asiatic acid, and pycnogenol.... Agent: Inhouse Ip

20070265212 - Drug transport and delivery system: Described are tripeptides or tetrapeptides comprising a proteolytic enzyme cleavable amiino acid moiety as a drug or pharmacologically active site or pharmacologically active group binding, transport by blood cells and delivery system as well as to the transport and delivery system coupled drugs. Such transport and delivery system is especially... Agent: Marshall, Gerstein & Borun LLP

20070265213 - Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy: The present invention relates to a new method of adjuvant therapy in the treatment of early breast cancer, comprising administering six cycles of docetaxel, doxorubicin and cyclophosphamide to a patient in need thereof, wherein said dosages have a marked therapeutic effect when compared to other adjuvant therapies.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20070265214 - Antisense antiviral agent and method for treating ssrna viral infection: The invention provides antisense antiviral compounds and methods of their use in inhibition of growth of viruses of the picornavirus, calicivirus, togavirus and flavivirus families, as in treatment of a viral infection. The antisense antiviral compounds have morpholino subunits linked by uncharged phosphorodiamidate linkages interspersed with cationic phosphorodiamidate linkages.... Agent: Perkins Coie LLP

20070265215 - Antisense restenosis composition and method: The present invention provides an improved method for reducing the risk or severity of restenosis following cardiac angioplasty. The method includes administering to a target vessel region, a morpholino antisense compound having a phosphorus-containing backbone linkages, and spanning the start codon of a human c-myc mRNA. Also disclosed are novel... Agent: Perkins Coie LLP

20070265216 - Enhanced medical treatment in diabetic cardiomyopathy: A method of treating a living mammal having diabetic cardiomyopathy comprises administering an effective amount of an inhibitor to the mammal performing a shotgun lipidomics analysis on the mammal and determining that the treatment was successful when and if serum or tissue biopsy cardiolipin levels are increased and/or lysocardiolipin levels... Agent: Patrick W. Rasche (15060) Armstrong Teasdale, LLP

20070265220 - Methods and compositions for the specific inhibition of gene expression by double-stranded rna: The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070265221 - Methods to improve creatine kinase metabolism and contractile function in cardiac muscle for the treatment of heart failure: The present invention relates to novel treatments of mammalian and human heart failure directed at improving cardiac creatine kinase metabolism, the prime energy reserve of cardiac muscle. The invention also relates to novel treatments using gene transfer vectors to increase myocardial creatine kinase protein expression and/or creatine kinase activity, as... Agent: Wiley Rein LLP

20070265219 - Modulation of thyroid hormone receptor interactor 3 expression: Compounds, compositions and methods are provided for modulating the expression of thyroid hormone receptor interactor 3. The compositions comprise oligonucleotides, targeted to nucleic acid encoding thyroid hormone receptor interactor 3. Methods of using these compounds for modulation of thyroid hormone receptor interactor 3 expression and for diagnosis and treatment of... Agent: Isis Pharmaceuticals Inc

20070265218 - Nucleic acid and amino acid sequences relating to staphylococcus epidermidis for diagnostics and therapeutics: The invention provides isolated polypeptide and nucleic acid sequences derived from Staphylococcus epidermidis that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting... Agent: Drinker Biddle & Reath (dc)

20070265217 - Single nucleotide polymorphisms as prognostic tool to diagnose adverse drug reactions (adr) and drug efficacy: The invention provides diagnostic methods and kits including oligo and/or polynucleotides or derivatives, including as well antibodies determining whether a human subject is at risk of getting adverse drug reaction after statin therapy or whether the human subject is a high or low responder or a good a or bad... Agent: Law Office Of Karen Canaan

20070265222 - Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection: The present invention provides nucleoside aryl phosphoramidates which are precursors to inhibitors of RNA-dependent RNA viral polymerase. These compounds are precursors to inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as precursors to inhibitors of hepatitis C... Agent: Merck And Co., Inc

20070265223 - Compositions and methods of enhancing survivability and reducing injury of cells, tissues, organs, and organisms under hypoxic or ischemic conditions: The present invention provides methods, compositions, and articles of manufacture comprising adenosine, an adenosine derivative or analog, an adenosine receptor agonist, a chemical entity that is taken up by a nucleoside transporter, or a chemical entity that binds to and/or modulates a nucleoside transporter, which protect biological material from cellular... Agent: Seed Intellectual Property Law Group PLLC

20070265224 - Nucleotide mimics and their prodrugs: The present invention relates to nucleoside diphosphate mimics and nucleoside triphosphate mimics, which contain diphosphate or triphosphate moiety mimics and optionally sugar-modifications and/or base-modifications. The nucleotide mimics of the present invention, in a form of a pharmaceutically acceptable salt, a pharmaceutically acceptable prodrug, or a pharmaceutical formulation, are useful as... Agent: Morrison & Foerster LLP

20070265226 - Hydrolytically-resistant boron-containing therapeutics and methods of use: Compositions and methods of use of boron derivatives, including benzoxaboroles, benzazaboroles and benzthiaboroles, as therapeutic agents for treatment of diseases caused by fungi, yeast, bacteria or viruses are disclosed, as well as methods for synthesis of said agents and compositions thereof.... Agent: Morgan, Lewis & Bockius LLP (sf)

20070265227 - Inhibition of hiv infection fhrough chemoprophyalxis: A process is provided for protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus. Protection is achieved by administering to the primate host a combination of a pharmaceutically effective amount of a nucleoside reverse transcriptase inhibitor and a pharmaceutically effective amount of a nucleotide reverse transcriptase inhibitor... Agent: Gifford,krass,sprinkle,anderson&citkowsi, PC

20070265228 - Cinnamoyl compound and use of the same: The present invention relates to a cinnamoyl compound represented by the formula (I):... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070265229 - Pesticidal compositions: R is hydrogen, C1-C6alkyl, phenyl-C1-C4alkyl, C3-C6cycloalkyl, C2-C6alkenyl or C2-C6alkynyl; and X is N—NO2 or N—CN, in the free form or in salt form, if appropriate tautomers, in the free form or salt form, and one or more of the compounds (I) to (CLXXXIV) mentioned according to the invention and at... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20070265230 - Radiopharmaceuticals for diagnosis and therapy: A method for treating a human patient is provided, including administering a radiolabeled form of a therapeutic agent to the patient at a first substantially non-therapeutically-effective dose, wherein pharmacological activity of the therapeutic agent is not due to radioactivity of the therapeutic agent. The method also includes determining information related... Agent: Wolf, Block, Shorr And Solis-cohen LLP

20070265232 - Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives: A method of increasing the bioavailability of balsalazide by administration of an oral dosage form with food is provided, as well as an article of manufacture comprising an oral dosage form of balsalazide in a suitable container and associated with printed labeling which describes the increased bioavailability of the medication... Agent: Edwards Angell Palmer & Dodge LLP

20070265231 - Hydrazide compounds for combating animal pests: The present invention relates to new hydrazide compounds which are useful for combating animal pests, in particular insects, arachnids and nematodes and to the salts thereof. The invention also relates to a method for combating insects, nematodes and arachnids. The hydrazide compounds of the invention are described by the general... Agent: Hutchison Law Group PLLC

20070265233 - Arginine heteromers for topical administration: The invention is directed to a strategy for providing therapeutic or cosmetic benefit to skin by topically applying arginine chemically bound to a second (non-oligoarginine) compound in order to increase transepithelial delivery of arginine through a combination of increased solubility and flux across the skin. The arginine heteromers of the... Agent: King & Spalding

20070265234 - Methods for stabilizing oxidatively unstable compositions: Ophthalmic compositions and methods of preparing such compositions are disclosed.... Agent: Philip S. Johnson Johnson & Johnson

20070265235 - Methods for treating or preventing disorders using ecdysteroid compositions: This invention relates to methods and compositions which are useful in the modulation of endogenous growth hormone levels in a mammal. Also included are methods of treating a mammal which include the administration of said compositions.... Agent: Mathews, Shepherd, Mckay, & Bruneau, P.A.

20070265236 - Asthma treatment methods: The invention relates to the use of compounds to ameliorate or treat an condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3β-hydroxy-17β-aminoandrost-5-ene, 3β-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3α-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3β-hydroxy-16β-fluoro-17β-aminoandrost-5-ene, 1α,3β-dihydroxy-4α-fluoroandrost-5-ene-17-one, 1α,3β,17β-trihydroxy-4α-fluoroandrost-5-ene, 1β,3β-dihydroxy-6α-bromoandrost-5-ene, 1α-fluoro-3β,12α-dihydroxyandrost-5-ene-17-one, 1α-fluoro-3β,4α-dihydroxyandrost-5-ene and 4α-fluoro-3β,6α,17β-trihydroxyandrostane.... Agent: Hollis-eden Pharmaceuticals, Inc.

20070265237 - Pure rocuronium bromide: The invention encompasses substantially pure rocuronium bromide.... Agent: Kenyon & Kenyon LLP

20070265238 - Method for accelerating reentrainment of a circadian rhythm: Exposure to a pheromone or an analog thereof will function to accelerate the reestablishment of a disrupted circadian rhythm resultant from cross time zone travel, shift work, exposure to artificial environments or the like. Therapeutic compositions may include pheromones associated with the sex opposite that of the patient being treated,... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20070265239 - Topically applicable anti-inflammatory o/w emulsions comprising pro-penetrating glycols: Stable, topically applicable, non-greasy and non-tacky oil-in-water (O/W) anti-inflammatory emulsions, useful, e.g., for the treatment of psoriasis, contain: a. a therapeutically effective amount of at least one steroidal anti-inflammatory agent, notably clobetasol propionate; b. a pro-penetrating system which includes at least one pro-penetrating glycol and at least one other pro-penetrating... Agent: Buchanan, Ingersoll & Rooney PC

20070265240 - Sequence selective pyrrole and imidazole polyamide metallocomplexes: The present invention relates to sequence selective compounds for targeting therapeutic or diagnostic groups to polynucleotides. More particularly, the present invention relates to sequence selective targeting of metallocomplexes, such as metallodrugs and metallodiagnostics, to polynucleotides.... Agent: Buchanan, Ingersoll & Rooney LLP

20070265241 - Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance: This invention relates to use of the combined action of a nicotinic acetylcholine receptor agonist and a monoaminergic substance for the treatment of affective disorders, as well as to pharmaceutical compositions comprising these substances and chemical substances for use according to the invention.... Agent: Birch Stewart Kolasch & Birch

20070265242 - Novel carbapenem compound: i

20070265243 - Antibiotic-bound poly(caprolactone) polymer: This invention is the design and synthesis of a caprolactone monomer which bears a pendant protected carboxyl group. This monomer has been copolymerized with caprolactone in varying ratios. After polymerization, the protecting group can be removed and an antibiotic can be attached as a new pendant group. The bioactivity of... Agent: Smith Hopen, Pa

20070265244 - Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-n-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them: i

20070265245 - S-mirtazapine for the treatment of hot flush: The invention provides a method of treatment of hot flush with S-mirtazapine and the use of S-mirtazapine for the manufacture of a medicament for the treatment of hot flush.... Agent: Organon Usa, Inc. Patent Department

20070265246 - Treatment of an intestinal adenoma and/or adenocarcinoma by inhibition of notch pathway activation: The invention relates to the field of biochemistry and medicine. More specifically the invention relates to methods and pharmaceuticals for the treatment of intestinal neoplasia. The invention discloses the surprising finding that inhibitors of Notch pathway activation (for example γ-secretase inhibitors) are extremely useful in the treatment of intestinal adenoma... Agent: Trask Britt

20070265247 - Method of reducing contact lens intolerance with non-drying antihistamines: A method and preparation for reducing dry eye symptoms and promoting tear secretion in a subject in need of such treatment is disclosed. The method is useful in treating dry eye diseases. The method is also useful in reducing contact lens intolerance in the eyes. The method comprises administering to... Agent: Howery LLP

20070265249 - Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction: m

20070265250 - Imidazole compounds: Imidazole compounds, compositions, and methods of using them in leukocyte recruitment inhibition, in modulating H4 receptor expression, and in treating conditions such as inflammation, H4 receptor-mediated conditions, and related conditions.... Agent: Philip S. Johnson Johnson & Johnson

20070265248 - Substituted piperazines and methods of use: Selected substituted piperazine compounds are effective for prophylaxis and treatment of diseases, such as obesity and the like. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving activation of the melanocortin... Agent: Amgen Inc.

20070265251 - Muscarinic antagonists with parp and sir modulating activity as cytoprotective agents: The present invention relates to generally to the cytoprotective activity of mixed muscarinic inhibition/PARP modulation and in particular to the use of dual inhibitors of M1 muscarinic receptor and poly(ADP-ribose) polymerase (PARP) as neuroprotective medicaments, particularly as medicaments for the prevention and/or treatment of neurological diseases. Particularly preferred compounds are... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070265252 - 3,4-dihydro-2h-benzo[1,4]oxazine and thiazine derivatives as cetp inhibitors: The invention is directed to compounds of Formula (I) described herein useful as CETP inhibitors, compositions containing them, and methods of using them.... Agent: Philip S. Johnson Johnson & Johnson

20070265253 - Anti-inflammatory compounds: The invention relates to compounds of formula (I) or formula (II) which have anti-inflammatory activity and comprise a new class of NSAIDs. The compounds are therefore useful for treating inflammatory diseases or disorders. The invention also relates to pharmaceutical compositions containing these compounds, as well as methods of treating inflammatory... Agent: Nixon & Vanderhye, PC

20070265254 - Naphthaline derivatives as h3 inverse agonists: e

20070265255 - Synthesis, structure and use of bisoxazolidines for asymmetric catalysis and synthesis: One aspect of the invention relates to chiral bisoxazolidines and their use in asymmetric catalysis. The chiral bisoxazolidines are a novel class of compounds that is expected to find multiple applications, for example, in asymmetric synthesis. For example, a bisoxazolidine ligand enabled the catalytic enantioselective alkynylation and alkylation of a... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20070265256 - Phosphodiesterase 10 inhibitors: The present invention is directed to certain cinnoline compounds that are PDE10 inhibitors, pharmaceutical compositions containing such compounds and process for preparing such compounds. This invention is also directed to methods of treating diseases treatable by inhibition of PDE10 enzyme, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive... Agent: Jones Day

20070265257 - Morpholine compound: wherein ring A is aryl optionally having substituent(s) and the like; ring B is arylene optionally having substituent(s) and the like; m=0-2; n=1-5; X is a bond and the like; Y is a bond and the like; and Z is hydrogen atom and the like or a pharmaceutically acceptable salt... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070265258 - Quinazoline derivatives as phosphodiesterase 10 inhibitors: The present invention if directed to certain quinazoline compounds that are PDE10 inhibitors, pharmaceutical compounds containing the same and processes for preparing the same. The invention is also directed to methods of treating diseases treatable by PDE10 enzyme such as obesity, non-insulin dependent diabetes, schizophrenia or bipolar disorder, obsessive-compulsive disorder,... Agent: Jones Day

20070265259 - Proline derivatives: Novel compounds of the formula (I), in which X, Y, R1, R2, R3, R4 and n have the meaning indicated in Patent Claim 1, are inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic diseases and for the treatment of tumours.... Agent: Millen, White, Zelano & Branigan, P.C.

20070265260 - Quinazoline derivatives: or a pharmaceutically acceptable salt thereof, a hydrate thereof, a solvate thereof, an optically active compound thereof, a racemate thereof or a diastereomer mixture thereof has a superior tyrosine-specific protein kinase inhibitory activity and is useful as a pharmaceutical agent, particularly as an agent for the prophylaxis or treatment of... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070265261 - Dpp-iv inhibitors:

20070265263 - Heterocyclic inhibitors of erk2 and uses thereof: wherein Z1 and Z2 are each independently nitrogen or CH and Ring A, TmR1, QR2, UnR3, and Sp are as described in the specification. The compounds are especially useful as inhibitors of ERK2 and for treating diseases in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such... Agent: Vertex Pharmaceuticals Inc.

20070265262 - N-(6-membered aromatic ring)-amido anti-viral compounds: Disclosed are compounds having Formula (I) and the compositions and methods relating to these compounds, for treating or preventing a viral infection mediated at least in part by a virus in the Flaviviridae family of viruses, wherein A, R2, m, R, V, W, T, Z, R1, Y, and p are... Agent: Foley & Lardner LLP

20070265264 - Thia-tetraazaacenaphthylene kinase inhibitors: s

20070265265 - N-(5-membered aromatic ring)-amido anti-viral compounds: Disclosed are compounds having Formula (I) and the compositions and methods thereof for treating or preventing a viral infection mediated at least in part by a virus in the Flaviviridae family of viruses, wherein A, R2, m, R, V, W, T, Z, R1, Y, and p are disclosed herein.... Agent: Foley & Lardner LLP

20070265266 - Active agents combination exhibiting insecticidal and acaricide properties: The novel active compound combinations of cyclic ketoenols of the formula (I) and the active compounds of the formula (II) listed in the description have very good insecticidal and acaricidal properties.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070265267 - Fungicidal compositions: e

20070265268 - Hsp90 family protein inhibitors: [wherein n represents an integer of 0 to 10; R1 represents substituted or unsubstituted lower alkoxycarbonyl, substituted or unsubstituted aroyl, or the like; R2 represents —NR14R15 (wherein R14 and R15 may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted... Agent: Fitzpatrick Cella Harper & Scinto

20070265270 - Cinnoline derivatives as phosphodiesterase 10 inhibitors: The present invention is directed to certain cinnoline compounds that are PDE10 inhibitors, pharmaceutical compositions containing such compounds and process for preparing such compounds. The invention is also directed to methods of treating diseases treatable by modulation of PDE10 enzyme, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive... Agent: Jones Day

20070265269 - Water soluble esters of [n-(4-amino-2-butynyl)] with anticancer activity: The present invention relates to water soluble esters of [N-(4-amino-2-butynyl)] or 4-(N-substituted amino)-2-butynyl-1-esters and methods for production of said esters and the use of the esters for treatment of cancer.... Agent: Joyce Von Natzmer Pequignot + Myers LLC

20070265272 - Triazolopyrazine derivatives: e

20070265271 - Novel diazabicyclic aryl derivatives as cholinergy ligands: This invention relates to novel diazabicyclic aryl derivatives, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse... Agent: Birch Stewart Kolasch & Birch

20070265273 - Pyrimidin-2-amine derivatives and their use as a2b adenosine receptor antagonists: This invention is directed to new potent and selective antagonists of the A2B adenosine receptor having the general formula (I); to processes for their preparation; to pharmaceutical compositions comprising them; and to their use in therapy.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070265274 - 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide for treating mutated-ret kinase associated diseases: The invention relates to the use of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide or a pharmaceutically acceptable salt thereof for the treatment of mutated-RET kinase associated disease, especially mutated-RET kinase associated thyroid cancer.... Agent: Novartis Corporate Intellectual Property

20070265275 - Treatment of mastitis: The invention relates to the simplified treatment of mastitis with enrofloxacin or ciprofloxacin, in particular in the case of cows.... Agent: Shook, Hardy & Bacon LLP Intellectual Property Department

20070265276 - Use of flibanserin for the treatment of post-menopausal sexual desire disorders: The invention relates to the use of flibanserin for the preparation of a medicament for the treatment of post-menopausal Sexual Desire Disorders.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070265277 - Serotonin 5-ht3 receptor agonist: A serotonin 5-HT3 receptor agonist containing a compound represented by the general formula (1) [R1, R3 and R5 represent hydrogen atom, a lower alkyl group, a lower alkenyl group, a halogen atom, hydroxyl group, amino group, a lower alkoxy group, carboxyl group, carbamoyl group, or nitro group, R2 and R4... Agent: Greenblum & Bernstein, P.L.C

20070265278 - 2-phenyl-indoles as prostaglandin d2 receptor antagonists: wherein R, R2, R3, R4, R5, R6, R7 and n are as defined herein, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, a pharmaceutically acceptable prodrug thereof, or a pharmaceutically acceptable salt, hydrate or solvate of the prodrug, a pharmaceutical composition comprising a pharmaceutically effective amount of one or... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20070265279 - Use of mglur5 antagonists for the treatment of pruritic conditions: The invention relates to the use of mGluR5 antagonists for treating pruritic conditions.... Agent: Novartis Corporate Intellectual Property

20070265280 - Methods of using sodium channel blockers: e

20070265281 - Organic compounds and their uses: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.... Agent: Novartis Corporate Intellectual Property

20070265282 - Novel compounds: The invention provides new triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation.... Agent: Nixon & Vanderhye, PC

20070265283 - Xanthine oxidase inhibitor: in which R1 represents OR4 or others, in which R4 is an alkyl group having 1-8 carbon atoms which may have a substituent or the like; R2 is halogen, nitro, cyano, carboxyl, or the like; R3 is hydrogen, halogen, hydroxyl, amino, carboxyl, or the like; X is NR11, oxygen, or... Agent: Reed Smith, LLP Attn: Patent Records Department

20070265284 - Substituted 8-aminoalkylthioxanthines, and their use as inhibitors of dipeptidyl peptidase iv:

20070265285 - Quinazolinone derivatives and their use as cb agonists:

20070265286 - Quinazoline derivatives as vegf inhibitors: The invention relates to quinazoline derivatives of formula (I), wherein m is an integer from 1 to 3; R1 represents halogeno or C1-3alkyl; X1 represents —O—; R2 is selected from one of the following three groups: 1) C1-5alkylR3 (wherein R3 is piperidinyl-4-yl which may bear one or two substituents selected... Agent: Morgan Lewis & Bockius LLP

20070265291 - 2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin d2 receptor antagonists: wherein Cy1, Cy2, L1, L2, and R1 are as defined herein, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds according to Formula (I) in admixture with a pharmaceutically acceptable carrier, and a method of treating a patient suffering from a PGD2-mediated disorder including, but not... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20070265289 - 2-aminopyrimidine derivative: The invention relates to a compound useful as remedies or preventives for IKK2-related inflammatory diseases or autoimmune diseases, or that is, a 2-aminopyrimidine derivative having a 2-hydroxyphenyl group at the 6-position thereof and having a saturated cyclic group that contains one nitrogen atom, such as piperidine, at the 4-position thereof.... Agent: Sughrue Mion, PLLC

20070265290 - Heterocyclic selective androgen receptor modulators and methods of use thereof: This invention provides a class of androgen receptor targeting agents (ARTA). The agents define a new subclass of compounds, which are selective androgen receptor modulators (SARM). Several of the SARM compounds have been found to have an unexpected androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor.... Agent: Pearl Cohen Zedek Latzer, LLP

20070265287 - Method for producing 2-amino-4,6-dichloro-5-formamidopyrimidine: The invention relates to a method for producing 2-amino-4,6-dichloro-5-formamidopyrimidine from 2,5-diamino-4,6-dihydroxypyrimidine or a salt thereof. According to said method, a) 2,5-diamino-4,6-dihydroxypyrimidine or the salt or tautomer forms thereof are reacted with a chlorination agent and a formamide of formula (I) wherein R1 and R2 independently represent a C1-C4 alkyl radical... Agent: Law Office Of Michael A. Sanzo, LLC

20070265292 - N-phenyl-2-pyrimidine-amine derivatives: e

20070265288 - Stable crystal form of imatinib mesylate and process for the preparation thereof: The invention relates to a stable, non hygroscopic alpha crystalline form of methane sulfonic acid addition salt of 4-(4-methyl piperazin-1yl methyl)-N-[4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-yl amino)phenyl]-benzamide (imatinib mesylate). A process for the preparation of the crystalline form is also described.... Agent: Conley Rose, P.C.

20070265293 - (s)-n-methylnaltrexone: This invention relates to S-MNTX, methods of producing S-MNTX, pharmaceutical preparations comprising S-MNTX and methods for their use.... Agent: Wolf Greenfield & Sacks, P.C.

20070265294 - Formulations and methods for vascular permeability-related diseases or conditions: Described herein are formulations and methods for treating, inhibiting, preventing, delaying onset, or causing regression of a disease or condition relating to vascular permeability.... Agent: Morrison & Foerster LLP

20070265295 - 1-heterocyclyl-1,5-dihydro-pyrido[3,2-b]indol-2-ones: s

20070265296 - Nuclear receptor binding agents: The present invention relates to a novel class of selective estrogen receptor modulators (SERMs). The SERM compounds are applicable for use in the prevention and/or treatment of a variety of diseases and conditions including prevention and treatment of cancers such as prostate and breast cancer, osteoporosis, hormone-related diseases, hot flashes... Agent: Pearl Cohen Zedek Latzer, LLP

20070265298 - Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity: This invention relates to certain biphenyl-4-yl carbonylamino acid compounds, compositions, and methods for treating or preventing obesity and related diseases.... Agent: Jeffrey M. Greenman

20070265297 - Thiazolopyridine derivatives, pharmaceut ical conditions containing them and methods of treating glucokinase mediated conditions: i

20070265299 - Compounds for the treatment of inflammatory disorders:

20070265300 - Pyridine derivatives of alkyl oxindoles as 5-ht7 receptor active agents: The present invention is concerned with new 3,3-disubstituted indol-2-one derivatives of the general Formula (I). Compounds according to the invention are useful for the prophylaxis or treatment of the disorders of the central nervous system.... Agent: Birch Stewart Kolasch & Birch

20070265301 - Dpp-iv inhibitors: The invention relates to compounds of formula (I), wherein Z, R1-8, n, A1, X1 and X2 have the meaning as cited in the description and the claims. Said compounds are useful as DPP-IV inhibitors. The invention also relates to the preparation of such compounds as well as the production and... Agent: Kilyk & Bowersox, P.l.l.c.

20070265302 - Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-iv (dpp-iv): The present invention relates to compounds which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis, and various immunomodulatory diseases.... Agent: Robert Deberardine Abbott Laboratories

20070265304 - 1,2,3,4-tetrahydro-quinoline derivatives as cetp inhibitors: The invention is directed to compounds of Formula (I) described herein useful as CETP inhibitors, compositions containing them, and methods of using them.... Agent: Philip S. Johnson Johnson & Johnson

20070265303 - Amine derivatives: e

20070265305 - Biphenyl compounds useful as muscarinic receptor antagonists: wherein a, b, c, d, m, n, p, s, t, W, Ar1, R1, R2, R3, R4, R6, R7, and R8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such... Agent: Theravance, Inc.

20070265306 - 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions: The present patent application is directed to 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonic acid salt (formula I), its synthesis and a method for treating and/or preventing a serotonine and/or norepinephrine mediated disease or condition. The present invention is also directed to pharmaceutical compositions comprising the same.... Agent: Intellectual Property / Technology Law

20070265307 - Administration of 4-aminopiperidine compounds for inducing and/or stimulating the growth of keratin fibers and/or preventing loss thereof: Agents for inducing and/or stimulating the growth of human keratin fibers and/or preventing their loss and/or increasing their density include at least one 4-aminopiperidine compound of formula (I):... Agent: Buchanan, Ingersoll & Rooney PC

20070265308 - Nitrogenous heterocyclic compound and pharmaceutical use thereof: wherein all the symbols are as defined in the description, or its salt, N-oxide or solvate, or a prodrug thereof. Further, there are provided a process for producing the same and usage thereof. The compound of the general formula (I) has a p38 MAP kinase inhibitory activity and is useful... Agent: Sughrue-265550

20070265309 - Substituted bis aryl and heteroaryl compounds as selective 5ht2a antagonists: Wherein X, Y, Z, A, B, D, Ar, R1 and R2 are as defined herein. The compounds of this invention are selective 5HT2A antagonists, and are therefore, useful in treating a variety of diseases including but not limited to a wide variety of sleep disorders as disclosed and claimed herein.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20070265310 - Biphenyl compounds useful as muscarinic receptor antagonists: wherein a, b, c, m, p, s, t, W, Ar1, X1, R1, R2, R3, R4, R6, and R7 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and... Agent: Theravance, Inc.

20070265311 - Therapeutic salt compositions and methods: Therapeutic salt compositions and methods are disclosed herein.... Agent: Allergan, Inc.

20070265313 - 2-n butanedioic acid, methods of preparation and compositions with rosiglitazone maleate: e

20070265312 - 2-n{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate:

20070265314 - Novel polymorph forms of (2s)-(4e)-n-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine: Polymorph forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine p-hydroxybenzoate, and methods for their preparation, pharmaceutical composition containing said polymorph(s) and use, are disclosed. The polymorphs can be administered to patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, to treat and/or prevent such disorders.... Agent: Paul K. Legaard, Ph.d. Pepper Hamilton LLP

20070265315 - Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors: This invention relates to urea compounds containing a pyridine, quinoline, or isoquinoline functionality which is oxidized at the nitrogen heteroatom and which are useful in the treatment of (i) raf mediated diseases, for example, cancer, (ii) p38 mediated diseases such as inflammation and osteoporosis, and (iii) VEGF mediated diseases such... Agent: Millen, White, Zelano & Branigan, P.C.

20070265316 - Compounds having activity in increasing ion transport by mutant-cftr and uses thereof: The invention provides compositions, pharmaceutical preparations and methods for activation of the ΔF508 cystic fibrosis transmembrane conductance regulator protein (ΔF508 CFTR) that are useful for the treatment and study of cystic fibrosis (CF). The compositions and pharmaceutical preparations of the invention may comprise one or more tetrahydrobenzothiophene, benzofuran, pyramidinetrione, dihydropyridine,... Agent: Bozicevic, Field & Francis LLP

20070265317 - Modified chalcone compounds as antimitotic agents: Antimitotic agents comprising a modified chalcone or modified chalcone derivative are disclosed. The modified chalcone or modified chalcone derivative compounds are of the general formula CHAL-LIN—COV, wherein CHAL is a chalcone or chalcone derivative portion, LIN is an optional linker portion, and COV is a covalent bonding portion (e.g., an... Agent: Banner & Witcoff, Ltd.

20070265318 - Estrogen receptor modulators: The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone... Agent: Merck And Co., Inc

20070265319 - Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides: This invention relates to compounds of Formula I and the use of compounds of Formula I as neuroprotective agents in the treatment of neuronal disorders of the central and peripheral nervous systems. Formula I:... Agent: Philip Swain, Phd C/o Gowling Lafleur Henderson

20070265320 - Bicycloamide derivative: i

20070265321 - Therapeutic compounds:

20070265322 - Compounds for the treatment of metabolic disorders: Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.... Agent: Lewis J. Kreisler

20070265323 - Compounds for the treatment of metabolic disorders: Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.... Agent: Lewis J. Kreisler

20070265324 - Combination therapy with parp inhibitors: The present invention describes benzimidazole derivatives of Formula (I) which constitute potent PARP inhibitors in combination with radiotherapy or in combination with other chemotherapeutic agents.... Agent: Robert Deberardine Abbott Laboratories

20070265325 - Nitro indazole derivatives: e

20070265326 - Novel compounds:

20070265327 - Pyrazole-amine compounds for the treatment of neurodegenerative disorders: wherein R1, R3, R4, R5, R6, R7 and R8 are as defined. Compounds of the Formula I have activity inhibiting production of Aβ-peptide. The invention also relates to pharmaceutical compositions and methods of treating disorders and diseases, for example, neurodegenerative and/or neurological disorders, e.g., Alzheimer's disease, in a mammal comprising... Agent: Pfizer Inc

20070265328 - Certain substituted spirocyclic lactams and use thereof as pharmaceuticals: e

20070265329 - Methods for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (cinv): A pharmaceutical composition for the sustained release of an effective amount of a selective 5-hydroxytryptamine 3 (5-HT3) receptor antagonist for the prevention, reduction or alleviation of acute and delayed chemotherapy-induced nausea and vomiting (CINV) following a course of emetogenic chemotherapy, wherein the composition is administered by subcutaneous injection, the composition... Agent: Heller Ehrman LLP

20070265330 - Substituted gamma lactams as therapeutic agents: p

20070265331 - Novel gamma-lactams as beta-secretase inhibitors: wherein R1, R2, R3, R4 and R5 are defined herein, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein (APP) by β-secretase and, more specifically, inhibit the production of Aβ-peptide. The present invention is directed to compounds useful in the treatment of... Agent: Louis J. Wille Bristol-myers Squibb Company

20070265332 - Antidiabetic bicyclic compounds: Tricyclic compounds containing a cyclopropyl carboxylic acid or carboxylic acid derivative (e.g. amide) fused to a bicyclic ring, including pharmaceutically acceptable salts and prodrugs thereof, are agonists of G-protein coupled receptor 40 (GPR40) and are useful as therapeutic compounds, particularly in the treatment of Type 2 diabetes mellitus, and of... Agent: Merck And Co., Inc

20070265333 - Macrocyclic kinase inhibitors: i

20070265334 - Method for treating amyloidosis: Therapeutic compounds and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is inhibited by the administration to a subject of an effective amount of a therapeutic compound comprising an anionic group and a carrier molecule, or a pharmaceutically acceptable salt thereof, such... Agent: Lahive & Cockfield, LLP

20070265335 - Polymorphs of 5-cyclopropyl-2-(4-fluorophenyl)-6-[(2-hydroxyethyl)(methylsufonyl)amino]-n-methyl-1-benzofuran-3-carboxamide and methods of making the same: Substantially pure polymorphic forms of 5-cyclopropyl-2-(4-fluorophenyl)-6-[(2-hydroxyethyl)(methylsulfonyl)amino]-N-methyl-1-benzofuran-3-carboxamide are produced by recrystallization in an organic solvent.... Agent: Fitzpatrick Cella Harper & Scinto

20070265336 - Application of l-n-butylphthalide in preventing and treating dementia: The invention discloses the application of l-n-butylphthalide as formula (I) in preparing a medicine for preventing and treating dementia, in special Alzheimer's disease and vascular dementia.... Agent: Scully, Scott, Murphy & Presser, P.C.

20070265337 - Method and composition for delivering zinc to the nasal membrane: A viscous gel for delivering minor effective amounts of active substances through the nasal membrane into the body.... Agent: Snell & Wilmer L.L.P. (main)

20070265338 - Use of l-carnitine or of alkanoyl l-carnitines for the preparation of a physiological supplement or medicament for ophthalmic use in the form of eye drops: Use of L-carnitine and/or of one or more alkanoyl L-carnitines or one of their pharmaceutically acceptable salts for the preparation of an opthalmic physiological supplement or medicament in the form of eye-drops, for the treatment of corneal diseases.... Agent: Lucas & Mercanti, LLP

20070265339 - Storage-stable aqueous composition comprising a magnesium compound and l-carnitine: The present invention relates to a storage-stable aqueous or gel-like composition or solution comprising a magnesium compound selected from a magnesium salt or a magnesium complex compound, and L-carnitine, and the use thereof for the preparation of a medicament for supporting metabolism, in particular in muscle tissue, and for supporting... Agent: Renner Otto Boisselle & Sklar, LLP

20070265341 - Compositions and methods for treating eye disorders and conditions: The present invention relates to compositions comprising omega-6 and/or omega-3 fatty acids and uses thereof. The present invention also relates to methods of treatment using such compositions.... Agent: Cozen O'connor, P.C.

20070265340 - Treatment of fatty liver: Methods and compositions comprising peroxisomal and/or mitochondrial beta oxidation stimulating agents to reverse or resolve, slow the progression of, treat or prevent the development of fatty liver and conditions stemming from fatty liver, such as NASH, liver inflammation, cirrhosis and liver failure. An active agent that by itself is associated... Agent: Arent Fox LLP

20070265342 - Prodrugs of excitatory amino acids: This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.... Agent: Eli Lilly & Company

20070265343 - Method for alleviating signs and symptoms of spasticity: A method of alleviating signs and symptoms of spasticity in human patient comprising orally administering to said human patients once in a day a controlled drug delivery system comprising an effective daily dose of baclofen or its pharmaceutically acceptable salt. The controlled drug delivery system is operable to produce a... Agent: Sughrue Mion, PLLC

20070265344 - Non-steroidal anti-inflammatory oral powder and liquid preparations for administration to animals: A soluble formulation of a non-steroidal anti-inflammatory drug that can be orally administered to animals. The formulation includes a non-steroidal anti-inflammatory drug, a base of an amino acid, and a strong base. The formulation can be prepared in a dry or liquid form. The formulation can be dissolved in an... Agent: Crowell & Moring LLP Intellectual Property Group

20070265345 - Novel biphenyl compounds and their use: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and Y are as defined below, and to pharmaceutically-acceptable salts thereof. The compounds of the invention are KSP inhibitors, particularly human KSP inhibitors, and can be useful for the treatment for a variety of diseases and conditions, such as cancer,... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070265346 - Combination therapy for the treatment and improvement of scars: The present invention is a composition, methods of using that composition and kits including that composition, useful for reducing the size and improving the appearance of a closed wound wherein the composition comprises a therapeutically effective amount of a hydrophilic or hydrophobic carrier (or a mixture thereof), at least one... Agent: Brinks Hofer Gilson & Lione

20070265347 - Encapsulated oil-in-water type emulsion composition: Encapsulated oil-in-water type emulsion compositions, which comprise an acylamino acid alkylamide or an acylglutamine alkyl ester, an oily base, a polar solvent and water, do no exhibit coalescence of the dispersed phase, and can be produced by a simple method without resort to a special apparatus, are excellent in stability... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20070265348 - Therapeutic guanidines: The present invention provides therapeutically useful substituted guanidines, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more of such guanidines.... Agent: Fish & Richardson P.C.

20070265349 - Medicinal association of a biguanine and a carrier, for example metformin and arginine: A medicinal combination for the treatment of diabetes, in particular of type 2 diabetes, combining a biguanide, in particular an N-dimethylbiguanide, as a first medicament, and an agent for transporting the said biguanide, as a second medicament, said combination comprising: e [sic] a therapeutically active quantity of the biguanide f... Agent: Oliff & Berridge, PLC

20070265350 - Method of identifying compounds useful to treat neuronal degenerative diseases: Methods of identifying agents that inhibit ROS by altering the binding of a GTPase such as Rac to SOD, agents identified by the method, and methods of using compounds that inhibit ROS to inhibit or treat neuronal degenerative diseases, are provided.... Agent: Schwegman, Lundberg & Woessner, P.A.

20070265351 - Novel xanthophyll composition containing trans, meso-zeaxanthin, trans, r, r-zeaxanthin and trans, r, r-lutein useful for nutrition and health care and a process for its preparation: The present invention relates to xanthophyll composition containing (trans, meso)-zeaxanthin), (trans, R,R)-zeaxanthin and (trans, R,R)-lutein useful for nutrition and health care and a process for its preparation. More particularly, the invention relates to a xanthophylls composition containing at least 80% by weight of total xanthophylls, out of which the (trans,3R,3′S,... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20070265352 - Synergistic mixtures of at least one 1,2 alkanediol such as 1,2-hexanediol and 1,2-octanediol with a further compound having antimicrobial properties: Antimicrobial active compositions and substances comprising at least one, preferably two, unbranched (straight-chain) 1,2-alkanediols and preferably a further preservative and also to products containing such mixtures in an antimicrobially effective quantity. One example of an antimicrobial mixture comprises: (a) 1,2-hexanediol and 1,2-octanediol and also optionally 1,2-pentanediol and/or 1,2-decanediol and (b)... Agent: Akerman Senterfitt

20070265353 - Eye drops for the treatment of dry eye: Eye drops for the treatment of dry eye is disclosed. The eye drops is a solution-type, emulsion-type or two separate phase-type eye drops containing squalane and is, among others, an oil-in-water-type emulsion further containing a water-soluble macromolecular compound such as polyvinylpyrrolidone. Also disclosed are use of squalane for the production... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20070265354 - Silicon structure: The invention concerns a silicon structure comprising a metallic component and a silicon component, the metallic component and the silicon component being arranged such that at least part of the silicon component is in electrical contact with at least part of the metallic component, characterised in that the silicon component... Agent: Nixon & Vanderhye, PC

20070265355 - Polyketal polymers, and methods of making and using same: Polyketal polymers, and methods of making and using such polyketal polymers are disclosed herein. The polyketal poylmers can be useful for applications including, for example, medical devices and pharmaceutical compositions. In a preferred embodiment, the polyketal polymers are biodegradable.... Agent: Mueting, Raasch & Gebhardt, P.A.

20070265356 - Aliphatically modified biodegradable block copolymers as thermogelling polymers: A thermogelling, aliphatically modified polymer for use in drug delivery is described. Illustrative embodiments include poly(lactic-co-ε-caprolactone)-poly(ethylene glycol)-poly(lactic-co-ε-caprolactone) hexanoate and poly(lactic-co-ε-caprolactone)-poly(ethylene glycol)-poly(lactic-co-ε-caprolactone) laurate. Another illustrative embodiment includes a composition having a thermogelling amount of an aliphatically modified poly(lactic-co-ε-caprolactone)-poly(ethylene glycol)-poly(lactic-co-ε-caprolactone) and an effective amount of a drug. The thermogelling polymers are made... Agent: Alan J. Howarth

20070259821 - Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture: Glucopyranosyl-substituted benzonitrile derivatives defined according to claim 1, including the tautomers, the stereoisomers thereof, the mixtures thereof and the salts thereof. The compounds according to the invention are suitable for the treatment of metabolic disorders.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070259822 - 8a,11-bicyclic 8a-azalide derivatives: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the... Agent: Elmore Patent Law Group, PC

20070259806 - Brain-associated inhibitor of tissue-type plasminogen activator: The present invention relates to a novel BAIT protein which is a member of serpin superfamily which is expressed primarily in brain tissue. In particular, isolated nucleic acid molecules are provided encoding the human and recombinant methods for producing the same. The invention further relates to screening methods for identifying... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20070259807 - Growth factor htter36: The present invention discloses Growth Factor HTTER36 (GDF3) polypeptides and polynucleotides encoding such polypeptides. Also provided is a procedure for producing such polypeptides by recombinant techniques and therapeutic uses of the polypeptides which include the diagnosis, prevention, and treatment of wasting disorders. Also disclosed are antagonists against such polypeptide and... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20070259808 - Method for treating wounds to promote healing: A method of treating a mammal to promote wound healing in the mammal in need thereof, comprising orally administering to the mammal an effective amount of a palatable, concentrated protein composition comprising an effective amount of hydrolyzed gelatin and tryptophan, and an ingestible carrier, the composition comprising the essential amino... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20070259805 - Remedy for melanoma: The present invention was aimed at reducing transcription activating activity of MITF-M to inhibit production of BCL2 gene product and thereby to allow treatment and/or prevention of melanoma The present invention provided a method of inhibiting production of BCL2 gene product and an agent for inhibiting the same, which inhibit... Agent: Kilyk & Bowersox, P.l.l.c.

20070259809 - Methods of using high affinity atiii variants: Disclosed are compositions and methods related to binding of ATIII under low and high shear rate conditions.... Agent: Needle & Rosenberg, P.C.

20070259811 - Method of modulating the proliferation of medullary thyroid carcinoma cells: The present invention is directed to a method of decreasing the rate of proliferation of medullary thyroid carcinoma cells which comprises contacting medullary thyroid carcinoma cells with one or more SSTR2 agonist. A somatostatin receptor antagonist having the formula Cpa-cyclo(D-Cys-4-Pal-D-Trp-Lys-Thr-Cys)-Nal-NH2 is also disclosed.... Agent: Alan Feeney, Esq.

20070259810 - Pharmaceutical compositions for lipophilic drugs: Stable solutions of lipophilic drugs, such as cyclosporin, forming a polar lipid self-emulsifying drug delivery system. The solutions can include lipophilic drugs, such as cyclosporin, dissolved in a polar lipid, such as having a C6-C12 fatty acid monoglyceride content of at least about 50%, surfactants and triglycerides. The composition forms... Agent: Rissman Jobse Hendricks & Oliverio, LLP

20070259812 - Peptide deformylase inhibitors as novel antibiotics: A macrocyclic peptide deformylase (PDF) inhibitor comprising a peptide or peptide mimetic having three residues, P1′, P2′, and P3′, wherein P2′ connects P1′ and P3′, wherein P1′ and P3′ each have a side chain, and wherein the side chains on P1′ and P3′ are crosslinked to form the macrocyclic PDF... Agent: Calfee Halter & Griswold, LLP

20070259815 - Albumin fusion proteins: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070259813 - Anti-bacterial composition especially for controlling gram-negative bacteria, comprising a peptide and an advantageously hydrophobic anti-bacterial agent: The invention relates to an anti-bacterial composition, especially for controlling gram-negative bacteria, containing a combination of: a) at least one peptide of between 10 and 25 amino acid residues comprising: i) two positively charged domains with a neutral pH consisting of between 3 and 9 amino acid residues, at least... Agent: Hunton & Williams LLP Intellectual Property Department

20070259816 - Drg11-responsive axonal guidance and outgrowth of neurite (dragon) gene family: This invention features methods and compositions useful for treating and diagnosing diseases of the nervous system, retina, skin, muscle, joint, and cartilage using a Dragon family protein. Protein and nucleic acid sequences of human, murine, zebrafish, and C. elegans Dragon family members are also disclosed.... Agent: Clark & Elbing LLP

20070259814 - Platelet derived growth factor and methods of use thereof: A method for promoting growth of bone, periodontium, ligament, or cartilage in a mammal by applying to the bone, periodontium, ligament, or cartilage a composition comprising platelet-derived growth factor at a concentration in the range of about 0.1 mg/mL to about 1.0 mg/mL in a pharmaceutically acceptable liquid carrier and... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP

20070259817 - Clk-peptide and slk-peptide: The invention describes methods for inhibiting angiogenesis in a tissue by administering an antagonist that specifically binds to a proteolyzed or denatured collagen type-IV with substantially greater affinity than to the native triple helical form of collagen type-IV. Methods utilizing such antagonists for therapeutic treatment of tumor growth, tumor metastasis... Agent: Wilson Sonsini Goodrich & Rosati

20070259818 - Methods and compositions for treating conditions: The invention relates to compositions that can be used to treat, prevent, and modulate pain, inflammation, and metabolic processes in various organisms including plants and animals. Such compositions can be formulated with an acceptable pharmaceutical excipient for administration to a human or a plant. The compositions can be administered topically... Agent: Wilson Sonsini Goodrich & Rosati

20070259819 - Cosmetic use of at least natural tetrapeptide ac-ser-asp-lys-pro or one of its analogs as a skin anti-aging and restructuring agent: e

20070259820 - Methods and reagents for activating heat shock protein 70: The present disclosure is directed to new compounds useful as modulators of Heat Shock Proteins (HSP). In particular, the present disclosure provides new small molecule peptide-derived compounds having HSP modulation activity, especially Hsp70 modulation activity, and methods of preventing or ameliorating beta-amyloid or polyglutamine aggregation, decreasing cell proliferation, or increasing... Agent: Marshall, Gerstein & Borun LLP

20070259823 - Diketo acids with nucleobase scaffolds: anti-hiv replication inhibitors targeted at hiv integrase: A new class of diketo acids constructed on nucleobase scaffolds, designed as inhibitors of HIV replication through inhibition of HIV integrase, is described. These compounds are useful in the prevention or treatment of infection by HIV and in the treatment of AIDS and ARC, either as the compounds, or as... Agent: Henry D. Coleman

20070259830 - Antisense agents combining strongly bound base-modified oligonucleotide and artificial nuclease: The present invention provides compounds having a chelating moiety and an oligonucleotide sequence wherein the oligonucleotide includes one or more modified nucleobases, such as hydroxynucleobases. The disclosed compounds are suitable for antisense therapy. The chelating moiety can be complexed to an ion of a lanthanide metal. These compounds are efficient... Agent: Marshall, Gerstein & Borun LLP

20070259826 - Chimeric (double) decoy: The present invention provides a prophylactic, ameliorative or therapeutic medicament for vascular restenosis, ischemic disease, allergic disease, inflammatory disease, autoimmune disease, or cancer metastasis, invasion (cancer metastasis/invasion) or cachexia based on the inhibitory action on a plural of transcriptional regulatory factor. A chimera (double) decoy of the present invention has... Agent: Nixon & Vanderhye, PC

20070259827 - Compositions and methods for enhancing discriminatory rna interference: The present invention provides methods for enhancing discriminatory RNA silencing by RNA silencing agents. In particular, the invention provides methods for generating RNA silencing agents which can discriminate between target and non-target mRNAs that differ in sequence by only one nucleotide. Also provided are improved RNA silencing agents with enhanced... Agent: Lahive & Cockfield, LLP

20070259824 - Methods of identifying immunoregulatory agents, immunoregulatory agents, and uses thereof: The present invention provides methods of identifying a substance that down-regulates or up-regulates an immune response and kits used for the identification methods. A method of this invention comprises detecting a substance that inhibits or enhances the interaction between CD26 and caveolin-1. Another method comprises detecting a substance that inhibits... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070259828 - Non-immunogenic, hydrophilic/cationic block copolymers and uses thereof: The present invention provides novel non-immunogenic, hydrophilic/cationic block copolymers comprising a neutral-hydrophilic polymer and a cationic polymer, wherein both polymers have well-defined chain-end functionality. A representative example of such a block copolymer comprises poly(N-(2-hydroxypropyl)methacrylamide) (PHPMA) and poly(N-[3-(dimethylamino)propyl]methacrylamide) (PDMAPMA). Also provided is a synthesis method thereof in aqueous media via reversible... Agent: Howrey LLP

20070259832 - Nucleotide mimics and their prodrugs: The present invention relates to nucleoside diphosphate mimics and nucleoside triphosphate mimics, which contain diphosphate or triphosphate moiety mimics and optionally sugar-modifications and/or base-modifications. The nucleotide mimics of the present invention, in a form of a pharmaceutically acceptable salt, a pharmaceutically acceptable prodrug, or a pharmaceutical formulation, are useful as... Agent: Morrison & Foerster LLP

20070259825 - Transgenic mammals and cell lines for the identification of glutamate transporter modulators: The invention includes a transgenic, non-human mammal useful for identifying candidate compounds for treating neurological and/or psychiatric disorders. Incorporated into the genome of the transgenic mammal is a transgene comprising a glutamate transporter promoter operatively linked to a reporter gene. The transgenic non-human mammal and cells isolated therefrom can be... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20070259831 - Treatment and screening methods for promoting neurogenesis: The invention features methods for promoting neurogenesis including treatment of psychiatric disorders (e.g., depression, bipolar disorder, and post traumatic stress disorder), drug abuse or addiction, neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, frontotemporal dementia, Huntington's disease, and prion disease), and head trauma (e.g., stroke and... Agent: Clark & Elbing LLP

20070259829 - Uses of diphenyl/diphenylamine carboxylic acids: The present invention demonstrates that chemical-induced degradation of Sp proteins by a specific sub-class of NSAIDs inhibited cancer cell growth, angiogenesis and metastasis of cancer cells. The inhibitory effects of these compounds were demonstrated in vitro and in vivo. Hence, the results discussed herein indicate that these compounds can be... Agent: Benjamin Aaron Adler Adler & Associates

20070259833 - Use of low-molecular-weight highly sulfated polysaccharide derivatives for modulating angiogenesis: The invention relates to the use of certain low-molecular weight highly sulphated polysaccharide derivatives obtained from a bacterial polysaccharide for preparing a pharmaceutical composition suitable for modulating angiogenesis, particularly for use in accelerating vascular endothelial repair with a low haemorrhage risk in the event of thrombotic injuries.... Agent: Marshall, Gerstein & Borun LLP

20070259834 - Dermally applicable liquid formulations for controlling parasitic arthropods on animals: The present invention relates to dermally applicable liquid formulations comprising synthetic or natural pyrethroids and halogen-free guanidines for controlling parasitic arthropods on animals.... Agent: Bayer Healthcare LLC

20070259835 - Phosphinic acid derivatives: The present invention relates to phosphinic acid derivatives as GABAB antagonists, their preparation, their use as pharmaceuticals and pharmaceutical compositions containing them.... Agent: Novartis Corporate Intellectual Property

20070259836 - Therapeutic cyclopentane derivatives: e

20070259837 - Use of non-glucocorticoid steroids for the treatment of muscular dystrophy: The invention relates to the therapeutic use of certain classes of steroid compounds for treatment of muscular diseases, in particular muscle diseases caused by mutations in the gene encoding for dystrophin (Duchenne Muscular Dystrophy, DMD, and Becker Muscular Dystrophy, BMD). The steroid compounds increase the levels of the dystrophin-related protein... Agent: Leydig Voit & Mayer, Ltd

20070259838 - 17,20(z)-dehydro vitamin d analogs and their uses: This invention discloses 17,20(Z)-dehydro vitamin D analogs, and specifically 17(Z)-1α,25-dihydroxy-17(20)-dehydro-2-methylene-19-nor-vitamin D3 and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as... Agent: Thomas M. Wozny Andrus, Sceales, Starke & Sawall

20070259839 - Triterpene quaternary salts as biologically active surfactants: The invention provides novel compounds that are quaternary amine derivatives of betulin and other triterpenes. The compounds have antibacterial, antifungal, and surfactant properties.... Agent: Schwegman, Lundberg & Woessner, P.A.

20070259840 - Multi-phase contraceptive preparation based on a natural estrogen: The multiphase preparation having higher contraceptive safety and reduced side effects is based on a combination of a natural oestrogen with dienogest or drospirenon. The multiphase preparation is characterized by a first phase consisting of 2 daily dose units of 3 mg of oestradiol valerate, a second phase consisting of... Agent: Michael J. Striker

20070259841 - Combinations for the treatment of rheumatoid arthritis: The invention features a method for treating a patient diagnosed with rheumatoid arthritis by systemically administering an azole and a steroid to the patient. The invention also features a pharmaceutical composition containing an azole and a steroid for the treatment of rheumatoid arthritis.... Agent: Clark & Elbing LLP

20070259842 - Triterpene quaternary salts as biologically active surfactants: The invention provides novel compounds that are quaternary amine derivatives of betulin and other triterpenes. The compounds have antibacterial, antifungal, and surfactant properties.... Agent: Schwegman, Lundberg, Woessner & Kluth, P.A.

20070259843 - Methods and compositions for treatment of macular and retinal disease: The present invention describes linking a therapeutic agent to a compound which is known to be naturally concentrated in a tissue affected by, or that is causing, a disease, to create a prodrug for treatment of the disease. Embodiments of the present invention include a new class of carotenoid-linked drugs... Agent: Kilpatrick Stockton LLP - M0351

20070259844 - Antiviral compositions and methods of using the same: Pharmaceutical compositions for and methods of preventing infection or treating an individual who has been identified as being infected with a Flavivirus, Pestivirus, picornovirus or coronavirus such as HCV, GB virus B, JEV, WNV, CSFV, BDV, BVDV, poliovirus, FMDV, or EMCV, comprising administering to the individual a therapeutically effective amount... Agent: Cozen O'connor, P.C.

20070259845 - Processes for the preparation of (3r,4s)-4-((4-benzyloxy)phenyl)-1-(4-fluorophenyl)-3-((s)-3-(4-fluorophenyl)-3-hydroxypropyl)-2-azetidinone, an intermediate for the synthesis of ezetimibe: wherein R is selected from the group consisting of: H or a hydroxyl protecting group. The invention also encompasses processes for preparing Compound 2a, preferably to form Compound 2a-Form 01. Also included are processes for preparing ezetimibe from Compound 2a-Form 01 or Compound 2a prepared according to the invention, compositions... Agent: Kenyon & Kenyon LLP

20070259846 - Compounds for the treatment of inflammatory diseases: and the pharmacologically acceptable salts, enantiomers, racemates, hydrates, or solvates thereof, which are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin, or eyes, diseases of the peripheral or central nervous system or cancers, as well as pharmaceutical compositions which contain these... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070259847 - 2-amido-4-phenylthiazole derivatives, the preparation and the therapeutic use thereof: d

20070259848 - Azetidine derivatives as ccr-e receptor: in free or salt form, wherein Ar, X, Y and T have the meanings as indicated in the specification, are useful for treating a condition mediated by CCR-3, particularly an inflammatory or allergic condition such as an inflammatory or obstructive airways disease. Pharmaceutical compositions that contain the compounds and processes... Agent: Novartis Corporate Intellectual Property

20070259849 - Azine-carboxamides as anti-cancer agents: The invention relates to chemical compounds, of the formula (I): or pharmaceutically acceptable salts thereof, which possess B-Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture... Agent: Astrazeneca R&d Boston

20070259850 - Constrained compounds as cgrp-receptor antagonists: The invention encompasses constrained bicyclic and tricyclic CGRP-receptor antagonists, methods for identifying them, pharmaceutical compositions comprising them, and methods for their use in therapy for treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and... Agent: Louis J. Wille Bristol-myers Squibb Company

20070259851 - Constrained compounds as cgrp-receptor antagonists: The invention encompasses constrained bicyclic and tricyclic CGRP-receptor antagonists, methods for identifying them, pharmaceutical compositions comprising them, and methods for their use in therapy for treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and... Agent: Louis J. Wille Bristol-myers Squibb Company

20070259852 - Bicyclic compounds and compositions as pdf inhibitors: This invention is directed to novel bicyclic compounds, to the uses of these compounds in various medicinal applications, including treating disorders amenable to treatment by peptidyl deformylase inhibitors such as treatment of bacterial infections, and to pharmaceutical compositions comprising these compounds.... Agent: Genomics Institute Of The Novartis Research Foundation

20070259853 - Tetrahydro-1h-1,2,6-triaza-azulene cannabinoid modulators: i

20070259854 - Triazole derivative or salt thereof: [Means for Solution] It has been found that a triazole derivative wherein the triazole ring is substituted with a trisubstituted methyl group in the 2-position or a pharmaceutically acceptable salt thereof has a strong 11β-HSD1 inhibitory activity. Moreover, the triazole derivative of the invention exhibits an excellent blood-glucose level-lowering action... Agent: Sughrue-265550

20070259855 - Thiazolyl-dihydro-indazole: wherein the groups R1, R2, Ra and Rb have the meanings given in the claims and specification, the tautomers, racemates, enantiomers, diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts, solvates and hydrates thereof, and processes for preparing these thiazolyl-dihydro-indazoles and the use thereof as pharmaceutical... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070259856 - Method for activating trpv4 channel receptors by agonists: This invention relates to methods for activating a TRPV4 channel receptor, thereby reducing the production and/or release of matrix degrading enzymes by a cell expressing a TRPV4 channel receptor, thereby reducing the breakdown of an extra-cellular matrix. Also contemplated within the scope of the invention are methods of attenuating the... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070259857 - Amorphous form of olanzapine: The present invention relates to an amorphous form of olanzapine Formula (I): and a process for its preparation. The present invention further relates to a pharmaceutical composition comprising an amorphous form of olanzapine (I). The pharmaceutical composition may be used, in particular, for the treatment of psychiatric, psychological or psychotic... Agent: Wolf Greenfield & Sacks, P.C.

20070259858 - Novel bis-pyrrolo[2,1-c][1,4]benzodiazepine-anthraquinone conjugates and a process for the preparation thereof: e

20070259860 - Mglur5 modulators v: The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.... Agent: Birch, Stewart, Kolasch & Birch, LLP

20070259859 - Muscarinic agonists to treat impulse control disorders: The invention relates to a novel use of compounds and pharmaceutically acceptable salts thereof, which are muscarinic, for example muscarine-1 (M1) agonists. These compounds are useful for the preparation of medicaments for treatment, amelioration or prevention of impulse control disorders. These include impulse control disorders ‘Not Elsewhere Classified,’ such as... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070259861 - Combination therapy with non-selective cox inhibitors to prevent cox-related gastric injuries: The present invention is directed to nicotinamide, nicotinamide derivatives and prostaglandin mimetics, alone or in combination with an NSAID, and their use in treating pain, inflammation, and/or gastrointestinal toxicty,... Agent: Drinker Biddle & Reath LLP One Logan Square

20070259862 - Mglur5 modulators i: The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.... Agent: Birch, Stewart, Kolasch & Birch, LLP

20070259863 - Arylphenylamino-,arylphenylamide-, and arylphenylether-sulfide derivatives: e

20070259864 - Novel oxabispidine compounds and their use in the treatment of cardiac arrhythmias: There is provided compounds of formula I, wherein R1, R2, R4, R41 to R46, A, B and G have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.... Agent: Pepper Hamilton LLP

20070259865 - Agent for promoting the recovery from dysfunction after the onset of central neurological disease: It is intended to provide a novel agent for promoting the recovery from dysfunction after the onset of a central neurological disease or an agent for enhancing and/or promoting the effect of rehabilitation for functional recovery. Namely, an agent for promoting the recovery from dysfunction after the onset of a... Agent: Sughrue-265550

20070259866 - Method of adenovirus, hiv and hpv prophylaxis:

20070259867 - 1,3-dioxoisoindole derivatives having selective antagonism of t-type calcium channel: wherein R1 is a phenyl or a benzyl group, optionally substituted with a moiety selected from the group consisting of a halogen atom, a C1-C6 alkoxy, a C1-C6 alkyl, and a cyano group; R2 is a heterocyclic group selected from the group consisting of piperidinyl, pyrrolidinyl, morpholinyl, and piperazinyl groups,... Agent: Frommer Lawrence & Haug

20070259868 - Novel 3-oxa-10-aza-phenanthrenes: e

20070259869 - Aminopyrimidines useful as kinase inhibitors: The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the invention.... Agent: Covington & Burling, LLP Attn: Patent Docketing

20070259871 - Hydroxybenzamide derivatives and their use as inhibitors of hsp90: e

20070259873 - Inhibitors of cathepsin s: The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme. The present invention also provides methods for treating a disease state in a subject by selectively... Agent: Genomics Institute Of The Novartis Research Foundation

20070259872 - Inhibitors of soluble adenylate cyclase: The invention relates to compounds of general formula I as well as the production and use thereof as a medication.... Agent: Millen, White, Zelano & Branigan, P.C.

20070259870 - Novel pyridazinone derivatives: e

20070259874 - Phosphodiesterase inhibitors: The present invention relates to isoxazoline derivatives and their analogues, which can be used as phosphodiesterase (PDE) type IV selective inhibitors. Compounds disclosed herein can be useful in the treatment of AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory... Agent: Ranbaxy Inc.

20070259875 - Triaryl substituted imidazole derivatives and taste-inhibiting uses thereof: e

20070259876 - Kinase inhibitors and methods of use thereof: Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as uveitis, retinopathies or macular degeneration, macular... Agent: Dla Piper US LLP

20070259878 - High throughput assay systems and methods for identifying agents that alter surface expression of integral membrane proteins: Disclosed are high throughput assay systems and methods for identifying agents that alter the level of surface expression of integral membrane proteins, such as cardiac ion channels, in mammalian cells. Also disclosed are therapeutic methods of using agents identified using such methods.... Agent: Duane Morris LLP

20070259877 - Piperazine derivatives useful for the treatment of gastrointestinal disorders: The invention provides compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Ra, Rb, Rc, Rd, Re, Rf and Y are as defined in the specification. The compounds are partial or full agonists at the growth hormone secretagogue (GHS) receptors. Pharmaceutical compositions comprising the compounds methods of preparing the... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070259879 - Piperazine and piperidine biaryl derivatives: or a pharmaceutically acceptable prodrug, salt, polymorph, solvate, enantiomer, diastereomer, racemate, mixture of stereoisomers thereof, or derivative thereof; and to processes for preparing the compounds or pharmaceutical compositions containing the same. The compounds and pharmaceutical compositions of the present invention are provided for use in the treatment of HIV infection... Agent: Myers Bigel Sibley & Sajovec

20070259880 - Thiazolidine derivatives and medicinal use thereof:

20070259881 - Substituted imidazo ring systems and methods: Imidazo ring systems, which include, for example, imidazopyridine, imidazoquinoline, 6,7,8,9-tetrahydroimidazoquinoline, imidazonaphthyridine, and 6,7,8,9-tetrahydroimidazonaphthyridine compounds substituted at the 1-position and/or the 2-position, pharmaceutical compositions containing these compounds, methods of making these compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment... Agent: 3m Innovative Properties Company

20070259882 - 3-substituted quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists: A compound of formula (I) below or a pharmaceutically acceptable salt or solvate thereof:... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20070259884 - 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity: c

20070259886 - Dihydroxyphenyl isoindolylmethanones:

20070259885 - Novel crystal form of(3-cyano-1h-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl] methanone, hydrochloride: The present invention relates to a hitherto unknown crystal form B of (3-cyano-1H-indol-7-yl)-[4-(4-fluorophenethyl)-piperazin-1-yl]methanone, hydrochloride, to a process for the preparation thereof, and to the use thereof for the preparation of a medicament... Agent: Millen, White, Zelano & Branigan, P.C.

20070259883 - Substitued a-piperazingly phenylpropionic acid derivatives as hppar alpha and/or hppar gamma agonists: The present invention relates to a compound of formula I, racemates, optically active isomers, or pharmaceutically acceptable salts or solvates thereof, and a pharmaceutical composition comprising the compound, the various radicals in the formula I are the same as defined in the claims. The present invention also relates to a... Agent: Lucas & Mercanti, LLP

20070259887 - Inhibitors of polyq-aggregation: Compounds of formula I, wherein R1, R2, R3, R4 and R5 have the meanings as given in claim 1, and their pharmaceutically tolerable derivatives, solvates and stereoisomers and their use for the preparation of a pharmaceutical for inhibiting the formation of polyQ-aggregation.... Agent: Pillsbury Winthrop Shaw Pittman LLP

20070259888 - Novel compounds: m

20070259890 - Compounds and compositions as ppar modulators: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated Receptor (PPAR) families, particularly the activity of PPARδ.... Agent: Genomics Institute Of The Novartis Research Foundation

20070259891 - Heterocycle-substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors: e

20070259892 - Method of inhibiting the expression and/or the activity of jnk:

20070259889 - Protein binding compounds: The present invention provides a prodrug compound comprising a therapeutically effective moiety coupled via a metabolically cleavable bond to a blood protein binding moiety.... Agent: Sughrue Mion, PLLC

20070259893 - Pyrazolopyrimidines: e

20070259895 - Mglur5 modulators vi: The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.... Agent: Birch, Stewart, Kolasch & Birch, LLP

20070259894 - Use of atazanavir for improving the pharmacokinetics of drugs metabolized by ugt1a1: A method for improving the pharmacokinetics of an orally administered drug that is directly metabolized by UGT1A1 comprises orally administering to a mammal in need of treatment with the drug a combination of the drug or a pharmaceutically acceptable salt thereof and atazanavir or a pharmaceutically acceptable salt thereof.... Agent: Merck And Co., Inc

20070259896 - Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors: Certain thienopyrimidine derivatives are useful for the inhibition of PDE10 enzymes, and thus are useful for treating psychiatric or neurological syndromes, e.g., pyschoses, obsessive-compulsive disorder and/or Parkinson's disease, as well as, for example, treating a disease state modulated by PDE10 activity.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070259897 - Fungicidal mixtures: r

20070259899 - 6-(2-alkyl-phenyl)-pyrido[2,3-d]pyrimidines useful as proteine kinase inhibitors: Objects of the present invention are the compounds of formula (I) their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as... Agent: Hoffmann-la Roche Inc. Patent Law Department

20070259898 - Novel 2-amino-3,4-dihydro-pyrido[3,4-d]pyrimidine derivatives useful as inhibitors of beta-secretase (bace): The present invention is directed to novel 2-amino-3,4-dihydro-pyrido[3,4-d]pyrimidine derivatives, pharmaceutical compositions containing them and their use in the treatment of Alzheimer's disease (AD) and related disorders. The compounds of the invention are inhibitors of β-secretase, also known as β-site cleaving enzyme and BACE, BACE1, Asp2 and memapsin2.... Agent: Philip S. Johnson Johnson & Johnson

20070259900 - Polymorphs: The invention relates to polymorphous crystal modifications of a DPP-IV inhibitor, the preparation thereof and the use thereof for preparing a medicament.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070259902 - Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer: (−)-5 -(3-Chlorophenyl)-α-(4-chlorophenyl)-α-(1-methyl-1H-imidazol-5 -yl)tetrazolo-[1,5-a]quinazoline-7-methanamine and its pharmaceutically acceptable acid addition salts, and the use of such compounds in medicine especially for the treatment of cancer... Agent: Philip S. Johnson Johnson & Johnson

20070259901 - Pharmaceutical compositions and use thereof: The present invention relates to pharmaceutical compositions and dosage compositions of compounds, including injectable formulations for the parenteral delivery of such compounds into patients in need of such treatment. Also featured are methods of making and using the compositions, including methods for the treatment of neoplastic diseases.... Agent: Myriad Genetics Inc. Intellecutal Property Department

20070259903 - Anti-viral uses for analogs of barbituric acid: where R1 and R2 are independently hydrogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 mercaptoalkyl, or aryl; R3 is O, S, Se or C(CH3)2; and R4 is hydrogen. One particularly preferred barbituric acid analog has the structure (S1) shown above where R1 and R2 are both... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP

20070259904 - Bi-aryl meta-pyrimidine inhibitors of kinases: The invention provides biaryl meta-pyrimidine compounds having the general structure (A). The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Jak kinase family, and various other specific receptor and non-receptor kinases.... Agent: Dla Piper US LLP

20070259905 - Camptothecin analogs and methods of preparation thereof: wherein R1 and R2 are independently the same or different and are hydrogen, an alkyl group, an alkenyl group, a benzyl group, an alkynyl group, an alkoxyl group, an aryloxy group, an acyloxy group, a carbonyloxy group, a carbamoyloxy group, a halogen, a hydroxyl group, a nitro group, a cyano... Agent: Bartony & Hare, LLP

20070259906 - Method of treatment of diarrhea-predominant irritable bowel syndrome in a subject: A method of treatment of diarrhea-predominant IBS in a subject, comprising administering a composition comprising cilansetron or a pharmaceutically acceptable derivative thereof to achieve a plasma cilansetron concentration between about 0.1 ng/mL and about 25 ng/mL.... Agent: Mayer, Brown, Rowe & Maw LLP

20070259907 - Aryl and arylalkylenyl substituted thiazoloquinolines and thiazolonaphthyridines: Thiazoloquinoline and thiazolonaphthyridine compounds having an aryl or arylalkylenyl substituent at the 6-, 7-, 8-, or 9-position, pharmaceutical compositions containing the compounds, intermediates, and methods of making and methods of use of these compounds as immunomodulators, for modulating cytokine biosynthesis in animals and in the treatment of diseases including viral... Agent: 3m Innovative Properties Company

20070259908 - Mitochondria activators: The present invention provides a mitochondrial activator containing pyrroloquinoline quinone, preferably pyrroloquinoline quinone and coenzyme Q (particularly reduced coenzyme Q) as active ingredients. In addition, the present invention provides a mitochondrial activator containing citric acid, preferably citric acid and coenzyme Q (particularly reduced coenzyme Q), as active ingredients. Since pyrroloquinoline... Agent: Sughrue Mion, PLLC

20070259909 - Novel difluoroethoxy-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors: e

20070259910 - Substituted indoles, compositions containing them, method for the production thereof and their use:

20070259911 - Novel compounds and use of tetrahydropyridothiophenes:

20070259912 - Polymorphic forms of a gabaa agonist: Two new crystalline monohydrates and two new crystalline anhydrates of gaboxadol are disclosed together with methods for preparing them.... Agent: Merck And Co., Inc

20070259913 - Prophylaxis of thromboembolic events in cancer patients: The present invention generally relates a method of prophylaxis of thrombotic and thromboembolic events in a cancer patient in need thereof comprising administering to said patient a therapeutically effective amount of a factor Xa inhibitor, especially apixaban or a polymorph or pharmaceutically acceptable solvate form thereof. The factor Xa inhibitor... Agent: Louis J. Wille Bristol-myers Squibb Company

20070259914 - Novel piperidine derivates as modulators of chemokine receptor ccr5.: Compounds of formula (I) compositions comprising them, processes for preparing them and their use in medical therapy (for example modulating CCR5 receptor activity in a warm blooded animal).... Agent: Morgan Lewis & Bockius LLP

20070259915 - Use of piperidine derivatives as dermo-decontracting agents: The present invention relates to a cosmetic process for treating wrinkled skin, in particular the skin of the face and/or of the forehead, through a dermo-decontracting effect, comprising the topical application to said skin of a composition comprising, in a physiologically acceptable medium, at least one piperidine derivative chosen from... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070259916 - Mglur5 modulators ii: The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.... Agent: Birch, Stewart, Kolasch & Birch, LLP

20070259917 - Processes for the synthesis of 3-isobutylglutaric acid: Provided are processes for the synthesis of 3-isobutylglutaric acid, an intermediate in the synthesis of (S)-Pregabalin.... Agent: Kenyon & Kenyon LLP

20070259918 - 2-hydroxymethyl-3,4,5-trihydroxy-1-(4-pentyloxybenzyl) piperidine as glucosylceramide synthase (gcs) inhibitor: The compound 3,4,5-piperidinetriol, 2-(hydroxymethyl)-1-[(4-(pentyloxy)phenyl)methyl]-, (2S,3S,4R,5S), or a pharmaceutically acceptable salt or prodrug thereof, is useful as an inhibitor of glucosylceramide synthase.... Agent: Dickstein Shapiro LLP

20070259919 - 2-substituted pyridines, processes for their preparation and their use for controlling harmful fungi:  is five- or six-membered hetaryl comprising 1 to 3 heteroatoms selected from the group consisting of O, N and S or is phenyl, and to processes for their preparation, intermediates for their preparation, pesticidal compositions and methods for controlling harmful fungi and animal pests using the compounds according to the... Agent: Birch Stewart Kolasch & Birch

20070259920 - P2x7, receptor antagonists and uses thereof: x

20070259921 - Polymorphic forms of esomeprazole sodium: Polymorphic crystalline Forms J, K, L, M, and N of esomeprazole sodium.... Agent: Dr. Reddy's Laboratories, Inc.

20070259922 - Aryl, aryloxy, alkyloxy substituted 1h-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1): l

20070259923 - Mglur5 modulators iv: The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.... Agent: Birch, Stewart, Kolasch & Birch, LLP

20070259924 - Factor xa inhibitors: The present invention is directed to compounds of formula (I) and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of Factor Xa. The present invention is also directed to intermediates used in making such compounds, pharmaceutical compositions containing such a compound, methods to prevent or treat a number... Agent: Foley & Lardner LLP

20070259926 - Mglur5 modulators iii: The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.... Agent: Birch, Stewart, Kolasch & Birch, LLP

20070259925 - Dpp iv inhibitors: e

20070259927 - Remedy for diabetes: The present invention provides an agent for increasing the pancreatic insulin content useful for the treatment of diabetes and the like. In one embodiment, the present invention provides an agent for increasing the pancreatic insulin content, which contains a blood glucose lowering drug that does not stimulate insulin secretion, and... Agent: Foley And Lardner LLP Suite 500

20070259928 - Medicinal composition for treating diabetes: To provide a therapeutic procedure for diabetes mellitus with an excellent efficacy and high safety by possibly reducing side effects. To administer a pharmaceutical composition comprising an FBPase inhibitor at a specified timing.... Agent: Frishauf, Holtz, Goodman & Chick, PC

20070259929 - Therapeutic compounds: Therapeutic substituted cyclopentane compounds, and compositions, medicaments, and therapeutic methods related thereto are disclosed herein.... Agent: Allergan, Inc.

20070259930 - Compositions and methods of using r(+) pramipexole: Pharmaceutical compositions of R(+) pramipexole and methods of using such compositions for the treatment or prevention of diseases associated with or related to mitochondrial dysfunction or increased oxidative stress are disclosed.... Agent: Pepper Hamilton LLP

20070259931 - Process of reducing the bitter taste of water soluble actives by co-grinding the acitve with beta cyclodextrin: A process for reducing the intensity of the intrinsic bitter taste of a water soluble active which comprises dry mixing of said active with β-cyclodextrin.... Agent: William J. Davis

20070259934 - Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes: The present invention provides novel pyrazoles that are useful as cannabinoid receptor antagonists and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, and/or cardiometabolic disorders.... Agent: Feldmangale, P.A.

20070259933 - Compositions, dosage forms and methods of treating emesis: Pharmaceutical compositions comprising an anti-emetic compound and a highly orally bioavailable form of propofol, oral dosage forms comprising an anti-emetic compound and a highly orally bioavailable form of propofol and methods of treating emesis in a patient comprising orally administering a therapeutically effective amount of an anti-emetic compound and a... Agent: Timothy A. Worrall, Ph.d., J.d. Dorsey & Whitney LLP

20070259932 - Benzimidazole derivatives, their production and use: wherein the ring A is a benzene ring which may optionally contain substitution in addition to the R′ group; R1 is hydrogen or an optionally substituted hydrocarbon residue; R2 is a group capable of forming an anion or a group convertible thereinto; X is a direct bond or a spacer... Agent: Foley And Lardner LLP Suite 500

20070259935 - Crystalline forms of letrozole and processes for making them: Crystalline forms of letrozole can be made by precipitation and are useful in making pharmaceutical compositions.... Agent: SynthonIPInc

20070259936 - Benzimidazole modulators of vr1: y

20070259937 - Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors:

20070259938 - Biocides and apparatus: There are provided methods for controlling microbial or biofilm growth, comprising mixing a hypochlorite oxidant and at least one nitrogen-containing compound or salt thereof selected from a particular group of nitrogen-containing compounds and salts to form a biocide, and applying the biocide. Apparatus for practicing the methods are also provided.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070259939 - Using naltrexone as a multi-purpose health supplement to improve the human condition and preventing multiple diseases and infirmities by stimulating immune system vitality and robustness: Naltrexone has been used to fight existing infections, afflictions, and substance abuse. Embodiments of the current invention provide naltrexone as a preventative medicine taken daily, usually in the late evening for greater efficacy. It is taken in a low dose like a vitamin supplement and may prevent many diseases by... Agent: Banner & Witcoff, Ltd.

20070259940 - Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment: The present invention relates to carvedilol phosphate salts, which include novel crystalline forms of carvedilol dihydrogen phosphate (i.e., dihydrogen phosphate salt of 1-(carbazol-4-yloxy-3-[[2-(o-methoxyphenoxy) ethyl]amino]-2-propanol) and/or carvedilol hydrogen phosphate,etc.), and/or solvates thereof, compositions containing the aforementioned salts and/or solvates, and methods of using the aforementioned salts and/or solvates to treat hypertension,... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20070259941 - Ramipril formulation: A Ramipril formulation which is suitably stabilised to control the degradation to the active metabolite ramiprilat.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070259942 - Use of gal3 antagonist for treatment of depression and/or anxiety and compounds useful in such methods: This invention is directed to pyrimidine and indolone derivatives which are selective antagonists for the GAL3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by combining a... Agent: Heller Ehrman LLP

20070259944 - Indoline derivatives: i

20070259943 - Ortho-substituted pentafluorosulfanyl benzenes, method for the production thereof and their use as synthesis intermediates:

20070259945 - Method for treating pain: wherein n is an integer of from 1 to 10, m is an integer of from 1 to 4 and the total carbon atoms in the alkenyl amide chain is from about 11 to about 20 as an active ingredient together with one or more pharmaceutically-acceptable additives, excipients or diluents.... Agent: Allergan, Inc.

20070259946 - N-(heteroaryl)-1h-indole-2-carboxamide derivatives and their use as vanilloid trpv1 receptor ligands: e

20070259947 - Therapeutic compounds:

20070259948 - Compounds with antifungal properties and process thereof: wherein R is substituted alkyl, alkenyl, aryl, heteroaryl, 2-thienyl, 3-thienyl, halothienyl, haloalkyl, halophenyl, or pyrrolyl; and R1 and R2, each independent of the other, are hydrogen, halogen, or alkoxy. The invention also relates to a process for the preparation of said compounds by contacting the intermediate alcohol, prepared from 1,2-O-isopropylideneglyceraldehyde... Agent: Blank Rome LLP

20070259949 - Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof: The invention relates to novel forms of compounds displaying broad spectrum antibiotic activity, especially crystalline polymorphic forms and amorphous forms of such compounds, compositions comprising such crystalline polymorphic forms and amorphous forms of such compounds, processes for manufacture and use thereof. The compounds and compositions of the invention are useful... Agent: Morgan Lewis & Bockius LLP

20070259950 - Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol: The present invention further provides a new Form T1 of nebivolol and its pharmaceutically acceptable salts. The present invention also provides pharmaceutical compositions and process for the preparation of a solid oral dosage form of nebivolol hydrochloride of formula (I), without the use of wetting agent, and optionally using binder... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20070259951 - Compounds, compositions and methods: Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070259952 - Uses of escitalopram: The present invention relates to the use of the compound escitalopram (INN-name), i.e. (S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile, or a pharmaceutically acceptable salt thereof for the preparation of a medicament for improving cognition in a condition where the cognitive processes are diminished.... Agent: Darby & Darby P.C.

20070259953 - 2-methylene-19-nor-(23s)-25-dehydro-1alpha-hydroxyvitamin d3-26,23-lactone and 2-methylene-19-nor-(23r)-25-dehydro-1alpha-hydroxyvitamin d3-26,23-lactone: Compounds of formula 1A and 1B are provided where X1 and X2 are independently selected from H or hydroxy protecting groups. Such compounds may be used in preparing pharmaceutical compositions and are useful in treating a variety of biological disorders.... Agent: Foley & Lardner LLP

20070259954 - Method for the production on metal carboxylates and the metal aminoate or metal hydroxy analogue methionate derivatives thereof, and use of same as growth promoters in animal feed: A method of production of metal carboxylates and of their metal carboxylate-aminoate or metal carboxylate-methioninate hydroxy analog derivatives, and their use as growth promoters in animal nutrition. It comprises mixing stoichiometric quantities of formic or butyric acid and oxide and of the dry basic salt of divalent metal, the oxide... Agent: Ladas & Parry

20070259955 - Process for the preparation of nateglinide: m

20070259956 - Compositions and methods for treating cancer: Methods of treating individuals identified as having cancer using ATP citrate lyase inhibitor and/or tricarboxylate transporter inhibitor are disclosed. Methods of inducing apoptosis in cancer cells using an ATP citrate lyase inhibitor and/or tricarboxylate transporter inhibitor are disclosed. Methods of treating an individual who has cancer comprising the steps of... Agent: Pepper Hamilton LLP

20070259957 - Jelly composition: A composition in which a preparation of the composition itself has an excellent disintegratability in the right place and excellent active ingredient releasability within the digestive tract, the active ingredient and the preparation itself have long-term stability, excellent ease of operation such as manufacturability and filling into containers, an amount... Agent: Birch Stewart Kolasch & Birch

20070259958 - Prevention of neutrophil recruitment: Aspirin (ASA) triggers a switch in the biosynthesis of lipid mediators, inhibiting prostanoid production and initiating 15-epi-lipoxin generation, through the acetylation of cyclooxygenase II.... Agent: Dorsey & Whitney LLP Intellectual Property Department

20070259959 - Ppar agonists for the treatment of hcv infection: The present invention concerns the use of PPARα agonists in methods and compositions for the treatment or prevention of infection by hepatitis C virus (HCV) in mammals, especially humans.... Agent: Merck And Co., Inc

20070259960 - Compounds and methods for treatment of stroke: The present invention relates to methods and agents useful for the treatment of stroke, including ischemic stroke and hemorrhagic stroke. In particular, methods and agents for treating stroke in a subject are provided, wherein the agent is administered prior to diagnosis of the stroke as an ischemic stroke or a... Agent: Fibrogen, Inc. Intellectual Property Department

20070259961 - Compounds for treatment of inflammation, diabetes and related disorders: Novel acyl urea, thiourea, carbamate, thiocarbamate and related compounds are provided which are effective in inhibiting the cytokine-mediated inflammatory response in cultured cells, in ameliorating bone destruction in an animal model of arthritis and in lowering blood glucose levels in animal models of Type II diabetes mellitus. The compounds are... Agent: Mayer, Brown, Rowe & Maw LLP

20070259963 - Pentafluorosulfanylphenyl-substituted benzoylguanidines, method for the production thereof, their use as a medicament or diagnostic agent, and a medicament containing these compounds: v

20070259962 - Use of n-arylhydrazine derivatives for combating pests in and on animals: R5, R6, R7 are H, halogen, nitro, cyano, amino, mercapto, hydroxy, alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, alkylamino, dialkylamino, alkylthio, alkylsulfonyl, or alkylsulfinyl, wherein the carbon atoms in these groups may be substituted, a 5 to 6-membered aromatic ringsystem which may contain 1 to 4 heteroatoms selected from oxygen, sulfur and... Agent: Hutchison Law Group

20070259964 - Process for the preparation of cinacalcet base: Provided is a process for preparing Cinacalcet, (R)-α-methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl]-1-naphthalenemethane amine and intermediates thereof.... Agent: Kenyon & Kenyon LLP

20070259965 - Acyclic 1,3-diamine and uses therefor: o

20070259966 - Coadministration of radiation, efaproxiral sodium, and supplemental oxygen for the treatment of cancer: Disclosed is a method of treating a cancer of the central nervous system in a host including administering radiation to the host; and administering efaproxiral sodium plus supplemental oxygen to the host; wherein the radiation and efaproxiral sodium and supplemental oxygen are administered in amounts effective to cause the arrest... Agent: Swanson & Bratschun, L.L.C.

20070259967 - Methods of diagnosis: Methods for determining whether an ADHD patient is suitable for treatment with a monoamine oxidase type B (MAO-B) inhibitor, and uses of MAO-B inhibitors in medicaments for treatment of ADHD. Nucleic acid probes and primer sequences useful for determining MAO-B activity in ADHD patients.... Agent: Nixon & Vanderhye, PC

20070259968 - Macroporous plastic bead: (EN) The invention relates to a macroporous plastic bead material with a mean particle diameter of 10 to 1000 pm, radically polymerised from the following monomer types a) 5-40 wt. % vinylic polymerisable monomers with a water-solubility of at least 1% at 20° C. which are not vinylic polymerisable monomers... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070259969 - Isolation and use of solid tumor stem cells: A small percentage of cells within an established tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give... Agent: Medlen & Carroll, LLP

20070254827 - Alpha-aminobenzyl-alpha,alpha,-diphosphoric acid selective chelation of beryllium: A method of remediation of one or more of an animal, mineral, or vegetable for beryllium. The method includes the steps of applying α-aminobenzyl-α,α,-diphosphoric acid to the one or more of the animal, mineral, or vegetable; and allowing chelation of the beryllium.... Agent: Eddie E. Scott Assistant Laboratory Counsel

20070254853 - Compositions and methods for promotion of wound healing: The present invention includes compositions and methods for the treatment of animals that are immunosuppressed by preparing a topical composition supplemented with one or more compounds selected from the group consisting of nucleotides, nucleosides, nucleobases and mixtures thereof in an amount effective for promoting wound healing and contacting the wound... Agent: Chalker Flores, LLP

20070254833 - Compositions and methods for treating diverticular disease: Agents, compositions, and implants are provided herein for treating diverticular disease (e.g., diverticulosis and diverticulitis). In particular, fibrosis-inducing agents, hemostatic agents, and/or anti-infective agents, or compositions containing one or more of these agents are provided for use in methods for treating diverticular disease.... Agent: Brian R. Woodworth

20070254829 - Compound ws727713: The present invention relates to a new compound useful as a modulator of melanxocortin receptors. In particular, the present invention relates to a compound WS727713, a process for production of the compound by culturing, in a culture medium, a WS727713-producing strain belonging to Pseudonocardia and recovering the compound from a... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070254830 - Interaction of colon cancer related gene c200rf20 with p120: The present invention provides methods and kits for identifying inhibitors of the interaction between C20orf20 and p120 which find utility in the treatment and prevention of colon cancer. Also disclosed herein are compositions for treating or preventing colon cancer identified by the screening method of the present invention and methods... Agent: Townsend And Townsend And Crew, LLP

20070254832 - Methods for the treatment of macular degeneration and related eye conditions: The invention provides an AIM-lipid complex for treating age-related macular degeneration and related conditions. The compositions and methods of the instant invention encompass a novel approach to the treatment of age-related macular degeneration and related conditions. Pharmaceutical compositions for this use are also provided.... Agent: Jones Day

20070254831 - Peptides that block the binding of igg to fcrn: The invention relates to peptides which bind to human FcRn and inhibit binding of the Fc portion of an IgG to an FcRn, thereby modulating serum IgG levels. The disclosed compositions and methods may be used for example, in treating autoimmune diseases and inflammatory disorders. The invention also relates to... Agent: Biogen Idec / Finnegan Henderson, LLP

20070254828 - Pharmaceutical composition with healing activity comprising at least one soluble dextran derivative and at least one platelet-derived growth factor: Pharmaceutical composition with healing activity comprising at least one soluble dextran derivative and at least one platelet-derived growth factor. The present invention relates to a pharmaceutical composition with healing activity comprising at least one soluble dextran derivative and at least one platelet-derived growth factor, and also to the use thereof... Agent: Oliff & Berridge, PLC

20070254834 - Glycopegylated erythropoietin: The present invention provides conjugates between erythropoietin and PEG moieties. The conjugates are linked via an intact glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified... Agent: Morgan, Lewis & Bockius LLP (sf)

20070254835 - Composition and method for treating neurological disorders: Compositions, kits and methods are provided for treating or preventing neurological disorders associated with aberrant silencing of gene expression by reestablishing the gene expression through inhibition of DNA methylation and/or histone deacetylase. The compositions and methods include administering to a patient suffering from the neurological disorder a therapeutically effective amount... Agent: Wilson Sonsini Goodrich & Rosati

20070254842 - Administration of growth factors for the treatment of cns disorders: A method and system that is directed to the local delivery of growth factors to the mammalian CNS to treat CNS disorders associated with neuronal death and/or dysfunction is described.... Agent: John P. O'banion O'banion & Ritchey LLP

20070254841 - Formulations and methods for treating dry eye: Provided are methods and compositions for treating and preventing dry eye and/or increasing tear film break-up time.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070254836 - Glycopegylated granulocyte colony stimulating factor: The present invention provides conjugates between Granulocyte Colony Stimulating Factor and PEG moieties. The conjugates are linked via an intact glycosyl linking group that is interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from both glycosylated and unglycosylated peptides by the action... Agent: Morgan, Lewis & Bockius LLP (sf)

20070254840 - High molecular weight derivatives of vitamin k-dependent polypeptides: Modifications of vitamin K-dependent polypeptides that lead to enhanced protein function on a weight or molar basis and/or increase of protein lifetime in the circulation are described. Both objectives are important for using vitamin K-dependent polypeptides for pro- and anti-coagulation therapies, as well as for other uses in the circulation.... Agent: Fish & Richardson P.C.

20070254843 - Methods for treating bone associated diseases by the use of methionine aminopeptidase-2 inhibitors: The instant invention provides methods and compositions for treating a subject suffering from bone associated diseases, such as osteoporosis.... Agent: Lahive & Cockfield, LLP

20070254839 - Orally administered peptides synergize statin activity: This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis. The peptides are highly stable and readily administered via an oral route. The peptides are effective to stimulate the formation and cycling of pre-beta high density lipoprotein-like particles and/or to promote lipid transport and detoxification. This invention... Agent: Beyer Weaver LLP

20070254838 - Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules: Compositions of modified cytokines and uses thereof generated using processes and systems for the high throughput directed evolution of peptides and proteins, particularly cytokines that act in complex biological settings, are provided. Also provided are modified cytokines formulated for oral delivery and uses thereof to treat diseases and conditions mediated... Agent: Fish & Richardson, PC

20070254837 - Treatment for necrotizing enterocolitis: The invention provides compositions and methods for the treatment of necrotizing enterocolitis (NEC). A treatment of epidermal growth factor (EGF) receptor agonist and L-arginine, a bioequivalent thereof, or NO-donor showed efficacy against NEC. The invention also provides kits, unit doses and uses comprising epidermal growth factor (EGF) receptor agonist and... Agent: Torys LLP

20070254844 - Melanoma antigens and their use in diagnostic and therapeutic methods: The present invention provides a nucleic acid sequence encoding a melanoma antigen recognized by T lymphocytes, designated MART-1. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognoses a mammal afflicted with melanoma or metastata melanoma. This invention... Agent: Leydig, Voit & Mayer, Ltd.

20070254845 - Nucleophosmin/b23-binding peptide to inhibit tumor growth and regulate transcriptional activity of p53: The Rev peptide that binds to nucleophosmin/B23 with the highest affinity exhibits the greatest cytotoxicity on Ras-3T3 cells and inhibits tumor growth most effectively in nude mice. The efficiency of colony formation in soft agar of Ras-3T3 cells is significantly inhibited by treatment with Rev peptide. In addition, Rev peptide... Agent: Rosenberg, Klein & Lee

20070254846 - Biologically active peptide comprising tyrosyl-seryl-valine(ysv): The tripeptide Tyrosyl-seryl-valine is disclosed with its use as a pharmaceutical composition. A method is also disclosed making a pharmaceutical composition comprising providing the tripeptide Tyrosyl-seryl-valine and mixing said tripeptide with a pharmaceutically acceptable carrier.... Agent: EagleIPLimited

20070254847 - Pharmaceutical composition containing steroidal saponins, the preparation method and use thereof: The present invention provides a pharmaceutical composition containing steroidal saponins. The pharmaceutical composition comprises 5˜25 parts by weight of furostanal saponins represented by general formula A or general formula B and 1˜10 parts by weight of spirostanol saponin represented by general formula C. The present invention further provides a method... Agent: Workman Nydegger

20070254848 - Algin oligosaccharides and the derivatives thereof as well as the manufacture and the use of the same: The present invention provides an alginate oligosaccharide and its derivatives with the degree of polymerization ranging from 2 to 22. The alginate oligosaccharide is composed of β-D-mannuronic acid linked by 1,4 glycosidic bonds. The derivatives with the reduced terminal in position 1 of carboxyl radical can be prepared by oxidative... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20070254849 - Ryanodine receptor inhibitors and methods relating thereto: The present invention provides novel ryanodine receptor type 2 (RyR2) inhibitors and methods of their use in the treatment of cardiac conditions. In general, the RyR2 inhibitors of the present invention assist in the normalization of intracellular calcium homeostasis. In certain embodiments, the RyR2 inhibitors are store-overload-induced Ca2+ release (SOICR)... Agent: Fulbright & Jaworski L.L.P.

20070254851 - Chemically-defined non-polymeric valency platform molecules and conjugates thereof: Chemically-defined, non-polymeric valency platform molecules and conjugates comprising chemically-defined valency platform molecules and biological or chemical molecules including polynucleotide duplexes of at least 20 base pairs that have significant binding activity for human lupus anti-dsDNA autoantibodies.... Agent: Morrison & Foerster LLP

20070254852 - Improved nitroreductase enzymes: Compositions and methods are provided for the treatment of cancer.... Agent: Bozicevic, Field & Francis LLP

20070254850 - Methods for treating and preventing apoptosis-related diseases using rna interfering agents: The present invention is based, at least in part, on the discovery of compositions and methods useful in the modulation, e.g., inhibition, of gene expression or protein activity. In particular, the present invention is based on novel RNA interfering agents, e.g., siRNA molecules which target apoptosis-related genes or proinflammatory cytokines,... Agent: David S. Resnick

20070254854 - Aqueous antiseptic solution and compatible anionic dye for staining skin: Aqueous antiseptic solutions and compatible dyes and methods for making and using such solutions are provided. More specifically, in one embodiment, the present invention relates to an aqueous antiseptic solution comprising an aqueous solution of chlorhexidine or a salt thereof, an anionic dye in an amount sufficient to stain a... Agent: Shook, Hardy & Bacon LLP Intellectual Property Department

20070254855 - Method for the treatment of acne: A method for treatment of acne with tetracyclines is provided. A lower sustained dose and no loading dose is employed, with an optional once-a-day dosing regimen.... Agent: Knobbe Martens Olson & Bear LLP

20070254856 - Use of acetylsalicylic acid (asa) in the application of a membrane lung: Acetylsalicylic acid (ASA) is used as a medicament which is administered to a human patient in connection with a treatment of the patient with a membrane lung, in order to avoid or reduce a deposition of blood constituents in the membrane lung. The administration of the medicament involves ASA initially... Agent: Morrison & Foerster LLP

20070254857 - 2alpha-methyl-19-nor-(20s)-1alpha-hydroxy-bishomopregnacalciferol and its uses: This invention discloses 2α-methyl-19-nor-(20S)-vitamin D analogs, and specifically 2α-methyl-19-nor-(20S)-1α-hydroxy-bishomopregnacalciferol and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as... Agent: Thomas M. Wozny Andrus, Sceales, Starke & Sawall

20070254858 - Contraceptive and acne medication combination and treatment of acne and other diseases with reduced side effects: The present invention provides pharmaceutical compositions for the treatment of acne, psychotic illnesses, such as schizophrenia, cancer, such as cancer of the head, neck and lung, and emphysema, comprising co-administering a therapeutically effective amount of isotretinoin and a contraceptive in a contraceptively effective dosage. The contraceptive preferably does not contain... Agent: Duane Morris, LLPIPDepartment

20070254859 - Compounds exhibiting efflux inhibitor activity and composition and uses thereof: a pharmaceutically acceptable salt or ester thereof, a solvate thereof, a chelate thereof, a non-covalent complex thereof, a prodrug thereof, and mixtures of any of the foregoing, wherein: n is a number from 1 to 900, wherein the individual units may be the same or different; W is chosen from... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070254860 - 15 beta-substituted steroids having selective estrogenic activity: The invention provides 15β-substituted steroidal compounds having selective estrogen receptor activity according to Formula (I) wherein, R1 is H, C1-5 alkyl, C1-12 acyl, di-(C1-5 alkyl)aminocarbonyl, (C1-5alkyl)oxycarbonyl or sulfamoyl, R2 is H, C1-3alkyl, C2-3alkenyl or C2-3alkynyl, each of which may be optionally substituted with a halogen, R3 is C1-2alkyl, ethenyl or... Agent: Organon Usa, Inc. Patent Department

20070254861 - Methods for the prevention and/or treatment of peripheral arterial disease: A method for the prevention and/or treatment of peripheral arterial disease by compound (I) or its pharmaceutically salts are provided. The compound (I) or its pharmaceutically salts have inhibitory activity against heterotrimeric G protein Gq/11.... Agent: Sughrue-265550

20070254862 - Pharmaceutical compositions comprising cbx cannabinoid receptor modulators and potassium channel modulators: Described herein are pharmaceutical compositions comprising therapeutically effective quantities of (i) a KATP channel modulator; and (ii) a CBx modulator. Also described herein are methods of making and using these compositions.... Agent: Mayer Brown LLP

20070254863 - Use of cbx cannabinoid receptor modulators as potassium channel modulators: Methods of treating one or more medical conditions by administering to a subject in need thereof an effective amount of a CBx modulator having KATP channel modulating properties are described herein. Also described are methods of using a CBx modulator having KATP channel modulating properties to treat one or more... Agent: Mayer Brown LLP

20070254864 - Chromium complexes: The invention provides a complex which comprises at least one chromium ion and at least one pyridyl carboxylic acid moiety. The compounds of the invention are of use in controlling body mass and treating diseases caused by or characterized by deficiency of chromium metabolism, e.g., type 2 Diabetes, obesity, vascular... Agent: Morgan, Lewis & Bockius LLP (sf)

20070254865 - Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes: The present invention is directed to novel substituted aminocyclohexanes which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DPP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also... Agent: Merck And Co., Inc

20070254866 - Aminoquinolones as gsk-3 inhibitors: Provided herein are aminoquinolones and pharmaceutically acceptable derivatives thereof. In certain embodiments, provided herein are compounds, compositions and methods for treating, preventing or ameliorating GSK-3 mediated diseases.... Agent: Jones Day

20070254867 - Heterocyclic kinase inhibitors: o

20070254868 - C-met protein kinase inhibitors: The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides processes for preparing the compounds of this invention, pharmaceutically acceptable compositions comprising the compounds of the invention, and methods of using the compositions in the treatment of various disorders.... Agent: Vertex Pharmaceuticals Inc.

20070254869 - Compounds and methods for treating dislipidemia: e

20070254870 - Compounds, compositions and methods: Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070254871 - Compounds for the treatment of inflammation of the central nervous system: KATP channel openers (KCOs) are useful for the prophylactic and/or therapeutic treatment of CNS chronic inflammation associated with a disease or state in a mammal, including a human. The administration of KCOs, including the groups of benzopirans, cyanoguanidines, thioformamides, benzothiadiazines, pyridyl nitrates, pyrimidine sulfates, cyclobutenediones, DHP-related compounds, tertiary carbinols, 6-sulfonil-chromenes,... Agent: Trask Britt

20070254872 - Antibacterial agents: Naphthalene, quinoline, quinoxaline and naphthyridine derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070254873 - Chemical compounds: where R1, R2, R3, U and V are defined below and to pharmaceutically acceptable salts thereof. The compounds of the invention are inhibitors of IKK2 and can be useful in the treatment of disorders associated with inappropriate IKK2 (also known as IKKβ) activity, such as rheumatoid arthritis, asthma, and COPD... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070254874 - Modulators of preripheral 5-ht receptors: Novel modulators of 5-HT4 receptors have been developed which have a selectivity for peripheral receptors rather than those of the central nervous systems. Theses include novel derivatives of known modulators as well as entirely novel entities. Surprisingly, the derivatised compounds of the known modulators maintain a high binding affinity to... Agent: Knobbe Martens Olson & Bear LLP

20070254875 - Androgen receptor modulator compounds and methods: Provided herein are compounds having a structure selected from among Formula (I), Formula (II), Formula (III), Formula (IV), Formula (V) and Formula (VI) that are androgen receptor modulators and/or androgen receptor binding agents. Also disclosed are methods of making and using such compounds, including, but not limited to, using such... Agent: Fish & Richardson, PC

20070254876 - Glucuronate salt of a piperazine compound: The present invention provides a salt form, and compositions thereof, useful as a modulator of one or more GPCRs and which exhibits desirable characteristics for the same. The present invention also provides methods for preparing said salt form.... Agent: Choate, Hall & Stewart LLP/wyeth

20070254878 - Administration of carboline derivatives useful in the treatment of cancer and other diseases: In accordance with the present invention, compounds that inhibit the expression of VEGF post-transcriptionally have been identified, and compositions, and methods for the administration and use of those compounds. provided. In one aspect of the invention, compounds useful in the inhibition of VEGF production, in the treatment of solid tumor... Agent: Arnold & Porter LLP Attn:IPDocketing Dept.

20070254877 - Indole derivative and use for treatment of cancer: wherein A is a benzene ring optionally having substituents, R1, R2a and R3 are each a hydrogen atom, a hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents, R1 and R2a may form a ring via X, when R1 and R2a form a ring via X, R1... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20070254879 - Inhibitors of checkpoint kinases: The instant invention provides for compounds which comprise substituted triazoloquinazolinones that inhibit CHK1 activity. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting CHK1 activity by administering the compound to a patient in need of treatment of cancer.... Agent: Merck And Co., Inc

20070254880 - Heteroaryl piperidine glycine transporter inhibitors: The present invention is directed to pyridyl, pyridazinyl, pyrimidinyl and pyrazinyl piperidine compounds that inhibit the glycine transporter GlyT1 and which are useful in the treatment of neurological and psychiatric disorders associated with glycinergic or glutamatergic neurotransmission dysfunction and diseases in which the glycine transporter GlyT1 is involved.... Agent: Merck And Co., Inc

20070254881 - Pyrazole derivative: e

20070254882 - Sulfamide derivatives and pharmaceutical composition for upregulation of lipid metabolism comprising same: The present invention relates to a novel sulfamide derivative, a pharmaceutically acceptable salt thereof and a pharmaceutical composition for upregulation of lipid metabolism comprising same as an active ingredient.... Agent: Sughrue Mion, PLLC

20070254883 - Unsaturated mtor inhibitors: e

20070254884 - Compositions and methods for inducing cell dedifferentiation: The present invention provides compositions and methods for dedifferentiating lineage committed mammalian cells.... Agent: Townsend And Townsend And Crew, LLP

20070254885 - Use of type v phosphodiesterase inhibitors in the treatment of exercise induced pulmonary hemorrhage in the equine: The use of type V phosphodiesterase inhibitors as a novel independent therapeutic modality in the treatment of exercise induced pulmonary hemorrhage in equine is described. The type V phosphodiesterase inhibitor is injected into the horse intravenously as a stand-alone agent from about one-half hour to about seven (7) days prior... Agent: Michael F. Scalise

20070254886 - Chemokine receptor antagonist and medical use thereof: The compound represented by formula (I) has chemokine receptor (especially in CCR4 and/or CCR5) antagonistic activity. Therefore it is useful for prevention and/or treatment of a chemokine receptor-mediated disease such as inflammatory and/or allergic diseases [systemic inflammatory response syndrome (SIRS), anaphylaxis, anaphylactoid reaction, allergic angiitis, transplant rejection reaction, hepatitis, nephritis,... Agent: Sughrue Mion, PLLC

20070254887 - Pharmaceutical composition for transdermal administration of perospirone: e

20070254889 - Compounds and methods useful for rescuing cells from beta-amyloid toxicity and treatment of alzheimer's disease: The present invention is directed to pharmaceutical compositions comprising one or more compounds of Formulae I, II, III, IV, V, VI, VII, VIII, IX and X, or pharmaceutically acceptable salts thereof and excipients. The present invention provides a method of inhibiting β-amyloid plaque aggregation, the method comprising introducing into a... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070254888 - Piperazinediones as oxytocin receptor antagonists: wherein R1 is 2-indanyl, R2 is 1-methylpropyl, R3 is a group selected from 2,6-dimethyl-3-pyridyl or 4,6-dimethyl-3-pyridyl, R4 represents methyl and R5 represents hydrogen or methyl or, R4 and R5 together with the nitrogen atom to which they are attached represent morpholino and pharmaceutically acceptable derivatives thereof are described, as are... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070254890 - 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders: e

20070254891 - Crystalline forms of 4-(2-fluorophenyl)-6-methyl-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine: The present invention is directed to novel crystalline forms of 4-(2-fluorophenyl)-6-methyl-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine salts, including 4-(2-fluorophenyl)-6-methyl-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine hydrochloride crystalline forms. The present invention is also directed to compositions including such crystalline forms and methods for making and using such crystalline forms, e.g., in the treatment of gastrointestinal and/or genitourinary disorders.... Agent: Lahive & Cockfield, LLP

20070254892 - Dihydropyrazolopyrimidinone derivatives: e

20070254893 - Combination product comprising src kinase inhibitor azdo530 and an antioestrogen or egfr-tk-inhibitor: The invention relates to a combination for use in the synergistic treatment of breast cancer comprising an antioestrogen and the Src kinase inhibitor AZD0530, a combination for the synergistic treatment of cancer comprising an EGFR TKI and the Src kinase inhibitor AZD0530 and a triple combination for the synergistic treatment... Agent: Morgan Lewis & Bockius LLP

20070254894 - Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation: e

20070254895 - Crystalline solvate of glucokinase activator: Provided is a crystalline IPA solvate of 2(R)-(3-Chloro-4-methanesulfonyl-phenyl)-3-((R)-3-oxo-cyclopentyl)-N-pyrazin-2-yl-propionamide as a glucokinase activator which increases insulin secretion in the treatment of, for example, type II diabetes.... Agent: Hoffmann-la Roche Inc. Patent Law Department

20070254897 - Compositions and methods for the treatment of cardiovascular disease: The invention relates to methods of treating cardiovascular disease comprising administering a resolvin, lipoxin, or oxylipin compound.... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070254896 - Substituted pyrimidine kinase inhibitors: e

20070254899 - Soluble salts of thieno[2,3-d]pyrimidine derivatives: The present invention is directed to novel salts of thieno[2,3-d]pyrimidine derivatives, including 4-(2-fluorophenyl)-6-methyl-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine salts. The present invention is also directed to compositions including such polymorphs and methods for using such salts, e.g., in the treatment of gastrointestinal and/or genitourinary disorders.... Agent: Lahive & Cockfield, LLP

20070254898 - Thienopyrimidine and thienopyridine derivatives substituted with cyclic amino group: e

20070254900 - Treatments for congestive heart failure: Methods and pharmaceutical preparations for treating heart failure by administering to a human or animal subject a therapeutically effective amount of at least one substance selected from the group consisting of a) SOD mimics (e.g., Tempol), b) NADPH oxidase inhibitors (e.g., Apocynin) and c) other substance that inhibit or reduce... Agent: Moazzam & Associates, LLC

20070254901 - Inhibitors of akt activity: The present invention is directed to compounds which contain substituted 5-deazapteridine moieties which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention.... Agent: Merck And Co., Inc

20070254902 - Methods and compositions utilizing quinazolinones: Quinazolinones of formulae 1a, 1b, 1c and 1d are disclosed. They are useful for treating cellular proliferative diseases and disorders associated with KSP kinesin activity.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070254903 - Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof: and pharmaceutically acceptable salts, solvates and stereoisomers thereof, wherein A, B, E, G, W, X, Y, Z, o, and R1 are as disclosed herein (“Compound(s) of the Invention”), which are useful as cardio-protective and/or neuro-protective agents. The invention also provides pharmaceutical compositions comprising a Compound of the Invention and methods... Agent: Bozicevic, Field & Francis LLP (arena Pharmaceuticals, Inc.)

20070254904 - Substituted diaza-spiro-[4.5]-decane derivatives and their use as neurokinin antagonists: d

20070254905 - Pharmaceutical formulation for increasing solubility of 10-hydroxycamptothecin compounds in non-aqueous polar solvents: The present invention relates to a pharmaceutical formulation for increasing the solubility of a 10-hydroxycamptothecin compound in non-aqueous polar solvent, comprising a 10-hydroxycamptothecin compound and an amine compound whose pKa value is 7.4 or more. By using the formulation according to the present invention, the solubility of the 10-hydroxycamptothecin compound... Agent: Birch Stewart Kolasch & Birch

20070254906 - Method of administration of dopamine receptor agonists: Methods for treating a patient having pulmonary edema are described. The methods include administering to the lung endobronchial space of the airways of the patient an effective amount of a dopamine D1 receptor agonist. Dopamine D1 receptor agonists, including hexahydrobenzophenanthridine, hexahydrothienophenanthridine, phenyltetrahydrobenzazepine, chromenoisoquinoline, naphthoisoquinoline dopamine receptor agonists, and their pharmaceutically... Agent: Barnes & Thornburg LLP

20070254907 - Compositions and methods for controlling infestation: The present invention is directed to methods of treating pest infestation by inhibiting metabolic processes of the pest such as for example, processes involved in invertebrate remodelling.... Agent: Marshall, Gerstein & Borun LLP

20070254908 - 7-azaindoles, pharmaceutical compositions and their therapeutic applications: in which the R-groups are herein defined, together with their pharmaceutically acceptable salts, therapeutic methods for their use and processes for their preparation. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20070254909 - Novel pyridine derivatives, a process for their preparation and a pharmaceutical composition containing the same: The invention relates to novel pyridine derivatives having an inhibitory effect on production of cytokines, which are involved in inflammatory responses, thus suggesting its usefulness as therapeutic agents for treating diseases related to inflammation, immune, chronic inflammation as well as an agent having an anti-inflammatory and analgesic effect. Further, this... Agent: Ronald R. Santucci, Esq C/o Frommer Lawrence & Haug LLP

20070254912 - Benzimidazolyl-pyridine compounds for inflammation and immune-related uses: e

20070254910 - Chemical compounds: The present invention provides novel compounds that demonstrate protective effects on target cells from HIV infection in a manner as to bind to a chemokine receptor, and which affect the binding of the natural ligand or chemokine to a receptor such as CXCR4 of a target cell.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070254913 - Phosphodiesterase 4 inhibitors: Selective PDE4 inhibition is achieved by aryl and heteroaryl pyrazole compounds. The compounds exhibit improved PDE4 inhibition as compared to compounds such as rolipram and show selectivity with regard to inhibition of other classes of PDEs.... Agent: Millen, White, Zelano & Branigan, PC

20070254911 - Tetrahydro-pyrazolo[3,4-c]pyridine cannabinoid modulators: l

20070254914 - Low-concentration atropine solution for preventing myopia progression and preparing method thereof: A low-concentration atropine solution for preventing myopia progression contains an atropine concentration less than 0.1% (w/w). Preferably, the atropine concentration is 0.05% (w/w) in optimal situation. The low-concentration atropine solution in treatment causes less photophobia and systemic side-effects to patients and has excellent compliance to reduce damages from ultraviolet and... Agent: Nikolai & Mersereau, P.A.

20070254915 - Cxcr4 modulators: The present invention is directed to novel compounds and pharmaceutical compositions that inhibit the binding of the SDF-1 chemokine to the chemokine receptor CXCR4 and/or the binding of the SDF-1 or I-TAC chemokines to the chemokine receptor CCXCKR2 (CXCR7). These compounds are useful in preventing tumor cell proliferation, tumor formation,... Agent: Townsend And Townsend And Crew, LLP

20070254916 - Aryl and heteroaryl compounds, compositions, and methods of use: This invention provides aryl and heteroaryl compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention may be useful as antagonists, or partial antagonist of factor IX and/or factor XI and thus, may be used to... Agent: Kilpatrick Stockton LLP - 41305 Charles Calkins

20070254917 - Intracellular receptor modulator compounds and methods: This invention relates to compounds that bind to intracellular receptors and/or modulate activity of intracellular receptors, and to methods for making and using such compounds.... Agent: Knobbe Martens Olson & Bear LLP

20070254918 - Dopamine-, norepinephrine- and serotonin- transporter-selective heterocyclic compounds and their therapeutic applications: One aspect of the invention relates to piperidine compounds that are useful as inhibitors of monoamine transporters. The invention also relates to pharmaceutical compositions, comprising a piperidine compound of the invention. Another aspect of the present invention relates to the use of the aforementioned compounds in a method of treating... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20070254919 - Aroyl-o-piperidine derivatives for the treatment of diabetes-related problems: The present invention relates to derivatives of aroyl-O-piperidine structure of the general formula (I): in which R1, R2, R3 and R4 are as defined in the description. Application of the compounds of the formula (I) to the treatment of hyper-triglyceridaemia, hypercholesterolaemia and dyslipidaemia, and to the prevention or treatment of... Agent: Millen, White, Zelano & Branigan, P.C.

20070254920 - Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use: is a biologically-active moiety comprising a carboxylic acid functional group, and Rb is a homotopically-symmetrical alcohol bonded to the biologically-active moiety through the carboxylic acid functional group to form an ester linkage, as well as optical isomers, enantiomers, pharmaceutically acceptable salts, biohydrolyzable amides, esters, and imides thereof and combinations thereof.... Agent: Michael Best & Friedrich LLP

20070254921 - Therapeutic and diagnostic methods dependent on cyp2a enzymes: A method of regulating the activity of human cytochrome P450 isozyme CYP2A6 to control nicotine metabolism or decrease to production of carcinogens from procarcinogens, such as those present in tobacco smoke, in an individual by selectively inhibiting CYP2A6. Various prophylactic (i.e., prevention and treatment) compositions and methods are also described,... Agent: Bereskin And Parr

20070254922 - Computer system and control method for the computer system: A computer system including a first storage system connected to a first host computer, a second storage system connected to a second host computer and a third storage system connected to the first and second storage systems. The second storage system sets transfer setting before an occurrence of a failure,... Agent: Mattingly, Stanger, Malur & Brundidge, P.C.

20070254924 - Salts of benzimidazole compound and use thereof: A sodium salt, magnesium salt, lithium salt, potassium salt, calcium salt or barium salt of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole, and a pharmaceutical composition comprising the salt. The novel salt is useful as an excellent antiulcer agent.... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20070254923 - Therapeutic salt compositions and methods: Therapeutic salt compositions and methods are disclosed herein.... Agent: Allergan, Inc.

20070254925 - Thiazole and thiadiazole compounds for inflammation and immune-related uses: e

20070254927 - High concentration topical insecticide containing insect growth regulator: A topical insecticide is provided which can be safe to use and avoids many common deleterious side effects of conventional topical insecticides. The insecticide contains an insecticide and an insect growth regulator effective for killing fleas, flea larvae and flea eggs. The insecticide is formulated by dissolving an insecticidal (tetrahydro-3-furanyl)... Agent: Stroock & Stroock & Lavan LLP

20070254926 - Pyridylphenyl compounds for inflammation and immune-related uses: t

20070254928 - Use of roflumilast for the prophylaxis or treatment of emphysema: The invention relates to the use of roflumilast for the prophylaxis of or the treatment of emphysema.... Agent: Nath & Associates PLLC

20070254929 - Fluoro-and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof: are provided where T is CHO, COR8, or C(OH)R1R2; R1 and R2 are hydrogen, optionally substituted lower alkyl, CF3, optionally substituted alkenyl, or optionally substituted alkynyl; R3 is hydrogen or optionally substituted lower alkyl; R4 is (CF3)nalkyl, (CF3)n(substitutedalkyl), (CF3)nalkylphenyl, (CF3)nalkyl(substitutedphenyl), or (F)ncycloalkyl; n=1-3; R5 is hydrogen, halogen, CF3, diene fused... Agent: Howson And Howson/wyeth Cathy A. Kodroff

20070254930 - Oral preparation having improved bioavailability: The present invention relates to an oral preparation of N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl) phenoxy]pentoxyl-benzamidine having improved bioavailability. More particularly, the present invention relates to an oral preparation comprising: N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl) phenoxy]pentoxy}-benzamidine or pharmaceutically acceptable salt thereof; and one or more carbonates selected from the group consisting of alkalimetal carbonate, alkalimetal bicarbonate and alkaline earth... Agent: Lucas & Mercanti, LLP

20070254931 - Thiazole derivatives having vap-1 inhibitory activity: A compound of the formula (I), (II), (III) or (IV): wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof useful as a vascular adhesion protein-1 (VAP-1) inhibitor, a pharmaceutical composition, a method for preventing or treating a VAP-1 associated disease, especially macular edema, which... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070254932 - Drugs for treating duplication of hypertension with hyperuricemia and/or hypercholesterolemia: The purpose in this invention is to providing drugs for treating or preventing duplication of hypertension with serum hyperuricemia and/or hypercholesterolemia that is much frequency among the duplication onset in geriatric diseases. This invention is related to drugs for treating or preventing duplication of hypertension with serum hyperuricemia and/or hypercholesterolemia... Agent: Flynn Thiel Boutell & Tanis, P.C.

20070254933 - Diarylthiohydantoin compounds: The present invention relates to diarylthiohydantoin compounds and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.... Agent: Venable LLP

20070254934 - Antiviral drugs for treatment of arenavirus infection: Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain novel compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused... Agent: Bingham Mccutchen LLP

20070254935 - Pyrazole and imidazole compounds and uses thereof: Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment diseases, conditions and/or disorders modulated by cannabinoid receptor antagonists in animals are described herein.... Agent: Pharmacia Corporation Global Patent Department

20070254936 - Bactericidal composition for agricultural or horticultural use and method of controlling plant disease: m

20070254937 - Thienopyrazoles: Thienopyrazoles of formula I, their preparation, pharmaceutical compositions comprising these compounds, and their pharmaceutical uses in the treatment of disease states capable of being modulated by the inhibition of the protein kinases, in particular interleukin-2 inducible tyrosine kinase (ITK).... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20070254939 - Formulations containing amide derivatives of carboxylic acid nsaids for topical administration to the eye: Topical compositions of amide derivatives of carboxylic acid non-steroidal anti-inflammatory agents are disclosed. The compositions have a reduced potential to cause mitochondrial swelling when topically administered to the eye.... Agent: Alcon

20070254938 - Preventive or therapeutic agent for vascular intimal proliferative disease: The present invention provides pharmaceutical compositions for the prevention or treatment of diseases associated with intimal hyperproliferation of a blood vessel such as restenosis after percutaneous coronary intervention or the like. Moreover, a pharmaceutical composition for the prevention or treatment of diseases associated with intimal hyperproliferation of a blood vessel... Agent: Frenkel & Associates

20070254940 - 1,5 and 3,6- substituted indole compounds having nos inhibitory activity: The present invention features inhibitors of nitric oxide synthase (NOS), particularly those that selectively inhibit neuronal nitric oxide synthase (nNOS) in preference to other NOS isoforms. The NOS inhibitors of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing conditions such... Agent: Clark & Elbing LLP

20070254941 - Subtantially pure ropinirole hydrochloride, polymorphic form of ropinirole and process for their preparation: Ropinirole hydrochloride substantially free of impurities and a process for its preparation is provided. Also provided is ropinirole base substantially in polymorph Form A and a process for its preparation. Pharmaceutical compositions containing the same are also provided.... Agent: M. Carmen & Associates, PLLC

20070254942 - 7-amido-isoindolyl compounds and methods of its use: The invention encompasses 7-amido-isoindolyl compounds and methods of using these compounds and compositions in mammals for treatment, prevention or management of various diseases and disorders. Examples include, but are not limited to, cancer, inflammatory bowel disease and myelodysplastic syndrome.... Agent: Jones Day

20070254943 - Diphenylmethyl compounds useful as muscarinic receptor antagonists: wherein a, b, c, e, m, n, Ar1, R1, R2, R3, R4a, R4b, R5 and R6 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of... Agent: Theravance, Inc.

20070254944 - Use of organic compounds: A method for improving glucose control by administering metformin in combination with a DPP-IV inhibitor to a patient in need thereof, in an amount sufficient to control the glucose level over an extended period of time.... Agent: Novartis Corporate Intellectual Property

20070254945 - Aminocyclohexyl ether compounds and uses thereof: Aminocyclohexyl ether compounds are disclosed. The compounds of the present invention may be incorporated in compositions and kits. The present invention also discloses uses for the compounds and compositions, including the treatment of arrhythmia.... Agent: Seed Intellectual Property Law Group PLLC

20070254946 - Hair growth stimulants: The present invention provides a hair growth stimulant comprising a chromene compound as an active ingredient, and which exhibits excellent hair restoration effects. The present invention also provides a hair-restoring preparation for external use, hair-restoring preparation for oral use, and hair-restoring food containing the hair growth stimulant.... Agent: Knobbe Martens Olson & Bear LLP

20070254947 - Composition for external use: e

20070254948 - Lipase inhibitors:

20070254949 - Use of 3-(2,4,6-trimethylphenyl)-4-neopentylcarbonyloxy-5,5-tetramethylene-delta-3-dihydrofuran-2-one for controlling psyllids: The present application relates to the use of 3-(2,4,6-trimethylphenyl)-4-neopentyl-carbonyloxy-5,5-tetramethylene-Δ3-dihydrofuran-2-one for controlling insects from the family Psyllidae (psyllids).... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070254951 - High concentration dinotefuran formulations: A topical insecticide is provided which can be safe to use and avoids many common deleterious side effects of conventional topical insecticides. In one preferred embodiment of the invention, the active ingredient of the insecticide formulation is an amine derivative, having a nitro-methylene group, a nitroamino group or a cyanoamino... Agent: Stroock & Stroock & Lavan LLP

20070254950 - Oculoselective drugs and prodrugs: Compounds of the following formula are disclosed: wherein R1 and R2 are each independently H, W, or a phenoxyl protecting group; and R4 is H or W, provided that at least one of R1, R2, and R4 is W; R3 is hydrogen, straight chain or branched C1-C10 alkyl, cycloalkyl, amino,... Agent: Woodcock Washburn LLP

20070254952 - Cannabinoid receptor modulators: or the pharmaceutically acceptable salts or solvates thereof, wherein: Ar1 is a chlorophenyl group, Ar2 is a dichlorophenyl group, R1 is a —(CH2)m—X—(CH2)n—R2 group, X is a —NH—, —O—, —C(O)— or —S(O)2— group, and R2 is a substituted phenyl group. These compounds are CB1 receptor modulators. Also disclosed are methods... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070254953 - Topical compositions of urea and ammonium lactate: Pharmaceutical, cosmetic and cosmeceutical compositions for topical application, containing, as active ingredients, urea and/or derivatives thereof and alpha-hydroxy acid and/or an ammonium salt thereof, such as ammonium lactate, processes of manufacturing same and use of same in the treatment of medical and cosmetic skin and scalp conditions.... Agent: Martin D. Moynihan

20070254954 - Composition with preventive or improvement effect on symptoms or disesases associted with stress-induced behavior disorders: A composition with a preventive or improvement effect on symptoms or diseases associated with stress-induced behavior disorders, comprising arachidonic acid and/or a compound comprising arachidonic acid as a constituent fatty acid.... Agent: Drinker Biddle & Reath (dc)

20070254955 - Nail softener for use in deformed-nail corrective treatment or nail-structure modification, enclosure for external chemicals and method of correcting deformed nail: Disclosed is an enclosure for an external chemical, which comprises an enclosure body receiving the external chemical therein and having an opening for exposing the external chemical when used, a sealing film for allowing the external chemical to be sealingly enclosed in the external chemical, an adhesive layer provided at... Agent: Edward G. Greive Renner, Kenner, Greive, Bobak, Taylor & Weber

20070254956 - Medicament for therapeutic and/or preventive treatment of restenosis or reocclusion after vascular recanalization operation: A medicament for therapeutic and/or preventive treatment of restenosis or reocclusion after a vascular recanalization operation, which comprises as an active ingredient a compound represented by the following formula or a physiologically acceptable salt thereof, and a medical device for an intravascular treatment, which contains said compound or the physiologically... Agent: Greenblum & Bernstein, P.L.C

20070254957 - Triaryl compounds and derivates thereof: The present invention relates to compounds having the general formula (I) with the definitions of X, Y, R1, R2, R3, R4, R9, R10 given below, and solvates, hydrates, esters, and pharmaceutically acceptable salts thereof. Furthermore the invention relates to the use of said compounds for the treatment of Alzheimer's disease... Agent: Philip S. Johnson Johnson & Johnson

20070254958 - Phenyl carboxamide compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease: The present invention is directed to phenyl carboxamide compounds which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use... Agent: Merck And Co., Inc

20070254959 - Process for obtaining tolterodine: The process comprises reacting a compound of formula (II), where R is a hydroxyl protecting group, and the asterisk indicates an asymmetric carbon atom, with diisopropylamine in the presence of a reducing agent; optionally converting the resulting intermediate into a salt and, if so desired, isolating it; removing the hydroxyl... Agent: Mathews, Shepherd, Mckay, & Bruneau, P.A.

20070254960 - Pharmaceutical combination: A combination comprising as components (a) the compound 3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol, and (b) Paracetamol or a derivative thereof, a pharmaceutical formulation and a dosage form comprising said combination as well as a method of treating pain, e.g. chronic or acute pain, characterized in that components (a) and (b) are administered simultaneously or... Agent: Crowell & Moring LLP Intellectual Property Group

20070254962 - Methods of administering anti-inflammatory cyclooxygenase-2 selective inhibitors: Disclosed are novel anti-inflammatory pharmaceutical compositions and related methods that exhibit potent and selective inhibition of the cycloooxygenase-2 (COX-2) enzyme. The formulation can comprise a hops extract that exhibits COX-2 selectivity as defined by dividing the IC50 COX-2/IC50COX-1 concentrations that are determined by testing with the William Harvey Whole Blood... Agent: Paul, Hastings, Janofsky & Walker LLP

20070254961 - Polyisoprenylated benzophenones and their isomers as inhibitors of histone acetyltransferases and uses thereof: In this patent we describe the purification of prenylated benzophenones from the fruit rinds of Garcinia species and its evaluation as an inhibitor for Histone acetyltransferases p300 and PCAF. We have found that prenylated benzophenones are potent HAT inhibitors of p300 (IC50-1 μM) and pCAF (IC50-15 μM). The inhibitors significantly... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20070254963 - Ozonidzed pharmaceutical composition and method: A pharmaceutical composition to be externally applied as a topical preparation for treating several diseases, the composition comprising ozonized oils with MSM and dimethylsulfoxide (DMSO) for enhancing penetration of the active principles and permitting the treating of internal and external diseases.... Agent: Norris, Mclaughlin & Marcus, P.A.